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ABSTRACT
It was confirmed that U. urealyticum produces an IgAl protease, which 
cleaves human IgAl only into intact Faba and Fca fragments. By N-terminal amino 
acid sequencing of Fca fragments, the site of digestion was identified as a Pro235- 
Thr236 peptide bond within the a chain hinge-region of IgAl.
A number of assay systems were examined for their ability to detect and 
estimate IgAl protease activity. A reliable and reproducible immunoblotting 
method was developed, in conjunction with a quantifiable assay utilising I125j] 
IgAl. By these methods, IgAl protease activity was identified in fourteen serotypes 
of U. urealyticum, all of which appeared to digest IgAl at the same Pro235~Thr236 
peptide bond. The enzyme was active over a broad range of pH (pH 3-10) and 
was inhibited by the serine-protease inhibitors 3,4-DCI and DFP.
The IgAl protease was not located in 'spent' ureaplasma cultivation 
medium but appeared to be cell-associated. The activity was solubilised by a 
number of non-ionic detergents which were required in purification buffers to 
maintain enzyme stability, further suggesting a membrane-bound location. 
Although the enzyme was not purified to homogeneity, a number of protocols 
were established which provide a basis for future work.
A genomic library of U. urealyticum DNA was produced and a variety of 
strategies adopted for identification of the iga gene. Radiolabelled DNA probes 
were generated from a plasmid containing the iga gene for N. gonorrhoeae 
(pIP503). By Southern blot hybridisation, no significant homology was identified 
between the heterologous probes and ureaplasma genomic DNA. Based on 
regions of high nucleotide conservation between the iga genes from 
N. gonorrhoeae and H. influenzae, degenerate PCR primers were designed. While 
amplification products did not appear to contain regions of the iga, such an 
approach may be adapted and extended for use in future studies.
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Chapter 1: 
Introduction
1
SECTION A
PROPERTIES OF U. UREALrTKCJM
1.1 TAXONOMY AND PHYLOGENY
1.1.1 The class Mollicute
Mollicutes are a group of free living prokaryotes that have been isolated 
from a wide range of hosts including humans, animals, birds, insects and plants. 
They possess a number of unusual properties, the most notable being a lack of cell 
wall which places them within the division of walHess bacteria, Tenericutes. Their 
small genomes and unusual nutritional requirements justifies the creation of 
Mollicute as a distinct class within this division (Edward and Freundt, 1967)
(Fig. 1.1). Further sub-divisions are based on phenotypic characteristics such as 
genome size, oxygen s^jn^iiti^^ty and sterol requirements, producing a total of six 
genera; Acholeplasma, Anaeroplasma, Asteroleplasma, Spiroplasma, Mycoplasma,, 
and Ureaplasma (Robinson and Freundt, 1987). By convention, the trivial name 
’mollicute' is used to denote any member of this class and the names 
'acholeplasma', 'anaeroplasma', 'asteroleplasma', 'spiroplasma', 'mycoplasma' and 
'ureaplasma' denote members of the corresponding genera.
The evolution of mollioites is unclear; as wall-less bacteria they may 
represent primitive forms of prokaryotes or, alternatively, they may have evolved 
later as degenerate forms of walled relatives (Razin, 1978). Genomic comparisons 
have given some insight into their phylogeny and also support the broad 
taxonomic groupings described above. Initial characterisation of 16S RNA revealed 
that mollioites were related to gram-positive bacteria with low G+C compositions, 
such as the Bacillus-Lactobacillus cluster and Clostridia (Woese et al, 1980). 
Sequence comparisons of 5S RNA (Rogers et al, 1985) and 16S RNA from over 
forty species of mollicute (Weisburg et al, 1989) confirmed and extended these 
findings and has led to the construction of a detailed phylogenetic tree (Maniloff, 
1992) (Fig. 1.2). From these analyses, it has been proposed that asterolepaasmas
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Lactobacillus group
-------------------------- As. anaerobium
------- Anaeroplasma group
------- Acholeplasma group
Spiroplasma strain Y32
S. citri group
S. apis group
M. mycoides group
5
------  M. pneumoniae group
------  Ureaplasma group
M. hyorhinis group
M. fermentans group
M. hominis group
Fig. 1.2 Phylogenetic tree for Mollicutes
Taken from Maihloff (1992), the mollicute phylogenetic tree has been 
reconstructed from 16S RNA sequence comparisons. E. coli provided the root of 
the tree and closely related phylogenetic sublines have been grouped together. 
Branch lengths are proportional the number of base changes per 100 nucleotides, 
i.e. the evolutionary distance between groups. The scale to the left denotes the 
branch distance corresponding to five base changes per 100 nucleotides.
4
and acholeplasmas have evolved from the Lactobacillus group by a decrease in 
chromosome size to 1640-1700 kbp and that further divergence has produced the 
sterol-requiring anaeropksmas (1700 kbp) and helical spiropUsmas (1350­
1700 kbp). A number of independent and repeated genome reductions in the 
spiroplasma branch may have finally yielded mycoplasmas and ureaplasmas with 
genome sizes of 620-1160 kbp (Rogers et al., 1985, Maniloff, 1992),
These genomes are the smallest recorded for any self-replicating 
prokaryote and mollicutes therefore represent the simplest free-living biological 
system known (Razin, 1992). Their limited coding capacity imposes restrictions on 
their biosynthetic capabilities so that they live as parasites both in their hosts, 
where they are frequently pathogenic, and in rich tissue culture systems, where 
they are unwelcome contaminants. It is for these reasons that mollicutes are of 
scientific, medical, veterinary and agricultural importance.
1.1.2 The genera Mycoplasma and Ureaplasma
Of all mollicutes, the genus Mycoplasma has aroused the greatest interest 
as within its eighty species are a number of human pathogens that have been 
associated with respiratory, arthritic and urogenital diseases (Krause and Taylor- 
Robinson, 1992). These include Mycoplasma pneumoniae, (Af. pneumonae), 
Mycoplasma hominS (M. homing and Mycoplasma genitalium (M. genitalium). 
Most recently Mycoplasma fermentans (strain incognitus), Mycoplasma penetrans 
(Af. penetrans) and Mycoplasma pirum, have been implicated as cofactors in the 
progression of human immunodeficiency virus (HIV) infection to AIDS (Lo et al., 
1989,1991, Lemaitre et al, 1992, Chirgwin et al, 1993).
Ureaplasmas have many features in common with mycopksmas, but their 
unique ability among mollicutes to hydrolyse urea places them within a separate 
genus Ureaplasma (Shepard et al, 1974). They are widely distributed in nature 
and colonise most animal species that have been examined to date. Serologic and 
genomic analysis of some isolates has currently divided the genus into five 
species; Ureaplasma urealyticum. iU. urealyticum), isolated from humans, 
Ureaplasma diversum ( C7. diversum), isolated from cattle (Howard and Gourlay,
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1982), Ureaplasma gallorale, isolated from chickens (Koshimizu, et al, 1987), 
Ureaplasma felinum, and Ureaplasma cati, both isolated from cats (Harasawa 
et al., 1990). Identification of new species awaits further characterisation of 
isolates and the development of improved culture conditions, which at present 
may not support the growth of more fastidious organisms.
The human isolate, U. urealyticum, has presently been divided into 
fourteen serotypes on the basis of a complement-dependent mycoplasmacidal test 
(Lin and Kass, 1980), a modified metabolic inhibition test and a colony indirect 
epifluorescent test (Robertson and Stemke, 1982). The fourteen serotypes can be 
further sub-divided into two seroclusters based on their sensitivity to manganese 
salts (Robertson and Chen, 1984), protein profiles by ID and 2D polyacrylamide 
gel electrophoresis (Mouches et al, 1981, Swensen etal, 1983), hybridisation 
using rRNA probes (Razin and Yogev, 1986), restriction endonuclease patterns 
(Tully and Taylor-Robinson, 1986) and, most recently, by polymerase chain 
reaction (PCR), (Blanchard, 1990).
Since its isolation in from patients with non-gonococcal urethritis 
(Shepard, 1954), research on U. urealyticum has centred on elucidating the role of 
this mollicute in disease, particularly of the human urogenital tract. In order to 
achieve this goal, fundamental characterisation of the organism has been a 
requirement.
1.2 CHARACTERISATION OF UREAPLASMA UREALYTICUM
1.2.1 Growth
As a consequence of their lack of cell wall and limited coding potential, 
ureaplasmas require an osmotically balanced cultivation medium, rich in a supply 
of metabolic intermediates. Many of the complex media described for ureaplasma 
growth are based on that devised by Edward (1947). PPLO broth provides the base 
and consists of beef heart infusion, bactotryptose and sodium chloride. It is 
supplemented with yeast extract (containing nucleic acids, their derivatives and 
precursors) and with horse serum which provides essential cholesterol, urea, and
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other unidentified components beneficial to ureaplasma growth (Shepard and 
Masover, 1979). Additional urea may be included to give an optimum 
concentration of 0.01 M (Shepard and Lunceford, 1967). The hydrolysis of urea to 
ammonia and carbon dioxide by a urease enzyme seems to be an absolute 
requirement for growth in ureaplasmas, as indicated by the use of urea-free media 
and specific urease inhi^b^t^or^s (Kenny and Cartwright, 1977, Kenny, 1983, Smith 
etal, 1993).
It has been proposed that U. urealyticum has the unique ability among 
mollicuites to synthesise unsaturated and saturated fatty acids from acetate 
(Romano et al, 1976), but other workers have disputed this finding (Pollack et al, 
1984). Fatty acids provided in the serum may therefore also be necessary for 
growth. Very little is known about the nutritional requirements of ureaplasmas for 
amino acids, vitamins and cofactors. Thiols can improve the growth of 
U. urealyticum, but they may be serve to prevent inhibition of the urease enzyme 
rather than being incorporated for metabolic purposes. Supplements of L-histidine, 
arginine, methionine and cysteine can stimulate growth and calcium may also be a 
requirement (Shepard and Masover, 1979).
Inclusion of an indicator in the cultivation medium allows ureaplasma 
growth to be monitored, since the liberation of ammonia from urea hydrolysis 
results in a detectable pH rise. Utilising this property, cell numbers are estimated 
by serially diluting a suspension of the organism to extinction in liquid medium. 
After a suitable incubation period (at least 24 h after the last colour change was 
seen), the reciprocal of the highest dilution in which growth occurs (indicated by 
the colour change) is the estimated population size, expressed in colour-changing 
units (CCU.rm-1). By this method, it been established that the optimum pH for 
growth is 6.0-6.5 and that ureaplasmas follow the lag, exponential and stationary 
phases typical for bacterial growth. Beyond pH 8, however, there is rapid cell 
death so that cHara<^l:^l^ii^t:i^:al^y the CCU.ml"1 never rises above 10® (Shepard and 
Masover, 1979). This may be due to inactivation of the urease enzyme at pH 8, but 
buffering of the media fails to alleviate this effect (Razin et al, 1977a, Thirkell, 
personal communication). Growth is also not improved by replenishing urea,
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demonstrating that substrate is not limiting (Razin et al, 1977a). It is possible that 
growth is inhibited by an unidentified toxic product of metabolism (Furness,
1973).
An important consequence of this inhibitory effect is the very low yield of 
ureaplasma cells obtained from growth in artificial media (O' Brien and Barile, 
1983). Furthermore, the organisms are frequently harvested in association with 
non-specific adherents, probably serum components, which interfere with 
subsequent analysis of cell surface antigens (Masover and Hayflick, 1973). It may 
be possible to overcome this growth medium contamination by replacing the 
horse serum with PPLO serum, as recently described by Horowitz and Gal (1991).
1.2.2 Morphology, , size and infrastructure
Ureaplasmas were first identified on solid media as exceedingly small 
colonies (7-15 pm) and it is for this reason that they were originally named 'tiny 
form PPLO' or’T mycopaasmas' by Shepard (1954), They grow with an irregular 
border and only under certain conditions have the classical 'fried egg colony' 
appearance of other mycoplasmas (Razin et al, 1977b). In liquid culture, 
ureaplasmas generally exist as round or ovoid elements but show varied 
morphology, depending on medium composition, their stage of growth and the 
methods used for sample preparation (Reviewed by Shepard and Masover, 1979).
It has been important to establish the minimum size of these simple life forms, but 
there are errors inherent in the methods used to determine this. For example, 
passage through defined filters may only indicate that the wall-less organism can 
squeeze through a pore smaller than its own diameter. Likewise, measurements 
from electron micrographs vary according to the type of fixation and the plane of 
section taken. There is general agreement, however, that ureaplasmas and 
mycophsmas are no smaller than 300 nm, which represent the smallest living units 
reported to date that are capable of self-reproduction (Razin, 1978).
The means by which ureaplasmas reproduce is unclear, but identification 
of surface outgrowths suggests that it may be by budding (Razin et al, 1977b, 
Myles et al, 1991). In other mycophsmas, there is evidence for binary fission.
8
Electron micrographs following the stages of reproduction in M. hominis showed 
that rapidly growing cocci temporarily became filamentous (Bredt et al, 1973). 
This has been interpreted as binary fission where cytoplasmic division has lagged 
behind genome replication, thus producing multi-nucleate filaments. Filamentous 
forms have been observed in ureaplasma cultures by some workers (Rottem et ah, 
1971, Black et al, 1972a) but not others (Whitescarver and Furness, 1975, Razin 
et ah, 1977b). Since the absence of filaments may have been due to the poor 
growth of these organisms in the available media, binary fission has not been 
discounted as a form of replication in U. urealyticum.
There is more agreement on the ultrastructure of ureaplasmas; electron 
micrographs show them to be bound by a typical trilaminar membrane 
(7.5-10 nm) with an extra membranous electron-dense layer present in some 
preparations (Black et ah, 1972a, Whitescarver and Furness, 1975). Staining by 
osmium-ruthenium red and ConAion dextran stain shows that this 'capsule' 
contains mucopolysaccharide, and it may influence ureaplasma aggregation and 
adherence (Robertson and Smook, 1976). The precise means by which 
ureapaasmas adhere to cells is unknown, but small hair-like projections seen by 
freeze-fracture analysis may be involved (Black et al, 1972a). Specialised tip 
structures that mediate adhesion in M. pneumoniae and M. genitalium. (Razin and 
Jacobs, 1992) are not obvious in ureaplasma preparations.
Within the cells, the cytoplasm is quite uniform and contains ribosomes, 
vacuoles, and a double stranded circular DNA molecule. This has a low but 
constant G+C content of 28% (Bak and Black, 1968) and, as with cellular 
dimensions, estimates of its size vary depending on the methods used. Early 
studies using renaturation kinetics suggested a genome size of 620 kbp-720 kbp 
for U. urealyticum (Black et ah, 1972) but later work using pulse-field 
electrophoresis (PFGE) gave larger estimates of around 900 kbp (Neimark and 
Lange, 1990, Pyle et ah, 1988). These differences may be due to high A+T levels in 
ureaplasma DNA producing anomalous results. A refinement of PFGE, contour- 
clamped homogenous field agarose gel electrophoresis has divided 
U. urealyticum genome sizes into two groups; 760 kbp for the small serocluster
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and 840-1140 kbp for the large serocluster (Robertson et al, 1990). These values 
seem plausible, since by summing a series of overlapping cosmid clones that map 
the whole genome, a method that is not affected by the G+C content of the DNA, 
the genome size for M. pneumoniae has been estimated as 835-849 kbp (Wenzel 
and Herrmann, 1989). Since 29 restriction sites have now been mapped in the 
U. urealyticum genome (Cocks et ah, 1989), such an approach may be possible in 
this organism.
Assuming that the minimum genome size for ureaplasmas is 750 kbp then, 
along with mycopaasmas, these are the smallest genomes recorded for any self- 
reproducing prokaryote. It has been predicted that genomes of this size (600­
800 kbp) contain no more than 500 genes which should encode all the 
compounds necessary for growth and replication (Morowitz, 1967). These include 
enzymes for translation, transcription and protein synthesis, messenger, transfer 
and ribosomal RNA, structural proteins for ribosomes and cell membranes, and 
enzymes for the biosynthesis of cellular components and fuelling reactions. With 
such a small genome, it is likely that ureaplasmas have retained only the essential 
genetic information necessary to perform all these functions. This is indicated by 
their lack of a cell wall, simple ultrastructure and extensive nutritional 
requirement. If all the essential processes can be delineated in these simple free 
living organisms, then progress will be made in understanding the fundamental 
workings of a cell (Razin, 1992).
Information on the cellular reactions operating in U. urealyticum is scarce 
however, and a list of all the various protein functions is far from exhaustive. 
Limited progress has been made in examining each of the predicted functions 
described above and, for many, the economy in genetic material is apparent;.
1.2.3 Transcription, translation and protein synthesis
Since the only sequence data available for U. urealyticum is from the 
urease gene (Blanchard, 1990), knowledge of ureaplasma genetics is limited and 
very fragmented. In the urease operon, a putative promoter upstream from the 
initiation site contains a -35 region and a Pribnow box. Ribosome binding sites are
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located upstream from the g subunit in the urease operon (Blanchard, 1990) and 
ribosomes appear have a typical 30S:50S prokaryotic structure (Ohse and Gobel, 
1987). The basic mechanism of protein synthesis is retained in ureaplasmas but 
there are considerable savings in genetic information. Compared with the seven 
rRNA operons in E. coli, only two copies are found in U. urealyticum. rRNA genes 
are organised in the order 5'-16S-23S-5S-3' (Ohse and Gobel, 1987). There is also a 
saving in the number of tRNA species. For mollicutes in general, up to thirty 
different tRNA genes encoding 29 tRNA species have been identified, which is less 
than h!lf of the 78 tRNA genes found in E. coli (Razin, 1992). tRNAs appear to be 
highly conserved and have G+C values closer to prokaryotic tRNA. In many 
mycopaasmas, including U. urealyticum, the codon UGA codes for tryptophan 
rather than a stop signal (Blanchard, 1990). As with Gram-positive bacteria, 
mycoplasmas carry only one copy of the tufgene encoding the elongation factor 
Ef-Tu (Yogev et al., 1990). Gram-negative bacteria carry two copies of this gene.
Within the DNA replication complex of U. urealyticum, a single copy of 
the DNA polymerase gene, coding for an enzyme lacking 3'-5' exonuclease activity 
(Maurel et al., 1989) and a dnaA gene have been found (Miyata et al, 1992). A 
number of DNAases and RNAases have also been identified, which may have a 
role in DNA repair and restriction of foreign DNA (Romano and La Licata, 1978, 
O'Brien et al, 1983).
1.2.4 Membrane structure
In the absence of a cell wall, structural stability is maintained by the 
plasma membrane, which, like typical biological membranes, is composed mainly 
of proteins (50-60%), lipids (30-40%) and a small amount of carbohydrate 
(Shepard and Masover, 1979). The lipid fraction contains predominantly 
cholesterol and its esters, free fatty acids, glycolipids, phosphatidic acid and 
phosphatidyl ethanolamine (Rottem et al., 1971, Romano et al, 1972). Cholesterol 
is an integral part of the membrane and the acidic lipids may serve to neutralise 
the copious quantities of ammonia produced by urea hydrolysis. Purified 
membranes from several strains of U. urealyticum have been found to contain
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mannose, glucose and galactose (Whitescarver et al, 1975). It is thought that these 
are complexed as membrane-associated lipoglycan, which may constitute the 
capsular material described earlier (Smith, 1985).
Over 30 membrane proteins of U. urealyticum have been identified by 
various methods including [125I] Bolton and Hunter surface-labelling and phase- 
separation of hydrophobic proteins using Triton X-114 detergent, followed by 
SDS-polyacrylamide gel electrophoresis (Thirkell et al, 1989a). A number of these 
are antigenic, as demonstrated by Western Blotting with polyclonal anti-sera raised 
against U. urealyticum and three in particular have been characterised using 
monoclonal antibodies. These are a 17 kDa antigen (17K), a serogroup specific 
16 kDa antigen (16K) and a serotype 8 specific 96 kDa antigen (96K), (Precious 
et al, 1987, Thirkell et al, 1989a). The 1€>K and 17K are located internal to the 
membrane and may perform a structural role (Myles et al, 1991) and the 96K is 
surface exposed having at least four different epitopes, as detected by monoclonal 
antibodies (Thirkell et al, 1990). Binding by these antibodies suppresses growth 
and metabolism of U. urealyticum for six hours, suggesting an important 
metabolic function for the 96K antigen (Precious et al, 1987). In addition to other 
membrane proteins (~25%), the 96K can be labelled with 3h palmitic acid, which 
suggests a degree of acylation (Thirkell et al, 1991). Acylation may serve to anchor 
proteins into the lipid bilayer (Schmidt et al, 1979) and may also be necessary for 
maintaining cellular integrity (Dahl et al, 1983).
The functions of the other membrane proteins are unknown but it is 
presumed that some may act as adhesins (Manchee and Taylor-Robinson, 1969) 
and others may be involved in transport mechanisms. Since ureaplasmas require a 
number of preformed metabolites, efficient transport mechanisms are vital. A 
transport protein that has been characterised in some detail is the ureaplasma 
adenosine tr^p^hio^p)lia^t^ase (FoFi ATPase), first identified by Masover et al, (1977a). 
This integral membrane protein translocates protons into the cell under the 
influence of an electrochemical potential, resulting in concomitant production of 
ATP.
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1.2.5 Biosynthesis and fuelling reactions
It is likely that an FoFi ATPase is the primary source of ATP production for 
ureapaasmas as a large number of enzymes involved in the conventional energy 
generating pathways of glycolysis, tricarboxylic acid cycle (TCA cycle) and the 
electron transport chain are missing in this organism (Fig. 1.3). Low cell yields and 
enzyme instability may have prevented the identification of these metabolic 
pathways, or they may indeed be absent. The use of radiolabelled precursors has 
helped to resolve this problem and to answer the fundamental question of how 
ureaplasmas obtain energy and convert medium constituents into cell mass.
Unlike fermentative mycop^asmas, glucose is not an energy source for 
ureaplasmas (Pollack, 1986) due to the lack of hexokinase and phosphoglucose 
isomerase early in the glycolytic pathway. Other carbon-containing compounds 
may enter glycolysis at the glyceraldehyde 3 phosphate locus from either lipicte 
(via glycerol-3-phosphatase) or from nucleic acids via the non-oxidative enzymes 
of the pentose phosphate shunt. Here pentose phosphates from RNA and DNA 
degradation are converted to fructose-6-phosphate and glyceraldehyde-3- 
phosphate by the action of transketolase and transaldolase enzymes. These 
reactions appear reversible, so that nucleosides and nucleotides can be 
synthesised from glycolytic intermediates by pentose phosphates entering purine 
and pyrimidine salvage pathways. Ureaplasmas therefore have the potential to 
interchange carbon reversibly between lipids and nucleotides (Cocks et al, 1985). 
The contribution of this pathway to energy generation is at present unclear as 
there are no glycolytic enzymes beyond 1,3-bisphosphoglycerate to generate ATP 
from the common intermediate, glyceraldehyde-3-phosphate.
Localisation of enzymes at later stages of glycolysis suggest that pyruvate 
may be a metabolically useful intermediate. However, pyruvate is not converted 
into lactate or ethanol nor does it enter the TCA cycle via acetyl CoA since 
enzymes for these pathways are lacking in ureaplasmas. Davis et al, (1990) 
proposed that pyruvate can enter into a regenerative cycle involving pyruvate 
dehydrogenase, malate synthase, malate dehydrogenase and pyruvate carboxylase
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Fig. 1.3 Carbohydrate catabolism in U. urealyticum
(modified from Miles,[1992] and Pollack, [1992]). Bold arrows indicate reactions 
reported in U. urealyticum, shaded arrows represent those not yet identified in the 
organism. Numbers in superscript refer to the following publications:
2 Cocks et al, 1985
3 Davis et al,, 1990
8 O'Brien et al., 1983
9 PoUack, 1986
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(Fig. 1.3) which results in the overall production of ATP and carbon dioxide from 
one molecule of glyoxylate. The source of carbon (glyoxylate) for this cycle is 
unknown, since a number of enzymes from the glyoxylate cycle are missing in 
ureapaasmas, as are glycine oxidase and glycine dehydrogenase (Alozie et al.} 
1992). The cycle may be biosynthetically useful, since pyruvate may be converted 
to aspartate via aspartate amino transferase and it also may serve to regenerate 
NAD+ necessary for carbohydrate metabolism.
In other mollicuites, it has been proposed that the oxidation of NADH is 
catalysed by a copper or iron containing oxygen-dependant NADH oxidase (NAO) 
(Pollack, 1992). In this reaction, electrons pass directly from NADH to oxygen, 
resulting in the formation of a superoxide radical (O2'). This is subsequently 
converted to H2O2 and finally H2O and O2 via superoxide dismutase (SOD) and 
catalase enzymes, respectively. Known as flavin-terminated respiration, NADH 
oxidation may be responsible for the conversion of reducing equivalents to ATP, 
analogous to electron-transport chain reactions in E. coli. Although SOD and 
catalase enzymes have been identified in U. urealyticum (Meier and Habermehl, 
1990), NAO appears to be absent (Pollack, 1986), which suggests that 
carbohydrate metabolism results in the production of ATP from substrate level 
phosphorylation alone.
It is unlikely, however, that ATP production from substrate level 
phosphorylation in the reactions described so far will be sufficient to sustain life, 
so other energy-generalting systems must operate in U. urealyticum. It has been 
proposed by Romano et al., (1986) that urea hydrolysis within the ureaplasmas 
generates a transmembrane potential which drives protons into the cell via an 
ATPase, thus generating ATP via a chemiosmotic process. Simth et al. (1993), have 
shown that an ammonium ion potential is indeed generated by urea hydrolysis 
and that this can result in de novo ATP synthesis. Furthermore, inhibition of the 
urease by fluorofamide abolishes the chemical potential and ATP synthesis is 
reduced by 95%.
Not only does this proposed mechanism provide an energy source for 
ureaplasmas but it also answers the question of why these organisms have an
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absolute requirement for urea. It had been shown previously that the carbon 
component did not enter biosynthetic pathways but was metabolised completely 
to carbon dioxide (Ford et al, 1970). Urea nitrogen, however, may enter into a 
metabolically useful pathway by the carbamoyl synthetase-catalysed conversion of 
ammonia to carbamoyl phosphate (Fig. 1.4). This in turn combines with ornithine 
in the urea cycle to form citrulline. Detection of three enzymes (argininosuccinate 
synthetase, argininosuccina.se, arginine deaminase), which would complete the 
cycle of citrulline to aspartate, would confirm urea as a potential source of 
nitrogen for biosynthetic reactions, but to date these enzymes have not been 
identified (Smith et al, 1992). The role of urea in this pathway seems secondary to 
its role in energy generating mechanisms.
The urease enzyme is located in the cytosol (Masover et al, 1977a, Myles 
et al., 1991) and catalyses the conversion of urea to ammonia, carbon dioxide and 
water. A number of specific monoclonal antibodies have been raised against the 
enzyme which have been used in immuno-affinity chromatography for purification 
from cell extracts (Thirkell et al, 1989b). The urease enzyme appears to exist as 
two nickel-requiring isoenzymes of approximate molecular weight 200 kDa. 
Denaturation produces three subunit polypeptides; 72 kDa, 14 kDa and 11 kDa, 
which probably form a hexamer in an a2, p2, y2 configuration to give urease 
activity (Thirkell et al, 1989b). Other workers have suggested that the enzyme is a 
dimer, consisting of two 75 kDa subunits (Saada et al, 1990a). The urease gene 
has been cloned and sequenced and contains three open reading frames coding 
for deduced polypeptides of molecular weights 11.2 kDa, 13.6 kDa and 66.6 kDa 
(Blanchard, 1990). These are in close agreement with the subunit molecular 
weights reported by Thirkell et al, (1989b) and support the proposal for a 
hexameric urease structure.
An understanding of the basic properties of U. urealyticum, and in 
particular the urease enzyme, have allowed a number of specific diagnostic 
techniques to be developed for identification of the organism in clinical samples.
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Fig. 1.4 The urea cycle in U. urealyticum
The cycle proposes an anabolic function for urea nitrogen, via the synthesis of 
carbamoyl phosphate to citrulline. In the absence of argininosuccinate synthase 
and argininosuccinate, the fate of citrulline is unclear. Other related enzymes that 
have not been detected in the organism are indicated by shaded arrows. Numbers 
in superscript refer to the following publications:
3 Davis et al., 1990
6 Smith et al., 1992
7 Shepard and Lunceford, 1979
9 Pollack ,
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1.3 IDENTIFICATION OF U. UREALYTICUM IN CLINICAL SAMPLES
1.3.1 Cultivation
Early detection methods for U. urealyticum were based on the 
demonstration of urease activity in cultivation media (Shepard and Masover, 1979). 
Ureaplasmas grown on 'A7' differential agar (later improved to A8 by Shepard, 
1983) appear as deep brown colonies due to the reaction of ammonia with 
manganese sulphate which produces deposits of manganese dioxide. For liquid 
cultures, 'U9' media, containing phenol red (Shepard and Lunceford, 1970) or 
bromothymol blue media (Robertson, 1978), give a visible colour change on 
ammonia production. Although cultivation methods are accepted as a sensitive 
means of ureaplasma identification, in theory detection requires the presence of 
only one cell, they are not selective for different ureaplasma serotypes and for 
diagnostic purposes they are time consuming. Furthermore, an understanding of 
the complex and varied growth requirements of ureaplasmas is often restricted to 
specialised workers in the field and in diagnostic laboratories ureaplasmas are 
generally not screened for routinely. It has therefore been necessary to devise 
rapid and accurate diagnostic techniques which do not require the growth of the 
organism and which may be used by non-specialists. These include methods that 
identify host antibody raised in response to ureaplasma infection (serodiagnosis), 
and those that directly detect ureaplasma proteins or DNA.
1.3.2 Serodiagnosis
There is increasing evidence that ureaplasma infections are associated 
with a good humoral immune response (Krause and Taylor-Robinson, 1992) and 
methods such as Metabolic Inhibition (Purcell et al., 1966), ELISA (Brown et al., 
1983, Wiley and Quinn, 1984) and Immunoperoxidase assays (Quinn and Th'ng, 
1990) have detected patient antibody levels that correlate well with ureaplasma 
cultivations data. For serodiagnosis, ELISA-based methods are particularly useful 
since large numbers of samples can be processed together, the results are easily 
quantifiable and serotype-specific antibody can be detected. The high background
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levels sometimes reported for this technique may be eliminated in future by the 
use of species-specific and serotype-specific proteins, such as the 16K or 96K 
protein described in Section 1.2.4. The ability to clone such proteins and obtain 
them in large quantities may further reduce the cost and improve the sensitivity 
and selectivity of serodiagnostic techniques.
1.3.3 Protein detection
Alternatively, these species-specific and serotype-specific proteins may be 
used to generate monoclonal and polyclonal antisera for the detection of 
U. urealyticum in secretions, tissues and body fluids. Immunofluorescence using 
polyclonal antisera raised against whole organisms has detected ureaplasmas in 
clinical samples (Rudd et al., 1989) and the value of monoclonal antibodies (Mabs) 
for this technique has recently been assessed (Myles, 1990). The species specific 
anti-16 and 17K Mabs and the serotype 8 specific anti-96K Mab detected as low as 
10 ureaplasmas per ml of culture (101 ml*1) but the anti-urease Mab was not 
effective in immunofluorescence, probably because the urease enzyme is not 
surface-expressed. However, this Mab has been utilised in a 'catch test' where it is 
immobilised onto a 96-well plate or a wooden support ('dip stick'). In this form the 
Mab may capture soluble urease enzyme present in a clinical swab or urine. 
Addition of a urease-specific colour developing reagent (Berthalot reagent) leads 
to an easily quantifiable test that by the 96-well plate method has detected as low 
as 102 ureaplasma cells ml-1 (Precious, et al., 1987, Myles, 1990). Such preliminary 
experiments suggest that these two techniques may be of value in clinical 
diagnosis.
1.3.4 DNA detection
Since the identification of a number of ureaplasma genes, diagnostic tests 
based on the detection of ureaplasma DNA in clinical samples have been 
developed. Early work involved the use of DNA probes from ureaplasma rRNA. 
Although these hybridised to mycoplasma DNA, unique and identifiable patterns 
were produced with ureaplasma DNA (Razin et al., 1984). It has also been shown
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that rRNA probes can distinguish between the two seroclusters of U. urealyticum 
(Razin and Yogev, 1986). A probe generated from serotype 8 whole-chromosome 
DNA has been shown to hybridise with .all other serotypes of the organism tested, 
but not with other mycoplasmas or bacteria from the urogenital tract (Roberts 
et al, 1987). In clinical samples containing low ureaplasma cell numbers, 
however, the probe has shown limited sensstivity.
Diagnostic techniques based on DNA hybridisation have recently been 
superseded by the Polymerase Chain Reaction (PCR), which can amplify as low as 
1 ng of DNA using specific primers and a heat stable Taq polymerase. Cloning and 
sequencing of the urease gene has enabled this technique to be developed for 
U. urealyticum and in a preliminary clinical trial, positive identification of the 
organism in urogenital swabs, amniotic fluids and endotracheal aspirates by PCR 
was in good agreement with results obtained from cultivation (Blanchard et al, 
1992) Other workers have used this technique to detect U. urealyticum in arthritic 
joints of a hypogammaglobulinemic patient (Lee et al, 1992).
If PCR-based methods prove to be accurate and cheap diagnostic 
techniques, they may lead to a deeper understanding of the involvement of 
ureaplasmas from the many disease states from which they have been isolated. In 
this respect, establishing the pathogenic potential of U. urealyticum has been an 
area of great interest but of little conclusive evidence.
1.4 PATHOGENESIS OF U. UREALYTICUM
1.4.1 General principles
The isolation of U. urealyticum from men and women displaying a variety 
of genito-urinary infections has led to them being implicated as important human 
pathogens. The presence of the organism in the lower genito-urinary tract of over 
50% of sexually active individuals who show no obvious signs of disease (Cassell 
and Waites, 1984), however, has led to speculation as to the validity of these 
assumptions. In elucidating the role of ureaplasmas in disease, it has therefore 
been important not to equate association with cause and a number of criteria have
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been established which should be met before an etiologic role for U. urealyticum 
in any disease is proposed (Taylor-Robinson, 1983). These criteria apply to all 
mycoplasmas diseases and are described below:
a) Isolation
The organisms should be isolated more frequently and/or in larger 
numbers from patients with disease than from those without. It is critical that 
suitable isolation sites are chosen and that quantitative measurements are made.
b) Serology
Antibody responses should occur in patients with disease, and preferably 
follow the path of the disease. Detection of specific IgM or an increase in IgG titre 
of 4-fold or greater indicates an active infection.
c) Antibiotic treatment
Treatment with effective antibiotics should lead to the concomitant 
disappearance of organisms and symptoms. Interpretation of such studies is not 
always clear-cut as antibiotics are rarely selective for specific organisms.
d) Re-Inoculation
Isolated organisms should be able to reinfect an animal host, produce 
disease similar to that seen in man and be subsequently be recovered. The disease 
process in an animal model, however, may never be identical as that seen in a
human.
It is also critical to select appropriate human controls. The colonisation of 
individuals with ureaplasmas varies according to their age, sex, race, socio­
economic status, smoking habits, the number of sexual partners and the type of 
contraceptives used (Cassell and Waites, 1984). Many of these characteristics are 
predictive for other venereally transmissible organisms such as Chlamydiae and 
group B Streptococci. The presence of these and other microorganisms should 
therefore be taken into account in any assessment of causality (Cassell et al.,
1991).
The majority of studies have associated ureaplasmas with genito-urinary 
tract infections of the male, reproductive tract disorders in the female and a variety 
of diseases in new born infants. In the following section the evidence for these
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asscociations will be reviewed, highlighting where possible to what extent the 
above criteria and conditions have been satisfied.
1.4.2 Non-gonococcal urethritis
U. urealyticum may be responsible for some cases of acute urethral 
syndrome in women (Schiefer and Weidner, 1990) but the evidence for its 
asscocation with Non-Gonococcal Urethritis (NGU, urethritis in the absence of 
N. gonorrhoeae) is largely confined to within the male (Krause and Taylor- 
Robinson, 1992).
NGU may be caused by a variety of microorganisms including Chlamydia 
trachomatis (C. trachomatis), Haemophilus vaginalis, Trichomonas vaginaiis, 
herpes simplex virus, M hominis and U. urealyticum (O'Leary, 1990). Although in 
a large number of cases (40-50%) C. trachomatis appears to be the primary 
pathogen, there is considerable dispute about the relative involvement of the other 
agents in the remainder (Taylor-Robinson, 1983).
Since their original identification in urethral discharge from a patient 
displaying NGU (Shepard, 1954), ureaplasmas have been isolated from 70-80% of 
all cases of NGU and there is substantial evidence to suggest that U. urealyticum 
may be the primary pathogen in some of these cases. In fact, of all of the 
ureaplasma-associated diseases, NGU is the only one in which all of the 
requirements for incriminating a mycoplasma as the causative agent of a disease, 
as outlined above, have been fulfilled. The subject has been reviewed by Taylor- 
Robinson (1985) and the following sections summarise his findings:
a) Isolation
U. urealyticum has been isolated more frequently (qualitative studies) and 
in larger numbers (quantitative studies) from cases of NGU than from healthy 
controls. In one patient with hypogammaglobulinemia, NGU occurred 
intermittently over a period of years, only at times when ureaplasmas were present 
in the urethra and in large numbers (10^-108) (Webster, et al., 1982, Taylor- 
Robinson et al, 1985a). Moreover, no other microorganisms were co-isolated, 
suggesting that U. urealyticum. was the primary pathogen in these instances. It has
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been proposed that ureaplasmas only cause NCU in the absence of C. trachomatis 
but the precise interrelationship between microorganisms in mixed infections of 
the urogenital tract has not been established.
b) Serology
Early serological tests only detected an immune response to 
U. urealyticum in a small number of patients with NCU but in a later study using 
an ELISA with broad serotype cross-reactivity a change in antibody levels was 
detected in over 50% of NCU patients who were culture positive for ureaplasmas 
(Brown et al, 1983). Of these, 80% displayed a change in IgM levels which 
suggested an active infection. A more recent report found an antibody response in 
48% of patients with NCU, 24% of these were colonised with C. trachomatis, 
suggesting that U. urealyticum can induce a response in the presence of this 
organism (Deodhar and Cogate, 1990).
c) Antibiotic treatment
It was first demonstrated by Shepard (1974) that ureaplasma isolation 
followed a clinical course of infection by treating NCU patients with suboptimal 
levels of tetracyclines. Culture positive patients showed signs of recovery 
following initial antibiotic treatment and ureaplasma isolations fell to negligible 
levels. A subsequent relapse and return of symptoms was accompanied by an 
increase in ureaplasma colonisation. Although other workers have reported a 
similar effect with tetracycline, this antibiotic is not ideal for such investigations 
due to Chlamydia-sensitivity and the emergence of tetracycline-resistant strains of 
U. urealyticum. The use of selective antibiotics may therefore provide more 
valuable information.
By using aminocyditols (streptomycin and spectinomycin), which are 
active against ureaplasmas but inactive against Chlamydia, Bowie et al., (1976) 
found that persistent urethritis was associated with persistence of Chlamydia. 
Furthermore, using an antibiotic which is active against Chlamydia but not 
ureapaasmas (sulphonamide) these workers found a significant assoccation 
between persistent urethritis and the re-isolation of ureaplasmas after treatment. In 
trials using rifampicin, which is also effective against Chlamydia but not
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ureapaasmas, 55 out of 68 men continued to be ureaplasma-positive after 
treatment. Of these, 44% did not recover from symptoms of NGU, whereas in the 
group that had become ureaplasma-negative, only 8% were not cured (Coufalik 
et al, 1979). These findings emphasise the importance of both of these organisms 
in urethritis.
d) Re-inoculation
Intraurethral inoculation of two adult male volunteers with U. urealyticum 
that had been isolated from patients with NGU (2 strains of serotype 5) resulted in 
the onset of disease symptoms accompanied by ureaplasma colonisation, both of 
which receded after minocycline treatment (Taylor-Robinson et al., 1977). In 
animal studies, a urethral polymorphonuclear leukocyte response has been 
produced in male goats after intraurethral inoculation of caprine ureaplasmas 
(Taylor-Robinson, 1979) and urethritis has also been observed in male 
chimpanzees following inoculation of unpassaged human ureaplasmas (Taylor- 
Robinson et al, unpublished data cited by Krause and Taylor-Robinson, 1992).
These results provide convincing evidence for a role of ureaplasmas in the 
development of NGU. It is still a matter of controversy as to what proportion of 
cases can be attributed to U. urealyticum, but it has been predicted as 10-30% 
(Cassell and Waites, 1984). The question of why infection is only produced in a 
small proportion of individuals colonised with the organism will be addressed later 
in this section, since it is a question pertinent to all diseases with which 
ureapasmas have been associated.
1.4.3 Complications of NGU
Once the association between ureapasmas and NGU had been 
established, the involvement of ureaplasmas with diseases that can occur in 
conjunction with NGU, such as sexually acquired reactive arthritis (SARA), Reiter's 
syndrome (a triad consisting of urethritis, conjunctivitis and arthritis) and 
inflammation of the prostate (prostatitis), has been examined. Results are difficult 
to interpret in these cases since isolation rates or antibody titres should be elevated 
to levels higher than in patients with uncomplicated NGU before an association is
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suggested. Thus, although ureaplasmas have been isolated from the urethra of 
patients with SARA (Taylor-Robinson, 1985) and Reiter's syndrome (Martin et al., 
1984) they were not at stgI-Lificanily higher 1 eve^ than from control patterns. In 
contrast, specific antibodies to U. urealyticum have been detected in a higher 
proportion of patients with Reiter's syndrome than in patients attending a venereal 
disease clinic for other reasons (Ford and Henderson, 1976), suggesting a role for 
the organism in this syndrome.
In the case of chronic prostatitis, which can occur in over a quarter of 
NGU patients, it has been shown that ureaplasmas colonise the prostate in a 
higher percentage of symptomatic men than in heakhy controls (Weidner et al, 
1980). Brunner et al, (1983a, b) reported that following prostatic massage, high 
titres of U. urealyticum were present in prostatic secretions and urine from 14% of 
men suffering from chronic pr'ostatit^s. After tetracycline treatment, over 80% of 
these men were free of both ureaplasmas and symptoms. As with other antibiotic 
studies, another tetracycline-sensitive organism may have been the causative agent 
and the role of ureaplasmas in this condition remains unclear.
1.4.4 Urinary tract Involvement
The ability of ureaplasmas to ascend the urinary tract to the bladder has 
been demonstrated only infrequently (Birch et al, 1981), but in some of these 
cases the organisms have been associated with the formation of a type of urinary 
tract stone.
Urinary stones composed of struvite and carbonate-apatite account for 
20% of all urinary tract stones and are induced by the breakdown of urea by 
bacterial ureases, such those found in Proteus species. U. urealyticum inoculated 
into artificial urine has been shown to induce crystallisation of struvite and calcium 
phosphates, but at a slower rate than Proteus mirabilis (Takebe et al, 1984). Such 
renal caliculi have also been produced experimentally by the inoculation of 
U. urealyticum into the bladder and renal pelvis of rats (Frielander and Braude, 
1974). Furthermore, U. urealyticum, has been isolated from stones recovered by 
surgery in 6 of 15 humans and in four of these no other urease-producing
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organisms were isolated (Pettersson et al, 1983). As with NCU, it now seems 
generally accepted that ureaplasmas can elicit the production of urinary stones, 
but less frequently than other urease-positive bacteria.
Beyond the bladder, ureaplasmas have produced kidney infections in 
animal models (Kreiger and Kenny, 1986) but have not yet been implicated in 
human pylonephritis.
1.4.5 Infertility
It has been suggested that NCU, and prostatitis in particular, may impair 
male fertility (Taylor-Robinson, 1985), but there is little evidence to demonstrate 
that infertility occurs subsequent to ureaplasma-induced disease. Numerous 
studies, however, have attempted to relate ureaplasma colonisation to infertility in 
men who are apparently otherwise healthy (reviewed by Taylor-Robinson, 1986a).
U. urealyticum has been isolated more frequently from the semen of 
infertile than fertile men (Friberg and Cnarpe, 1974, Cracea et al., 1982, Busolo 
et al, 1984a) and in some of these cases and others an associated decrease in 
sperm quality, numbers and motility has been reported (O'Leary and Frick, 1975, 
Toth et al, 1978, Naessens et al, 1986). These findings are not universal (Taylor- 
Robinson and Furr, 1973, Taylor-Robinson et al, 1985) and it has been argued that 
ureapaasmas are unlikely to interfere with spermatogenesis since they have not 
been isolated from the vas deferens or testis (Taylor-Robinson, 1985).
Scanning electron microscopy (Fowkes et al, 1975) and fluorescent-light 
microscopy (Swensen and O'Leary, 1980) have revealed that ureapaasmas can bind 
to the mid-piece of sperm and thereby decrease motility and encourage multi­
sperm agglutination. Other workers have found no significant change in the 
morphology or motility of sperm after overnight incubation with ureaplasmas but 
have recorded a reduction in penetration of zona-free hamster cells when tested in 
a human-sperm-hamster egg fertilisation test (Busolo and Zanchetta, 1985). In an 
in vitro fertilisation study, it was found that fertilisation parameters were not 
affected by ureaplasma-^infected serum but that there was a reduction in the 
pregnancy rate per embryo transfer in these circumstances (Montagut et al, 1991).
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Neither of these studies clarify the effect of ureaplasmas on sperm functions but 
they do suggest that ureaplasma colonisation of the female may influence 
conception. For this reason, it has been more instructive to consider the effect of 
ureaplasma colonisation within an infertile couple, rather than in the male alone.
Most studies in this area examine either ureaplasma isolation rates from 
infertile couples or the effect of antibiotic treatment on conception success.
Gnarpe and Friberg, (1972) and Cassell et al, (1983a), isolated U. urealyticum 
more frequently from infertile couples than from fertile couples but De Louvois 
et al, (1974) and Gump et al, (1984) could not substantiate these findings. 
Doxycycline treatment produced a significant increase in conception rates in 
couples where the male had become free of ureaplasma colonisation, compared to 
couples where the male remained positive (Toth et al, 1983 and Busolo et al, 
1984b). In contrast, double blind-controlled trials found that while antibiotic 
treatment reduced ureaplasma colonisation, the rate of conception in these 
couples was no higher than in controls (Harrison et al, 1975, Upadhyaya et al, 
1983).
After over fifty studies attempting to elucidate the role of U. urealyticum in 
infertility, it is still only possible to suggest an assodation of the organism with the 
condition, which may only be significant in individuals who are subfertile for other 
reasons (Cassell et al, 1987).
1.4.6 Reproductive tract disease
If the adhesion of ureapasmas to sperm does not affect fertilisation, it 
certainly provides a means of transfer for the organism from the male to the female 
genital tract. In this regard, there is some debate as to whether U. urealyticum can 
cause infection in female genital tract. U. urealyticum has been isolated from 
women suffering from vaginitis, cervicitis, endometritis, salpingitis, oophoritis and 
pelvicperitonitis (pelvic inflammatory disease, PID) but it has also been found in 
the genital tract of 40-60% of women who are apparently asymptomatic (Cassell 
et al, 1987). Although evidence is contradictory, it is generally accepted that while 
ureaplasmas may be involved in PID (Sweet, 1986), they are not major pathogens
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of the lower genital tract and that isolation from inflamed tissue generally 
represents secondary colonisation rather than infection (Cassell et al, 1987). 
During pregnancy, however, up to 90% of women become colonised with 
U. urealyticum and there seems to be an increased susceptibiiity to ureaplasma- 
associated diseases (Cassell, 1986). This is a phenomenon that has been 
demonstrated for other infectious agents (Brabin, 1985), and may be due to 
changes in the local environment of the genital tract, brought about the altered 
metabolic, immunologic and hormonal status of the pregnant mother. In this 
regard, oestradiol treatment of female mice renders them more susceptible to 
ureaplasma colonisation (Furr and Taylor-Robinson, 1989).
In a proportion of pregnant women, ureapkismas colonising the 
endocervix appear to ascend the genital tract to the uterus and placenta (Cassell 
et al, 1991). Intact membranes do not prevent colonisation of the foetus (Cassell 
et al, 1983b, Waites et al, 1989) but colonisation is more common following 
membrane rupture and the onset of labour (CasseH et al, 1991). In addition 
ureapaasmas are frequently transmitted to infants during their passage through the 
birth canal (Klein et al, 1969). It is not always clear whether such colonisation has 
caused disease or whether it has followed disease resulting from another cause. In 
spite of this, there have been a plethora of reports implicating ureaplasmas with 
chorioamnionitis (the inflammation of foetal membranes, chorion and amnion), 
spontaneous abortion, still birth, prematurity, low birth weight, neonatal 
pneumonia and neonatal meningitis. In the following sections the evidence for the 
involvement of ureaplasmas with these adverse outcomes of pregnancy will be 
reviewed.
a) Chorioamnionitis (Histologic chorioamnionitis)
There are many reports where ureaplasmas have been isolated more 
frequently from placentas of patients with chorioamnionitis than from patients 
without but in three in particular the findings are significant since no other 
microorganisms were co-isolated and the studies were carefully controlled to take 
into account the duration of labour and membrane rupture (Kundsin et al., 1984, 
Quinn et al, 1985a, Hillier et al, 1986). Quinn et al, (1987) found that foetal
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antibodies to U, urealyticum were elevated to four-tiimes the maternal levels in 
cases of chorioamnionitis, suggesting an active infection. Further evidence has 
been provided by the examination of intra-amniotic fluid infection. Thus, Cassell 
et al, (1983b) isolated U. urealyticum from the amniotic fluid of two women in 
early gestation, prior to the rupture of foetal membranes. In the absence of any 
other identifiable causes, there was an intense inflammatory reaction 
(chorioamnionitis) followed by premature labour and neonatal death. The 
organism was subsequently isolated in pure culture from a variety foetal organs 
and tissues. Similar results were found by Foulon et al, (1986), which together 
with the work of Cassell and co-workers, impHcates U. urealyticum as a cause of 
chorioamnionitis via an invasive process, and suggests that this condition may lead 
to an adverse pregnancy outcome. A strong assotiation between chorioamnionitis 
caused by any agent and prematurity, congenital pneumonia, perinatal morbidity 
and mortality had been documented by other workers (Naeye, 1975, Russell,
1979).
b) Spontaneous abortion and still birth
Ureaplasma colonisation in the lower genital tract of habitual aborters 
does not differ from that in normal controls (Taylor-Robinson and McCormack, 
1979) but the organism has been isolated from the endometrium of habitual 
aborters (Stray-Pedersen et al, 1978) and from aborted placentas ((Embree et al, 
1980, Quinn et al, 1983a, Kundsin et al, 1984) more frequently than from the 
same site in control groups. At delivery, 49% of infants from women with a history 
of pregnancy wastage had a four-fold or greater elevation in specific antibody titre 
above the maternal levels (Quinn et al, 1983a). A number of workers have also 
shown an increase in normal pregnancies following treatment with doxycycline or 
erythromycin, but the elimination of other microorganisms was not examined and 
the effects therefore may not be specific for U. urealyticum (Quinn et al., 1983b, 
Kundsin and Driscoll, 1970, Toth et al., 1983). Others have found no role for 
ureaplasmas in spontaneous abortion (Harrison, 1986, Romero et al, 1989) and 
their involvement with this syndrome is only suggestive.
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The evidence associating ureaphsmas with still birth is also contradictory. 
One study showed that only 8.3% of still-birth foetal-tissue was colonised with 
ureaplasmas (Madan et al, 1988) but another isolated the organism in 78% of 
placentas from perinatal deaths compared to 32% from healthy births (Quinn 
et al., 1985a). An elevated antibody response to U. urealyticum was found in 45% 
of the former cases and none of the latter. In a later study by the same workers, 
antibody was detected in 73% of still-born foetuses compared to 6.3% of healthy 
controls (Quinn, 1986).
c) Prematurity and Low birth weight
If the foetus survives in utero, there may still be a danger of preterm 
labour, low birth weight and neonatal disease. A strong association exists between 
maternal colonisation with ureapasmas and prematurity, particularly since this 
commonly proceeds chorioamnionitis (Cassell et al, 1986). It has been suggested 
that the cytotoxic effects of inflammation lead to prostaglandin release which 
stimulates labour (McGregor, 1988). In addition, the direct action of ureaplasma 
phospholipases on placental membrane phospholipids may release archidonic 
acid which in turn activates prostaglandin synthesis (De Silva and Quinn, 1991). 
Alternatively, digestion of membrane phospholipids could so weaken membrane 
structure that they rupture under the weight of the amniotic fluid pressure. 
Although all seem plausible, it has not been proved that any of these mechanisms 
occur in vivo.
The involvement of ureaplasmas with prematurity is frequently examined 
in association with the birth of infants weighing less than 2,500 g (low birth 
weight). Embree et al., (1980) and Kundsin et al, (1984) found that placental 
colonisation was inversely related both to gestational age and birth weight and 
Hillier et al, (1986) confirmed that colonisation of this site was associated with 
preterm birth. Rudd et al., (1984) and Izraeli et al, (1991) reported that low birth 
weight and preterm infants were frequently colonised with U. urealyticum in the 
nose and throat and Rudd and colleagues found a specific antibody response to 
the organism in a number of cases. Serological evidence has also been provided 
by Kass et al., (1986), who showed that a four-fold increase in type-specific
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maternal antibody was linked to low birth weight. The same workers had 
previously shown, by a double blind placebo-controlled trial, that erythromycin 
treatment during the third trimester of pregnancy reduced low birth rates from 11% 
to 3% (Kass et al., 1981). The presence of Chlamydia, but no other anaerobes, 
were controlled for in this study. In a review examining twelve other similar 
studies, Romero et al, (1989) reported that there was no firm evidence to support 
an association of ureapaasmas with prematurity or low birth weight and its 
involvement with these syndromes therefore remains suggestive.
1.4.7 Infections of the new born
a) Respiratory tract disease
Low birth weight infants not only tend to show an increased incidence of 
ureaplasma colonisation but they are generally more susceptible to respiratory 
disease (Cassell et al, 1988a). In addition, chorioamnionitis is almost always 
associated with congenital pneumonia (Naeye et al, 1971). It is not surprising, 
therefore, that ureaplasmas have been associated with this syndrome but care must 
be taken to distinguish between respiratory distress caused by pulmonary 
immaturity and that caused directly by ureaplasma colonisation.
Early case studies reported that, in the absence of other microorganisms, 
ureaplasmas were isolated from the lungs of neonates with respiratory disease 
(Romano et al, 1971, Dische et al, 1979, Cassell et al, 1983b). An elevated t^t^ire of 
IgM-specific antibody to U. urealyticum in new-born infants with similar 
respiratory distress suggested that ureaplasma colonisation produced an active 
infection (Quinn et al, 1983c). Such a response was not found by other serological 
studies (Rudd et al, 1986) and a number of prospective cultural studies have also 
failed to show an association (Taylor-Robinson et al, 1984, Rudd et al, 1984,
Rudd and Carrington, 1985). A number of well documented case reports 
(discussed below), have provided definitive evidence that ureaplasmas are 
capable of producing clinical and histologic pneumonia.
It has been demonstrated that U. urealyticum induces ciliostasis and lung 
lesions in human foetal tracheal organ cultures (Dische et al, 1979) and Quinn
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et al, (1985b) reported that such effects may also occur in vivo. Scanning electron 
micrographs of lung sections from a case of fatal intrauterine pneumonia revealed 
that aggregates resembling ureaplasmas were closely associated with areas of the 
trachea completely devoid of cilia (Quinn et al, 1985b). Immunofluorescence 
confirmed the identity of U. urealyticum (serotype 8) in lung lesions and an 
elevated antibody titre to this serotype was also identified in neonatal serum. In 
examinations of new born infants with pneumonia and persistent pulmonary 
hypertension, Waites et al, (1989) found that U. urealyticum was the only 
organism to be isolated from multiple sites within the neonate, both before and 
after death, thus proving a causative role for ureaplasmas in pneumonia.
In addition to acute respiratory distress, U. urealyticum has been 
associated with chronic lung disease (CLD) of preterm infanis, defined as the need 
for increased inspired oxygen at 28 days of age. Sanchez and Regan (1988) and 
Wang et al, (1988) proposed that ureaplasmas contributed to the development of 
CLD and Cassell et al, (1988a) identified a sub-population of pre-term infants 
which seemed particularly susceptible to ureaplasma associated CLD. Thus, very 
low birth weight infants (<1000 g) who were endotracheally colonised with 
U. urealyticum within 24 hours of birth were more likely to develop CLD and die 
than were uninfected infants of similar birth weight or infected infants who 
weighed greater than 1000 g. Age also seemed to be a critical determinant in the 
development and severity of disease and this finding has been reproduced in 
animal studies by Rudd et al, (1989); when ureaplasma isolates from cases of CLD 
were inoculated into new born mice a histologic pneumonitis ensued, but only in 
mice younger than 14 days. Furthermore, exposure of new-born mice to 80% 
oxygen resulted in more severe lung lesions, organism persistence and death 
(Crouse et al, 1990). Increased oxygen requirements of very low birth weight 
human neonates may predispose them also to ureaplasma respiratory infections or 
alternatively ureaplasma infection may potentiate oxygen-induced injury (Cassell 
et al, 1988a). U. urealyticum is unlikely to be the primary cause of CLD but its 
contribution to the severity of this syndrome may be substantial.
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b) Systemic infections
In a minority of new born infants, ureapasmas are not confined to the 
respiratory tract but can migrate into blood or cerebro-spinal fluid. Waites et al., 
(1989) and Brus et al, (1991) have reported cases of neonatal pneumonia 
accompanied by septicaemia. In a prospective study of pre-term neonates with 
meningitis, Waites et al, (1988) found that U. urealyticum and M. bomwfswere 
the most commonly isolated organisms from the cerebrospinal fluid (CSF).
U. urealyticum has only once been identified as the cause of meningitis (Garland 
and Murton, 1987) and many workers have not been able to isolate the organism 
from the CSF of neonates with this disease (Taylor-Robinson and McCormack, 
1979, Mardh, 1983, Likitnukul et al, 1987). Others dispute any etiologic role for 
ureaphsmas in meningitis (Shaw et al, 1989).
An unpublished study by Cox et al. (cited by CasseH et al, 1S91), reported 
that pure cultures of U. urealyticum isolated from the CSF of human infants 
induced meningitis and hydrocephalus in new born mice and beagles, indicating 
that this organism does have the potential to cause such diseases. Although the 
precise involvement of ureaplasmas in human CSF infections has not been 
established, clinicians have been advised to test for U. urealyticum and 
M. homins in pre-term infants with symptoms of meningitis or progressive 
hydrocephalus (Waites et al, 1990).
Following labour and delivery, U. urealyticum may also gain access to the 
blood of the mother and in some cases isolation has been associated with post­
partum fever or septicaemia (Cassell and Cole, 1981). Such patients rarely have 
severe disease symptoms and frequently recover without antibiotic therapy (Risi 
and Sanders, 1989).
1.4.8 Extragenital infections
Ureaplasmas have been isolated in pure culture from septic arthritic joints 
in a number of hypergammaglobulinaemic individuals (Cole et al, 1985). Since 
reinfection of chimpanzees with one of these isolates produces a severe arthritis 
(Barile et al, 1990), it has been proposed that U. urealyticum is the principle
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pathogenic agent in these cases. The organism does not appear to be responsible 
for disease in immunosuppressive patients and there is no evidence that 
ureapkismas are associated with AIDS (Krause and Taylor-Robinson, 1992).
1.4.9 Conclusions
U. urealyticum can no longer be considered as a harmless commensal of 
the lower genito-urinary tract and there is much evidence to suggest that it causes 
a number of human diseases. Firm proof for most of these conditions has been 
difficult to obtain, mainly because ureaplasmas are found so frequently as 
apparently harmless members of the normal human flora. It has been proposed 
that the organism only elicits disease in a sub-population of individuals and it is for 
this reason that there has been difficulty in proving causal relationships by 
prospective studies. The predisposing factors that are operating in these sub­
populations have not been delineated, but some host -related and pathogen- . 
related properties have been suggested that may be relevant to the onset of 
disease in these individuals.
As far as the host is concerned, immunodeficient individuals are 
particularly susceptible to ureaplasma-associated diseases. This is emphasised by 
studies on hypogammaglobulinemie patients, which have provided the strongest 
evidence for the pathogenic capabilities of U. urealyticum (Webster et al, 1982, 
Taylor-Robinson et al, 1985b). Similarly, the gestational age-related susceptibilities 
of human neonates and mice may be due to a poorly developed immune system 
(Rudd et al, 1989). It has been suggested that in these cases there is insufficient 
neutrophil and macrophage function, particularly since neonatal rabbit pulmonary 
macrophages have demonstrated a decreased rate of bacterial killing (Sherman 
et al., 1982). In apparently immunologically competent hosts, there may be subtle 
differences in immune status that render some individuals more susceptible to 
ureaplasma infection than others.
Alternatively, the predisposing factors operating in these individuals may 
be pathogen-related. Taylor-Robinson (1986b) has proposed that ureaplasmas 
only cause disease when present in large numbers. In the case of the
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hypogammaglobulinemie patient, it was clearly demonstrated that urethritis was 
related to the levels of ureaplasma colonisation. Such an assoccation had been 
observed in other cases of NGU (Bowie et al., 1976, Weidner et al, 1980), but 
there are equally many reports which find no difference in ureaplasma numbers 
recovered from diseased and healthy men (Taylor-Robinson, 1985). It is a well- 
recognised phenomenon, however, that harmless members of the microbiological 
flora can cause disease if they are allowed to multiply excessively. For Candida 
albicans and Clostridium difficile, disease induced by increased levels of 
colonisation has been linked to excessive or prolonged use of broad-spectrum 
antibiotics (O'Leary, 1990). The conditions which might favour excessive 
ureaplasma growth have not yet been identified.
It has also been suggested that some serotypes of U. urealyticum are more 
pathogenic than others and that in healthy men the non-pathogenic serotypes 
prevail (Taylor-Robinson, 1983). There have been numerous attempts to determine 
whether certain serotypes are associated with disease states more than others, 
either by isolation studies or by comparing the pathogenic potential of different 
serotypes in animal and tissue culture systems.
Shepard (1974) reported that serotype 4 was recovered twice as frequently 
in men with NGU than from men who were symptom-free. Serotype 4 was also 
more effective than others in preventing sperm entry into hamster eggs in the in 
vitro fertilisation tests described earlier (Busolo and Zanchetta, 1984). When 
examining pregnancy complications, Naessens et al., (1990) isolated serotype 4 
more regularly from patients with a history of recurrent miscarriages than from 
normal pregnant women, and Quinn et al., (1983a), found that serotypes 4, 7 and 
8 were frequently associated with cases of spontaneous abortion. In trying to 
assess whether different serotypes produced different pathologies, Rudd et al, 
(1989) demonstrated that lung lesions following intranasal inoculation were more 
severe with serotype 10 than serotype 1, but the experiments were performed at 
different times so could not be compared directly. Another murine study suggested 
that clinical isolates of U. urealyticum varied in their ability to persist in kidneys 
(Fodor, 1980), but the serotypes involved in this study were not identified. In
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contrast, Zheng et al, (1992) found that invasiveness was not restricted to a limited 
number of serotypes and that representatives of each gene cluster (serotypes, 1,3, 
6, 8 and 10) were isolated from the CSF of thirteen infected infants.
There are numerous studies that have failed to relate any particular 
serotype of U. urealyticum to disease. These include examinations of female 
sterility (Cracea et al, 1984), spontaneous abortion (Robertson et al, 1986) and 
upper urinary tract disease (Hewish et al, 1986). Taking all these reports into 
consideration, it has not yet been convincingly demonstrated that ureaplasma 
serotypes differ with respect to their pathogenicity.
There may well be differences in virulence between ureaplasma strains, 
but the properties that have been used to serotype the strains may not bear any 
relationship to the properties which determine their pathogenicity. If there are 
indeed differences between pathogenic and harmless strains of ureapasmas, some 
other characteristics need to be identified which more reliably define these 
differences.
In summary, the colonisation of asymptomatic individuals with 
ureaplasmas does not rule out the possibility that these organisms can induce 
disease but suggests that this occurs only under certain circumstances. The precise 
circumstances have not been clearly elucidated but will depend on a number of 
interacting factors including the immune status of the host, the site and extent of 
ureaplasma colonisation, the presence of other microorganisms at this site and the 
pathogenicity of the ureaplasma strains involved.
It is now of value to examine the properties of U. urealyticum that could 
render it pathogenic as, once defined, these may serve as a more useful basis for 
classification than serotyping. Furthermore, an understanding of the pathogenic 
mechanisms operating in this organism may improve the therapy and 
prophylaxis of ureaplasma-induced disease.
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1.5 VIRULENCE PROPERTIES OF U. UREALYTICUM
To establish that a particular property is important in virulence, it is 
necessary to demonstrate that selective attenuation of th^s property renders a 
virulent microorganism avirulent on subsequent reinfection of the host (Smith, 
1984a). This is difficult to achieve for any microorganism since virulence is 
multifactorial and the pathogenic effect of a single factor can rarely be examined in 
isolation. For ureaplasmas there are additional problems. Avirulent and vimlent 
strains have not yet been defined, genetic manipulation of the organism has not 
advanced to the stage where a particular property can be selectively attenuated 
and suitable animal models for pathogenicity studies have not been fully 
developed or evaluated. An understanding of the mechanisms of ureaplasma 
pathogenicity is therefore only in its infancy, but a number of biological properties 
have been identified which may prove to be important in determining the 
virulence of this organism.
These properties can be artificially divided into two categories, those that 
cause damage to the host and those which interfere with innate and acquired host
defence mechanisms.
1.5.1 Damage to the host
A number of classical extracellular parasites, such as Vibrio cbolerae and 
Corynebacteium diphtheriae, produce toxins whose apparent function is to cause 
damage to the host (Mims, 1987). Likewise, Mycoplasma neurolyticum and 
Mycoplasma gallteepticum release potent neurotropic toxins that have been 
associated with diseases of the brain and nervous system (Gabridge et al, 1985). 
Other than an uncharacterised metabolite that inhibits their prolonged growth in 
vitro (Furness, 1973), no such toxin has been detected in ureaplasmas. It is more 
likely that ureaplasmas have a deleterious effect on their host simply as a result of 
their stringent metabolic requirements. Thus, metabolic enzymes may interact 
directly with host tissues or may exert an indirect effect by either depleting 
nutrients or releasing toxic waste products.
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a) Ureaplasma toxins
In the absence of an electron transport chain, it is likely that a number of 
reactive oxygen species are produced during ureaplasma metabolism which may 
be cytotoxic to the host. In other mycopasmas, hydrogen peroxide (H2O2) and 
superoxide anion-production has been well documented and for M. pneumoniae, 
high concentrations of H2O2 may be responsible for the lipid peroxidation of 
membranes observed in vitro (Cohen and Somerson, 1967). The ability of this 
mycopasma to inhibit host cell catalase, possibly via the action of a superoxide 
radical, may further exacerbate the damage (Almagor et al, 1984).
In ureaplasmas, H2O2 production and its impact on the pathogenesis of 
the organism has not been clearly established. Ureaplasma-mduced cell lysis is 
inhibited by catalase, which suggests that H2O2 may be the haemolysin (Manchee 
and Taylor-Robinson, 1970). Although Bauman (1989) has failed to detect H2O2 
production by U. urealyticum, Meier and Habermehl (1990) have reported both 
superoxide and H2O2 production in two isolates of this species. Furthermore, 
these workers identified superoxide dismutase (SOD) activity, which catalyses the 
recombination of superoxide anions to H2O2 and O2. By this mechanism, 
ureaplasmas may protect themselves from the harmful effects of the superoxide 
anion and its reaction products.
By virtue of its urealytic activity, U. urealyticum has the potential to 
generate large quantities of ammonium ions from urea. This induces a detectable 
cytopathology in a variety of established cell lines (Cassell and Cole, 1981) and it 
has recently been reported that mice intravenously injected with ammonium ions 
(200 JLtM), died within five minutes (Ligon and Kenny, 1991). Furthermore, 
intravenous injection of ureaplasmas produced the same lethal response but 
concomitant intraperitoneal injection of fluorofamide, a potent urease inhibitor, 
provided protection. This not only demonstrated the harmful effects of high 
concentrations of ammonium ions in vivo but confirmed that, in a mouse model, 
U. urealyticum can induce the same effect via the action of its urease enzyme.
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b) interfering with host metabolism
The requirement of U. urealyticum for pre-formed purines and 
pyrimidines and the demonstration of RNA and DNA endonudeases activity in this 
organism suggests that ureaplasma infection may serve to reduce the pool of 
nucleotides available to the host. Although this has not been examined directly, 
mycoplasma infection of mammalian cells in tissue culture has been shown to alter 
host cell metabolism (Russell, 1966) and may induce chromosomal aberrations 
(Paton et al, 1965). In the case of M. pneumoniae, damage to mycopaasma- 
infected hamster tracheal explants has been alleviated by incorporating adenine 
into the culture medium (Hu et al., 1975).
Phospholipase enzymes may also cause damage to the host by degrading 
phospholipids in closely associated epithelial cell membranes. Phospholipase A 
and C have been located in the plasma membrane of three serotypes (3, 4, and 8) 
of U. urealyticum (De Silva and Quinn, 1991). The association of U. urealyticum 
with spontaneous abortion, stillbirth and prematurity has been linked to the 
impact of phospholipases on placental membranes, as discussed in Section 1.4.6. 
Likewise, the susceptibility of neonatal lungs to ureaplasma infections may be due 
to the combined effect of phospholipase activity and the depletion of sterols, 
resulting in decreased surfactant levels (Rudd et al, 1989). Ureaplasma 
phospholipases require further characterisation before their role in ureaplasma 
metabolism and virulence is established.
When considering the above virulence properties, it seems likely that 
ureaplasma damage to the host occurs primarily as an undesirable side effect of 
their limited metabolic reactions. This is consistent with the proposal that it its not 
in the interests of a parasitic microorganism to cause damage to the host, since this 
may limit its chance of survival. In order to ensure colonisation and transmission,
U. urealyticum must also be able to resist or modulate the innate and specific 
defence presented by the host.
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1.5.2 Evading host defence mechanisms
a) Adhesion
U. urealyticum has a predilection for the urogenital tract and is transferred 
directly onto new mucosal surfaces by sexual contact. By this route, the organism 
avoids contact with the external environment and can gain access to the host via 
the mucosal epithelia rather than via the relatively impenetrable barrier of the skin. 
The urogenital tract, however, is maintained at a low pH and is continually flushed 
and cleansed by urine and mucocilliary action which serve to prevent the 
colonisation of invading microorganisms. The normally inhibitory acidic 
environment of the urogenital tract is favourable to the growth of ureaplasmas and 
the abundant supply of urea may in fact dictate the tissue specificity of this 
organism. To avoid expulsion, the organism may bind to mucosal epithelia, a 
property that has been demonstrated by a number of w^rke^s.
In urethral scrapings and semen samples, a close association between 
U. urealyticum and host epithelial cells has been reported by Shepard (1957) and 
Busolo et al, (1984a). In vitro, a number of ureaplasma serotypes adsorb a 
number of tissue-culture cell lines (Kotani and McGarrity, 1986) and a degree of 
binding to bovine fallopian tube mucosa cell cultures has recently been 
demonstrated (Saada et al, 1990b). Using erythrocytes, which allow adhesion to 
be monitored eassly but may not adequately represent mucosal epithelia,
U. urealyticum colonies bind guinea pig red blood cells (Robertson and 
Sherburne, 1991). Saada et al, (1991) have confirmed this property with human 
red blood cells and suggest that ureaplasma adhesins are protein in nature while 
erythrocyte binding sites appear to be sialyl and or sulphated compounds.
In this respect, adherence mechanisms in ureaplasmas may be analogous 
to those operating in M. pneumoniae. Here, a major adhesin (protein Pl), present 
on a specialised attachment tip organelle, acts in concert with a number of other 
adhesins, accessory membrane proteins and cytoskeletal elements to bind to host 
surface glycoproteins (Razin and Jacobs, 1992). Adherence appears to be a 
prerequisite to infection in this organism, since reduced cytadsorbance has been
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asscxciated with loss of virulence (Razin, 1978). This may not be the case for 
ureapasmas, as trypsin preireaimeni of U. urealyticum improved their infectivity 
towards fibroblast cultures (Masover et al, 1977b). However, the effect of trypsin 
on ureaplasma membranes was not examined in this study, which serves to 
emphasise that the precise adhesion mechanisms of ureaplasmas requires 
delineation.
Adherence not only prevents their removal but creates a close association 
between ureaplasmas and their hosts. While this may be nutritionally favourable 
for microorganism, the damage induced as result of its metabolic reactions 
(Section 1.5.1) may be enhanced. Thus, metabolic enzymes are held in close 
proximity to epithelial membranes and in the microenvironment created between 
host and parasite, the harmful effects of nutrient depletion and waste product 
accumulattion may be amplified. The cytopathic effects of M.pneumomae, for 
example, have been attributed to H2O2 production in conjunction with its 
adhesion properties. When the mycoplasma adheres to the host, high 
concentrations of H2O2 appear to act over short distances, causing cumulative 
damage to epithelial cell membranes (Almagor et al, 1983).
For a number of pathogens, adherence is a preliminary to traversing 
epithelial membranes to the nutritionally rich environment of the host cell (Finlay 
and Falkow, 1989). Here they are removed from competing microorganisms and 
from specific host defence mechanisms. Electron micrographs have shown 
ureaplasmas within bovine fallopian tube cultures (Kahane and Adoni, 1990) and 
it has recently been proposed that M. genitalium and M. penetrans can enter 
human lung fibrobasts and various tissue culture cells, respectively (Baseman, 
1992, Lo et al, 1992). It is not clear whether ureaplasmas and mycopasmas 
survive and replicate within these cells and, until this is demonstrated, they are not 
considered as intracellular pathogens. The organisms therefore remain vulnerable 
to phagocytosis and the induction of a specific immune responses. Alternative 
tactics may therefore operate to evade such host defences.
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b) Resisting phagocytosis
Ureaplasmas possess an external capsule which is lipoglycan in nature, 
consisting of polysaccharides covalently attached lipids (Smith, 1985). There are 
serotype difffe^:r^r^c^G^s in capsule composition which may relate to antigenic 
variations observed between serotypes, but its function in the organism is 
presently unclear and can only be predicted from examining similar structures in 
other organisms.
Lipoglycans are found on the surface of some acholepasmas, 
anaeroplasmas, and mycopasmas and may provide a stabilising function in the 
absence of a cell wall or alternatively may be involved in adhesion mechanisms. 
They do not necessarily correlate with pathogenicity but are immunogenic, 
eliciting the production of mainly IgM antibodies (Smith, 1984b, 1987). Pathogens 
such as Haemophilus influenzae and Neisseria meningitids have similar capsules 
which may serve to resist phagocyte mobilisation and stimulation (Finlay and 
Falkow, 1989). Although the capsule in ureaplasmas is different from the 
lipopolysaccharide found in piliated E. coli (LPS) it may provide a similar 
protective function, such as by preventing surface deposition of complement and 
thereby resisting phagocytosis. It has also been suggested that capsules may mask 
membrane proteins which may otherwise be antigenic (Joiner, 1988). In this 
respect, the pleomorphic nature of ureaplasmas allows them close contact with 
host membranes, which may also provide shielding of antigenic determinants from 
the immune system (Robertson, 1986). A number of other mechanisms may also 
operate in U. urealyticum to prevent the generation of a spe<^i^ic immune 
response, as discussed below.
c) Shielding antigenic determinants
For some microorganisms, virulence determinants are poor antigens, 
resulting in minimal induction of specific neutralising antibody. The epitopes 
responsible for adhesion on the Pl adhesin protein of M. pneumoniae;, for 
example, have demonstrated poor antigenic properties (Razin and Jacobs, 1992). 
Information on the antigenicity of U. urealyticum functional proteins is limited, but 
a number may achieve the same effect by mimicking host structures. The
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identification of epitopes on the urease enzyme that cross react with the HLA B27 
antigen suggests one possible mechanism for avoiding an immune response. In 
this case, however, it has been suggested that the opposite occurs and that 
antibodies raised against U. urealyticum may cross react with the host and induce 
an auto-immune disease, such as Reiter's syndrome (Davis et al, 1992). Similar 
molecular mimicry has also been reported in M. pneumoniae (Mims, 1987).
When proteins are antigenic, a secondary immune response may be 
avoided by continual alteration of antigenic epitopes, known as antigenic drift. In 
U. urealyticum (serotypes 3, 8 and 10), a number of predominant antigens have 
been detected that undergo a high rate of structural variation in vitro (Watson 
et al, 1990a). These are among the major antigens recognised during human 
infections and invasive isolates demonstrate structural variability, suggesting 
antigenic drift is also operating in vivo. By using monoclonal antibodies, common 
epitopes have been identified between these antigens and each produces a 
characteristic multiple banding pattern on SDS-PAGE, hence the name 'multiple 
banding' antigen, 'MB' antigen.
A potential role for the MB antigen in ureaplasma virulence is evident 
when parallels are drawn with the VI antigen of M. pulmonis (Watson et al, 
1990b). Also a 'multiple banding' protein, VI is the major antigen recognised in the 
natural infection of mice with M. pulmonis. It undergoes a high rate of antigenic 
variation both in vitro and in vivo and in some cases structural alterations within 
VI are the only differences between virulent and avirulent strains of M. pulmonte. 
The precise subunit composition of VI, the mechanism of antigenic variation and 
the relevance of the MB antigen in U. urealyticum awaits further investigation,
d) Interference with the immune response
If an immune response is elicited against U. urealyticum, the organism has 
the ability to cleave and inactivate the principle immunoglobulin at mucosal 
surfaces, IgA. This is mediated by an IgAl protease, an enzyme that specifically 
cleaves human IgAl to yield intact Fca and Faba fragments. IgAl proteases have 
not been identified in any other species of Mollicute, but they are elaborated by a 
number of other pathogenic bacteria that colonise mucosal epithelia.
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As the topic of this thesis, the properties of the IgAl protease isolated from 
U. urealyticum will be discussed in a separate section, Section C. To introduce this 
area, Section B will concentrate on the function of IgA and the properties and 
significance of bacterial IgAl proteases.
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SECTION B
PROPERTIES OF IGAI PROTEASES
1.6 THE IGA SYSTEM
The structure and function of IgA has recently been reviewed by Kilian 
et al, (1988), Childers et al, (1989) and Kerr (1990).
1.6.1 IgA structure
IgA has a typical immunoglobulin structure, consisting of two heavy 
chains (a) and two light chains (k or 1), bound by disulphide bonds to create a 'Y- 
shaped' molecule. The heavy chains consists of two 'Fc' constant domains (Ch3 
and Ch2) linked to third 'Fab' constant domain (ChI) via a flexible hinge region. 
The heavy and light chain variable domains (Vh and Vl, respectively) together 
form the specific antigen-binding sites of IgA (Fig. 1.5). By varying the distances 
between these two sites, the hinge region controls the efficiency of antigen­
binding and cross-linking reactions.
IgA is divided into two isotypes (or subclasses) known as IgAl and IgA2. 
These differ in levels of a chain glycosylation and amino acid sequence, 
particularly in the hinge region which is extended in IgAl (Fig. 1.5) but in IgA2 a 
stretch of thirteen amino acids is lacking. Genetic polymorphism is restricted to the 
IgA2 subclass, where the two allotypes are designated IgA2m(l) and IgA2m(2)
(Fig. 1.2a and b). In IgA2m(2), the two light chains are disulphide-bound to each 
other and are only non-covalently associated with heavy chains. IgA2m(l) appears 
to be a hybrid molecule between IgAl and IgA2m(2) as its Ch3 domain is identical 
to that found in IgAl and, apart from four allotypic determinants, its ChI and Ch2 
domains are identical to those found in IgA2m(2). It is thought that IgA isotypes 
and allotypes have evolved by a series Homologous crossover and point 
mutational events (Tsuzukida et al, 1979) and an examination of ancestral a chain 
genes suggests that IgA2 may have evolved prior to IgAl (Kawamura et al, 1990).
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a) IgA2m(l) b) lgA2m(2)
c) IgAl
d) Secretory IgAl
Fig 1.5 Theoretical structural models of monomeric LgA2m(l), LgA2m(2), IgAl 
and secretory I^l. (Modified from Kerr [1990]).
The models are based on the known structure of IgG. IgA consists of two heavy 
and two light chains associated by disulphide bonds to create a 'Y' shaped 
molecule. Each heavy chain is composed of three constant domains (ChI, Ch2, 
Ch3) and one variable domain (Vh) which together with light chain variable 
domains (Vh) form the antigen binding site. In IgA2m(l), the terminal cysteine 
residues of each light chain constant domain (Cl) are disulphide-bound to each 
other rather than the ChI domain, as in IgAl and IgA2m(2). An extended hinge 
region separates ChI and Ch 2 domains in IgAl. In secretory IgA, two heavy chains 
are linked by the J chain and the dimer is enveloped by a heavily glycosylated 
secretory component.
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These different isotypes of IgA are found in varying proportions in the 
numerous body fluids from which IgA has been isolated.
In serum, where IgA represents 20% of the total immunoglobulin present, 
IgAl is the predominant isotype. It is produced in the bone marrow and exists 
mainly as monomers. In secretions, however, IgA constitutes the major 
immunoglobulin and 65%-90% of molecules are found in polymeric form, mainly 
dimeric. Up to 60% of secretory IgA can consist of IgA2, although the relative 
proportions of IgA isotypes appear to vary between secretory sites. In the distal 
gut, mammary, and salivary glands, the relative levels of IgA2 production are 
higher than in the spleen, peripheral lymph nodes and upper respiratory tract 
where IgAl-producing plasma cells predominate (Kett et al, 1986, Brandtzaeg, 
1992).
Following synthesis, IgA is released from plasma cells primarily as dimers, 
the Fc portion of a chains being linked by a cysteine-rich polypeptide, the J chain. 
To reach the mucosal surface, the dimers bind to a glycosylated immunoglobulin 
receptor on epithelial membranes. The receptor: IgA complex is internalised and 
transported through epithelial cells so that upon release IgA becomes enveloped 
by the now covalently associated 'secretory component' (SC).
The differences in cellular origin, subclass distribution and molecular form 
between secretory and serum IgA reflect the distinct functions that IgA is required 
to perform in the secretory and systemic immune systems.
1.6.2 IgA function
a) Secretory IgA
In the secretory compartment, the primary role of IgA is to prevent 
damage and systemic invasion by the large numbers of colonising microorganisms. 
For this function, S-IgA seems ideally suited. As a polymeric molecule, it has a high 
antigen binding potential and its asstodation with the se<^jr<^t^<o;ry component 
provides molecular stability and protection in the proteolytic-rich environment of 
mucosal epithelia. In addition, the highly glycosylated secretory component may 
confer particular properties beneficial to defence at secretory sites.
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The means by which S-IgA provides protection are numerous but may 
include the prevention of epithelial attachment, antigen exclusion, neutralisation 
of Harmful enzymes or toxins, microbial opsonisation for phagocyte uptake and 
cell-mediated killing. Since the levels of complement, phagocytic and cytotoxic 
cells are relatively low in the secretory mucosa, compared with the High microbial 
challenge, it has been proposed that S-IgA is not primarily involved with 
opsonisation and Fc-mediated cytotoxicity at this site (Childers et al, 1989). It is 
more likely that S-IgA serves as an inhibitor of microbial adhesion, thereby 
allowing disposal of microorganisms by non-specific defence mechanisms such as 
cilliary-beating and mucous flow.
Microbial adhesion to mucosal epithelia may be via the specific 
recognition of Host receptors by complementary adHesin molecules or via less- 
specific Hydrophobic interactions occurring between microbial and Host surfaces. 
Using host mucosal epithelial cells or salivary-coated Hydroxyapatite (simulating 
dental enamel), it has been demonstrated that S-IgA can interfere with both of 
these processes (Kilian et al, 1988). It is thought that the ability of S-IgA to 
interfere with hydrophobic interactions is mediated by the highly glycosylated 
secretory component, since serum IgA does not have such an effect (HajisHengallis 
et al, 1992). This is supported by the fact that S-IgA Faba fragments, while 
retaining tHeir antigen binding potential, lose their ability to inhibit the binding of 
oral streptococci to saliva-coated Hydroxyapatite (Reinhoidt and Kilian, 1987). 
S-IgA may also act by increasing microbial agglutination, thereby reducing 
adhesion and encouraging disposal by innate defence mechanisms (Childers et al, 
1989).
b) Serum IgA
In the submucosa and systemic compartment, where, in contrast to the 
secretory compartment, microbial challenge is relatively light, it is likely that the 
role of IgA is to kill invading microorganisms via indirect Fc effector functions. For 
this, assoccation with a secretory component and multivalency are not so critical. 
The interaction of IgA with Humoral defence mechanisms, however, Has been the 
subject of much controversy. For many years, it was assumed that IgA served only
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to regulate the effects of IgG and IgM in complement activation and cdl-mediated 
immunity, thereby reducing potentially harmful inflammatory side-effects of these 
reactions. It has recently become apparent that IgA may in fact perform a more 
active role in systemic host defence mechanisms than had previously been 
anticipated.
Although it is well documented that IgA can reduce IgM and IgG-mediated 
complement activation of the classical pathway, aggregates of IgA have also been 
shown to activate the alternative and, on occasion, the classical complement 
pathways (Kerr, 1990). These contradictions in function may be explained by the 
work of Jarvis and Griffiss, (1991) who demonstrated that the action of IgAl was 
dependent upon the nature of the bound antigen. When specific for certain outer 
membrane proteins, IgAl-initiated complement-mediated lysis of Neisseria 
meningitidis, CN. muingittdiss but when bound to polysaccharide capsules, IgAl 
appeared to block IgG-induced complement-mediated lysis. The likelihood and 
significance of these factors operating in vivo is not clear.
As far as IgA-dependent cell-mediated effector functions are concerned, 
receptors for IgA (FcaR) have been detected on polymorphonuclearleucocytes 
(PMN), monocytes, macrophages and lymphocytes. As mentioned above, early 
workers• suggested that IgA inhibits the phagocytic, bactericidal and chemotactic 
effect of PMN at inflammatory sites (Kilian et at., 1988) but more recent studies 
have demonstrated that IgA has opsoninic activity and can induce phagocytosis by 
neutrophils and macrophages (Kerr, 1990). Although the structure and function of 
the lymphocyte FcaR is not known, IgA-mediated ADCC (antibody-dependent 
cell-mediated cytotoxicity) by human T lymphocytes has been well documented 
(Childers et al, 1989).
1.6.3 IgA degrading enzymes
A variety of human pathogens secrete proteases that digest IgA. A number 
have broad specificity, cleaving both IgA isotypes, IgG and other non­
immunoglobulin proteins (Table 1.1C). The best characterised of these are the 
enzymes from Serratia marcescens (5. marcescens), Candida albicans
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Table 1.1 IgA protease-producing bacteria
A. Classical IgAl proteases
Disease Species %
+ve
Reference
Meningitis 5. pneumoniae >99 Male, 1979, Mulks et al., 1980b
N. meningitids >99 Plaut et al., 1975, Mulks et al., 1978
H. influenzae >95 Male, 1979, Kilian et al., 1983a
Gonorrhoea N. gonorrhoeae >99 Plaut et al, 1975, Mulks et al, 1978
Urethritis U. urealyticum >99 Robertson et al, 1984
Conjunctivitis H. aegyptius 100 Kilian et al, 1979, Kilian et al,
1983a
Initial S. sanguis 100 Plaut et al, 1974b,
formation of S. oralis 100 ' Remholdt et al, 1990
dental plaque S. mitis biovar 1 >20 Remholdt et al, 1990
Destructive B. melaninogenicus -85 Kilian, 1981
periodontal B. loeschii Kilian et al, 1983a
disease B. oris
B. denticola
B. buccae
B. capillus
B. buccalis
B. oralis
B. verorals
B. pentosaceus
ii it
ii ii
ii ii
Frandsen et al, 1987
ii ii
ii ii
ii ii
ii ii
Miscellaneous H. parainfluenzae
H. parahaemolyticus 
G. haemolysans 
Bifidobacterium (sp. 
undefined^
Veillonella sp.
Male, 1979
Mulks et al, 1980, Male, 1979
Kilian et «/., 1983a
Fujiyama et al, 1985
Frandsen et al., 1986
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B. lgA2/lgA2m(l) proteases
Disease Species %
+ve
Reference
Inflammatory 
bowel disease
Clostridium
ramostm
C. septicum.
C. tertium
C. sporogenes
Kobayashi et al, 1987a
Hashim and Hassan, 1991
It ii
ii ii
ii ii
C. BroaS seesificitylgA proteases
Disease Species %
+ve
Reference
Urinary tract P. mirabilis 100 Senior et at, 1988
infection P. penneri 100 ii ii
P. vulgaris <10 ii ii
Destructive B. gingivalis <50 Kilian et al, 1983
periodontal B. intermedius 100 Kilian, 1981
disease B. asaccharolyticus Kilian, 1981
Miscellaneous P. aeruginosa
C. albicans
S. marcescens
Doring et al, 1984
Ruchel et al, 1982
MoUa ef al, 1986, 1988
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(C. albicanS, Pseudomonas aeruginosa ip. aeruginosa) and Proteus mirabilis 
(P. mirabitis). Clossridium ramosum (Ci. ramosum) is unique in releasing a 
protease that can digest only IgA2m(l) and IgAl (Table I .IB). Others are even 
more restricted in their choice of substrate and produce enzymes specific for IgAl 
alone (Table 1.1A). These are known as 'classical' IgA proteases or IgAl proteases. 
Since the enzyme elaborated by U. urealyticum falls into this category of IgAl 
proteases, the remaining sections will be devoted to a discussion of the properties 
of these group of enzymes. Recent reviews on the properties of IgAl proteases are 
provided by Mulks, (1985), and Kilian and Reinholdt (1986).
1.7 GENERAL PROPERTIES OF IGA1 PROTEASES
IgAl proteases are characterised by their release of intact Faba and Fca 
fragments from IgAl. The identification of intact Fca fragments in the faeces of 
patients with liver dysfunction (Mehta et al, 1973) fir^st alerted researchers to the 
existence of these enzymes since until then, enteric proteolytic activity had been 
confined to enzymes that extensively hydrolysed the Fca portions of IgA, such as 
trypsin and chymotrypsin. Since then IgAl proteases have been found in a small 
but clinically important group of pathogenic bacteria that all share predilection for 
human mucosal epithelia (Table 1.1 A).
1.7.1 Protease-positive organisms
The most notable of these bacteria is the cause of gonorrhoea, Neisseria 
gonorrhoeae (N. gonorrhoea), and the principle pathogenic agents in bacterial 
meningitis, N. meningitidis, Haemophilus influenzae (H. influenzae) and 
Streptococcus pneumoniae (S. pneumoniae). These last three can all exist as 
harmless flora in the human upper respiratory tract but under some circumstances 
cause meningitis, pneumonia, septicaemia and middle-ear infections. IgAl 
protease activity is not restricted to the pathogenic serotypes or biotypes of these 
species and over 95% of isolates elaborate the enzyme. This is also true for 
N. gonorrhoeae where -100% of isolates have been found to be IgAl protease­
positive, irrespective of colonial type (piliated of non-piliated) or site of isolation.
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igAl proeeases are expressed by members of the group 'viridans 
streptococci', which have been associated with dental caries and infective 
endocarditis. Of these, Streptococcus sanguis, (S. sanguis) and Streptococcus 
orals, (S. oralis, formerly S. mitior) are dominant among bacteria that colonise a 
newly cleaned tooth surface and thereby may initiate the formation of dental 
plaque. Since the recent reclassification of oral streptococci (Kilian et al, 1989), all 
isolates from these species have been found to be positive for igAl protease 
production (Reinholdt et al, 1990). Also within the oral cavity, those bacteria 
implicated in destructive periodontal disease such as Bacteroides (Prevotella) and 
Capnocytophaga species elaborate an igAl protease. While some of these express 
'classical' enzymes, digesting only igAl, others have a broader specificity and 
digest both igA2 and igG. it is possible that in these cases an igAl protease is 
elaborated in addition to less specific immunoglobulin-digesting enzymes (Kilian, 
1981).
A number of other, but less well characterised igAl proteases have been 
identified in Gemella haemolysans, (G. haemolysans). Bifidobacterium and
VeUlonella species.
1.7.2 Protease-negative organisms
There are many mucosal pathogens which have no apparent igAl 
protease activity and to date bacteria from over forty different genera have been 
examined for enzyme expression. These are detailed by Mulks, (1985) and Kilian 
and Reinholdt, (1986) and include strains of Campylobacter, Corynebacterium, 
Enterobacter, Escherichia, Klebsiella, Legionella, Mycobacterium, Salmonella, 
Shigella, Staphylococcus, Vibrio and Yersinia. Herpes Simplex, Polio or Influenza 
virus do not elaborate the enzyme nor do any of the class Mollicute, other than 
ureaplasmas.
1.7.3 Site of digestion within IgAl.
igAl proteases do not digest the light chain, secretory component or J 
chain of igAl (Kilian et al, 1980) but cleave within the exposed hinge region of
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the a chain (Fig. 1.6). The precise points of scission have been established by 
limited amino-terminal sequencing of Fca fragments followed by comparison with 
the known sequence of IgAl (Putnam et at., 1979). IgAl proteases do not share an 
identical substrate specificity but either cleave between Pro-Ser bonds (type 1 
enzymes) or Pro-Thr bonds (type 2 enzymes) in a duplicated octapeptide present 
within the hinge region of IgAl (see Fig. 1.6). IgA2 molecules are resistant to 
attack by classical IgA proteases since the thirteen amino acid region containing 
the duplicated octapeptide is lacking in this isotype.
1.7.4 Spstifitity typse
The IgAl proteases isolated from Bacteroides melaninogenicus,
(B. melaninogenicus), Capnocytophaga ochracea, (C. ochracea), S. sanguis and 
S. pneumoniae only cleave a single bond in the IgAl hinge region but two 
cleavage sites have been identified for the enzymes produced by H. influenzae,
N. gonorrhoeae and N. meningitidss. For the neisserial species, a given isolate 
produces one but not both of the two enzyme phenotypes (type 1 or type 2). This 
is also true for the majority of H. influenzae strains, but a number have been 
identified that appear to digest IgAl at both sites simultaneously (type 3). 
Inhibition studies using antibodies raised against type 1 and type 2 Haemophilus 
enzymes have suggested that these type 3 strains are expressing two different IgAl 
proteases (Kilian et al, 1983b). This was supported by Mortensen and Kilian, 
(1984b) who purified two proteins with IgAl protease activity (74 kDa, 34 kDa) 
from one of these strains (HK 295). Hybridisation studies using a radiolabelled 
probe from the Haemophilus type 1 IgA protease gene identified only one 
homologous fragment in a type 3 strain (18 F), which suggested expression of a 
single enzyme with two distinct substrate specificities (Bricker et al, 1983). 
Alternatively, the probe may have hybridised to only one of two separate genes 
specifying the IgAl protease or a gene duplication event may have yielded two 
distinct but adjacent genes.
A single IgAl protease gene {-iga gene) is also found in H. influenzae 
strains expressing only one IgAl proteases specificity type (Bricker et al, 1983).
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N. meningitidis-2? 
H. influenzae-]2 
N. gonorrhoeae-2?*
B. melaninogenicus9 
C. ochracetfl
C. ramosum1®
H. aegyptius11 
H. influenzae-2^ N. meningitidis-]? 
N. gonorrhoeae-]7
I
220
c\
IgAl -V
rCHOI CHOI CHO CHOI-ProCys-Pro-Val-Pro-Ser-Thr-Pro-Pro-Thr-Pro-Ser-Pro-Ser-Thr-Pro-Pro-Thr-Pro-Ser-Pro-Ser-Cys-Cys-His-Pro
IgA2m(l)
IgA2m(2)
-Pro-Cys-Pro-Val-Pro-
-Pro-Cys-Arg-Val-Pro-
[hinge deletion]
....... .......... —..............................Pro-Pro-Pro-Pro-Pro-Cys-His-Pro
---------------------------------------------- Pro-Pro-Pro-Pro-Cys-Cys-His-Pro
CH1 HINGE
—►
References: 1 = Plaut et al., 1974b
2 - Kilian et al., 1980
3 = Plaut et al., 1975
4 = Reinholdt et al., 1990.
5 - Mulks et al., 1980a
6 « Mulks et al., 1982
7 = Mulks and Knapp, 1987
8 = Frandsen et al., 1987
9 = Mortensen & Kilian, 1984a
10 = Fujiyama et al., 1986
11 - Kilian et al., 1983a
Rg 1.6 Primary sequence of human IgAl and IgA2 and the site of cleavage by microbial IgAl proteases.
This suggests that conversion from one specificity type is not mediated through 
silent copies of the iga gene. By the construction and expression of hybrid type 
1/type 2 genes, it has also been demonstrated that such a conversion does not 
occur via a simple inversion or deletion mechanism (Grundy et aL, 1990). it was 
established by these workers, however, that the cleavage site determinant for
H. influenzae is located in a 370 base pair domain near the amino terminal coding 
region of the iga gene.
An examination of specificity type-distribution among igAl proteases from 
Neisseria and Haemophilus strains has revealed a degree of asso^a^on between 
the site of igAl digestion and other phenotypic variables.
I. 7.5 Association between specificity types and phenotypic variables
Among N. meningitidis strains, the specificity type may be linked to the 
outer membrane serotype and capsular serogroup of the organism. All serotype 
2a, 2b and the majority of serotype 15: Pl. 16 strains produce a type 1 enzyme 
whereas all serotype 2c strains produced a type 2 protease. As far as capsular 
serogroups are concerned, all serogroup A isolates express type 1 enzymes but no 
clear association has been found between protease cleavage type and other 
serogroups (Mulks, 1985, Lomholt et al, 1992). Analysis of igAl protease genes 
iiiga genes) from representative isolates has failed to establish a correlation 
between restriction fragments length polymorphism (RFLP) patterns and igAl 
protease cleavage type or phenotypic characteristics but has served to demonstrate 
the high level of genetic polymorphism in this species (Lomholt et al, 1992).
in N. gonorrhoeae, a more clearly defined phenotypic linkage between the 
spec^cificity type and the nutritional auxotype, dam methylation and outer 
membrane protein i serovar-grouping of the strains has been demonstrated (Mulks 
and Knapp, 1987). The majority of type 1 igAl protease-producers require 
arginine, hypoxanthine and uracil (AHU) for growth, are dam methylase positive 
and belong to Protein lA-i or Protein iA-2 serovars. isolates producing the type 2 
enzyme are more diverse in auxotype and serovar grouping and can be dam+ or 
dam- (Mulks and Knapp, 1985). This pattern is reflected in gene organisation as
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there are eight different RFLP types for gonococci type 2 proteases compared to 
only one gene type coding for the type 1 protease. The restriction site 
polymorphisms found in type 2 genes do not directly relate to the other 
phenotypic differences (Mulks and Knapp, 1987). Simpson et al, (1988) have 
suggested that regions encoding these phenotypic traits may be closely linked on 
the gonococcal chromosome.
In contrast, it has been possible to relate the genotypic differences 
between encapsulated H. influenzae strains to capsular serotype and IgAl 
protease specificity. Two independent studies have established that all serotype b 
and the majority of serotype a and d strains produce a type 1 enzyme while 
serotype c and most serotype e and f strains produce a type 2 enzyme (Mulks 
et at, 1982, Kilian and Thomsen, 1983). Southern hybridisation analysis using an 
iga gene probe from a serotype d strain (type 1) with ^coRI-digested chromosomal 
DNA from five other H. influenzae serotypes revealed, with few exceptions, that 
each serotype produced a characteristic restriction enzyme pattern (Bricker et al, 
1983, 1985). In addition, serotype f strains gave two distinct patterns that 
correlated well with IgAl protease specificity types.
Of perhaps more significance to the function of different IgAl protease 
spe<^h^city types, these studies have revealed a potential correlation between the 
virulence of a particular bacterial isolate and the cleavage site specificity of its IgAl 
protease. Thus, a type 1 IgAl protease is expressed by all strains of the 
H. influenzae serotype primariiy responsstble for- invaswe disease Cs<^i*(^ttyipe b), in 
all but one of 58 M. meningitidis isolates obtained from meningococcal epidemics 
(Lomholt et al., 1992), and in all N. gonorrhoeae strains from the AHU auxotype, 
which have been shown to be associated with disseminated gonorrhoea (Knapp 
and Holies, 1975). While it seems unlikely that the function of cleaved IgAl will 
differ according to such small differences in cleavage site, if other substrates 
important in a disease process are selectively digested by different IgAl protease 
types, this correlation may prove to be significant.
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1.7.6 Alternative substrates
in the search for an alternative substrate, igAl proteases have
demonstrated an extremely narrow substrate specificity. For many years, the only 
known substrates for these enzymes were serum and secretory human igAl and 
serum igA from the gorilla (Gorilla gorilla) and chimpanzee (Pan troglodyte^. All 
other classes of human and animal immunoglobulins (igA2, igG, igM, igD and 
igE) and other substrates commonly digested by microbial proteases such as 
casein, gelatin, Azocoll and the oxidised (3chain of insulin are resistant to attack (A 
more detailed list of insusceptible substrates is provided by Kornfeld and Plaut, 
1981). A systematic approach of designing peptides based on the hinge region of 
igAl failed to uncover a synthetic substrate for igAl proteases but a number have 
proved to be important inhibitors of the enzyme (Plaut et al., 1982, Burton et al., 
1988, Wood et al., 1989, Bachovchin et al., 1990) (Table 1.2A).
it is only since the isolation of the iga gene from N. gonorrhoeae that this 
deadlock in finding alternative substrates for igAl proteases has been broken. By 
recombinant DNA technology, Pohlner et al, (1987) have identified three sites in 
an igAl protease precursor molecule which are autoproteolytically cleaved during 
secretion of the enzyme (see Section 1.8.1), These are not identical to sites within 
the igAl hinge region, but contain a number of similar features (Table 1.2B). 
Furthermore, synthetic decapeptides based on sites B and C (but not site A) act as 
substrates for the Neisserial enzyme but the efficiency of digestion is only 1/10 of 
that observed with the native the igAl substrate (Wood and Burton, 1991).
Following the suggestion that igAl proteases may have a self-regulatory 
function, Shoberg and Mulks, (1991) have demonstrated that a number of proteins 
in the outer and cytoplasmic membranes of N. gonorrhoeae are digested by the 
gonococcal enzyme. The relative molecular masses of these proteins range from 
21-78 kDa, but their precise cleavage sites and functions in the bacterial cell have 
not yet been established.
More recently, a substrate that may have applications for the assay of igAl 
proteases has been identified. Endogluconase A (Cen A) is isolated from the
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Table 1.2 Inhibitors and substrates of IgM proteases
A. Synthetic substrate
Synthetic peptide Sub 150 Reference
Based on IgAl hinge region:
P-V-P-S-T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S-C-C-H-P - 8 mM Plaut et al., 1982
T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S - 20 mM
T-P-P-T-P-S-P-S - 0.50 mM Burton et al, 1988
Ac-T-P-P-T-P-S-P-S - 0.51 mM
T-P-P-T-P-S-P-S-NH2 - 0.18 mM
(Ac-T-P-P-C-P-S-P-S-NH2)2 - 0.17 mM
Ac-T-P-P-T-P-S-P-C-NH2 - 0.49 mM
Ac-T- P-P-T- P-C-P-S- N H2 - 0.05 mM
A0-C-P-P-T-P-S-P-S-NH2 - 0.02 mM
Ac-S-T-P-P- - 9.70 pM Wood et al, 1989
T-P-P-T - 419 pM
P-P-T-P - 40.5 pM
P-T-P-S-NH2 - 0.5 pM
T-P-S-P - 33.1 pM
Ac-A-P-boroP-OH - 4 nM Bachovchin et al, 
1990
Boc-A-P-boroP-OH - 35 nM
MeOSuc-A-A-P-boroP-OH - 28 nM
CenA-S-T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-CenA + Miller et al, 1992
Based on IgAl protease precursor sites: Wood and Burton, 
1991.
A0-V-V-A-P-P-S-P-Q-A-N-NH2 +
AC-L-P-R-P-P-A-P-V-F-S-NH2 +
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B. Natural subetratse
IgAl hinge region: Reference
Type 1 cleavage P-P-T-P-P-T-P-S P-S-C-C-H -P-R Mulks, 1985
Type 2 cleavage T-P-S-P-S-T-P-P T-P-S-P-S-C-C-
IgAl protease precursors:
N. gonorrhoeae.
Site A cleavage site n-g-r-p-v-k-p-a •P-S-P-A-A-N-T Pohlner et al, 1987
Site B cleavage site P-Q-N-l-V-V-A-P P-S-P-Q-A-N-Q
Site C cleavage site R-R-1A-L-P-R-P- P-A-P-V- F-S-L
H. influenzae:
Serotype D cleavage V-E-T-A-P-V-P-P P-A-P-A-T-P-S - Pohlner et al, 1991
Serotype B cleavage V-D-E-A-P-V-P-P- P-A-P-A-T-P-S-
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bacterium Cellulomonasf^mi and consists of two functional subunits, an N- 
terminal cellulose binding domain and a C-terminal catalytic domain, which are 
linked by a short proline/threonine polypeptide resembling the hinge region of 
igAl. Although Cen A is not digested by igAl proteases, if the linker is replaced by 
the hinge region of igA, the hybrid molecule acts as substrate for the neisserial 
enzyme (Miller et al, 1992). The type 2 enzyme cleaves the hinge region at exactly 
the same site as within the native igAl molecule, but the type 1 enzyme cleaves 
the Pro-Ser bond in both octapeptide chains. The rate of digestion, however, is 
much slower than that found with the igAl heavy chain.
Although the precise determinants of igAl proteases substrate spedficity 
have not yet been determined, the findings of both Wood and Burton (1991) and 
Miller et al, (1992) have indicated that igAl proteases are not entirely sequence- 
specific, but show some conformational dependence. in the Cen A construct, the 
conformation of the first octapeptide Pro-Ser bond appears to resemble the second 
octapeptide bond more closely than in the native substrate, since both are digested 
by the type 1 enzyme. Likewise, peptides representing the gonococcal 
autocatalytic sites probably assume a more favourable conformation in free 
solution than those based on the hinge region of igAl. in this respect, it would be 
of interest to examine the efficiency of digestion of a Cen A construct where the 
linker is replaced with a sequence corresponding to one of these autoproteolytic 
sites. in addition, sequencing of the cleavage site within the neisserial membrane 
proteins may give further insight into the specific substrate requirements of igAl 
proteases.
As far as developing an assay is concerned, the separation of the two 
functional Cen A domains by enzyme cleavage within the hybrid linker molecule 
may provide a cheap and rapid means of quantifying igAl protease activity. The 
recent expression of recombinant igAl in mammalian cell culture (J. Woof, 
personal communication) may have similar applications.
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1.7.7 Enzyms aeeaye
Until such systems are developed, assaying for IgAl protease activity 
necessitates the use of human IgAl. Although, IgAl paraproteins can be purified in 
large quantities from the serum of patients with plasma cell neoplasms their high 
relative molecular mass has impeded enzyme kinetic studies where known 
molarities of substrate are required. The insolubility of IgAl at high protein 
concentrations and its instability at extremes of pH also pose a number of 
technical problems (Pla^ut et al, 1978a). In addition, each assay involves the 
incubation of enzyme preparations with IgAl followed by the separation of 
Faba/Fca fragments from intact IgAl and a final step to detect hydrolysis products, 
all of which may be time consuming. Despite these problems, a number of assay 
systems have been described which have enabled the qualitative and quantitative 
measurement of IgAl protease activity.
Using IgAl and an appropriate antiserum, this has been achieved by 
immuno-electrophoresis (Plaut et ail, 1974a), radioimmunodiffusion (Labib et al, 
1978), rocket immunoelectrophoresis (Lassiter et al, 1989), SDS-PAGE followed 
by immunoblotting (Proctor and Manning, 1990), and by ELISA (Reinhoidt and 
Kilian, 1983). Alternatively, radiolabelled IgAl has been used in combination with 
SDS-PAGE (Blake and Swanson, 1978), cellulose acetate electrophoresis (Plaut 
et al, 1978b) and with IgA Fca receptor-bearing haemolytic streptococci in an 
immuneprecipit.ation-based technique (Lindahl et al, 1981) to quantitatively 
measure IgAl protease activity. Two assays that detect IgAl protease-hydrolysis 
products more directly by HPLC (Mortensen and Kilian, 1984b) and continuous 
spectrophotometry (Bleeg et al, 1985) have also been described.
These various systems have been used successsully for the purification 
and basic characterisation of IgAl proteases.
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1.8 CHARACTERISATION OF IGA1 PROTEASES
1.8.1 Production of an extracellular enzyme
All of the IgAl proteases identified to date appear to be released 
extracellularly during growth of the bacteria (Kilian and Reinholdt, 1986). For the 
type 2 enzyme from N. gonorrhoeae, it has been reported that over 96% of total 
IgAl protease activity is present in the extracellular fraction but less than 2.5% is in 
periplasmic and cytoplasmic fractions (Simpson et al, 1988). By using the marker 
enzymes, p-lactamase, glucose-6-dehydrogenase and succinate dehydrogenase 
(for the periplasmic, cytoplasmic and membranous fractions, respectively) it has 
been confirmed that the extracellular activity detected was not simply a result of 
cell lysis. Thus, during the stationary phase of growth, periplasmic leakage of p 
lactamase was detected but at a fraction the rate of IgAl protease release. This 
suggested that a selective transport mechanism operated for neisserial IgAl 
proteases which was later described in detail by Pohlner et al, (1987).
Following the isolation and expression of the gene encoding the 
gonococcal type 2 enzyme in E. coli, these workers established that the IgAl 
protease was initially expressed as a 169 kDa precursor which was extensively 
processed during the course of secretion from the cell (Halter et al, 1984). 
Sequence analysis and expression of fusion proteins revealed that the precursor 
could be divided into three regions; a terminal leader peptide showing typical 
characteristics of a prokaryotic signal sequence, a central region of 106 kDa, 
coding for the IgAl protease and a carboxy terminal helper sequence (p domain), 
containing three sites that resembled the IgAl protease target sequence. From this, 
an elegant mechanism for IgAl protease transport in Neisseria species has been 
proposed, which is described pictorially in Fig. 1.7.
In brief, an amino terminal leader peptide directs the passage of the IgAl 
protease precursor across the bacterial inner membrane where the leader 
sequence is removed by a specific signal peptidase. Within the periplasm, the 
hydrophobic p domain forms a pore in the outer membrane which allows the 
remainder of the protease to be transported through to the exterior of the cell.
64
Fig. 1.7 Model for the extracellular secretion of IgAl protease from 
N. gonorrhoeae.
The model was first deduced from the N. gonorrhoeae iga gene sequence by 
Pohlner et al., (1987). An amino terminal leader domain directs the passage of the 
proform IgAl protease into the periplasmic space, where it is cleaved by a 
sequence-specific signal peptidase. In a second step, the hydrophobic p domain 
associates with the outer membrane to form a pore for the secretion of the 
molecule. Exterior to the cell, the protease achieves an active conformation and is 
released from the p domain by autoproteolysis (site *b' or 'c'). Further cleavage at 
site 'a' results in the production of the a protein and a mature 106 kDa enzyme 
(thick line).
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Here the protease is presumed to achieve an active conformation and by 
digestion of the internal site 'c' the extracellular enzyme (proform C) is released 
from the cell. Proform C is then further processed by enzymatic digestion at 
cleavage sites 'b' to yield proform B and the a protein. Final cleavage at site 'a' 
produces the mature 106 kDa IgAl protease. The double band frequently seen in 
gonococcal IgAl protease preparations examined by SDS-PAGE (Halter et al., 
1989), is presumed to represent the mature IgAl protease and the extracellular 
proform B.
The IgAl protease from H. influenzae is also synthesised as a larger 
precursor molecule that requires a C-terminal portion for full function and 
secretion of the enzyme (Bricker et al,, 1983; Grundy et al, 1987). Although 
regions corresponding to a signal peptide and four potential autocatalytic cleavage 
sites have been identified in the deduced amino acid sequence from an 
H. influenzae serotype b iga gene, recent evidence suuggesCs that ordy one of these 
sites is cleaved by the H. influenzae IgAl protease. This is supported by the fact 
that immunoblotting using specific anti-IgAl protease antisera detects only one 
molecular form of the enzyme is spent culture supernatants (Pohlner et al., 1991). 
These workers also identified the IgAl protease in H. influenzae cell lysates. To 
date, no other reports of a cell-associated IgAl protease activity have been 
documented,
The deduced amino acid sequence of the 5. sanguis iga gene has shown 
little structural similarity with the IgAl protease from N. gonorrhoeae or 
H. influenzae (GiVoet et al, 1991). Although a putative enzyme
(200 kDa) has been identified in the periplasm of E. co/i-expressing cells an 
amino-terminal leader sequence and helper regions have not been identified 
(Gilbert et al, 1988). One potential autoprctrolytlc site that resembles the 
sequence cleaved in the IgAl hinge region by 5. sanguis has been identified, but 
as it is not cleaved by the active enzyme accumulating in the periplasm it is likely 
that either this does not represent the processing site or that conditions in the 
E. coli periplasm are unfavourable for processing. It is therefore probable that
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secretion in wild-type 5. sanguis requires additional iga sequences or accessory 
gene products that have not yet been identified.
1.8.2 Enzyme purification
As a consequence of their extracellular production, bacterial spent 
medium has generally been used as the source of IgAl proteases for the purposes 
of enzyme purification and characterisation. In some instances, extracellular IgAl 
proteases are harvested from bacterial colonies grown on nutrient agar covered by 
dialysis membranes (Higerd et al, 1977).
A number of protocols have been described for enzyme purification which 
differ according to the bacterial species and type of IgAl protease involved. Early 
methods invariably included an initial ammonium sulphate 'salting-out' step 
followed by a series of chromatographic separations including anion exchange 
chromatography, isoelectric focusing and gel filtration. (N. gonorrhoeae; Blake 
and Swanson, 1978, Halter et al, 1984, Simpson et al, 1988, 5l sanguis ; Plaut 
et al, 1974b, Labib et ai, 1978). More recently high performance liquid 
chromatography (HPLC) has been used for the purification of the enzymes from 
N. gonorrhoeae (BIake and Eastby, 1991) and B, melaninogenicus (Mortensen and 
Kilian, 1984a). These have been reported to give IgAl proteases with a higher 
degree of purity and larger yields than have been obtained by more conventional 
means (Mortensen and Kilian, 1984a). Despite such refinements, no IgAl protease 
has been isolated in large enough quantities for structural studies but the highly 
active preparations have been useful for biochemical, and immunochemical 
studies.
1.8 3 Bioccemical characteristics
The biochemical properties of the bacterial IgAl proteases characterised to 
date are summarised in Table 1.3. All the purified IgAl proteases have an apparent 
relative molecular mass (Mr) of between 80 kDa and 100 kDa, apart from those 
isolated from B. melaninogenicus and C. ochracea which have a lower apparent 
Mr of 62 kDa and 48 kDa respectively. The type 2 gonococcal enzymes appear to
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Table 1.3 Biochemical characteristics of bacterial IgA proteases
Species Mr
(kDa)
Km
(M)
Pi pH Reference
N. gonorrhoeae
Type 1 112 8-8.2 Simpson et al, 1988
Type 2 114/109
110/105
8-8.2
8.6 6-9
Smpson et al, 1988 
Halter et al, 1984
N. meningitidis 7-8.5 Reinholdt and Kilian, 
1983
H. influenzae
HK 295
74/34
8x10-5 Bleeg et al, 1985 
Mortensen and Kilian, 
1984a
HK 393 105/80
85
6.6 Bleeg et al, 1985 
Reenholdt and Kilian, 
1983
HK 50 86 6*9 Mortensen and Kilian, 
1984a
S. sanguis
100
100
5.5x10-6
5.45
6-7
8
Plaut et al, 1978b
Plaut et al, 1978a
Labib et al, 1978 
Reenholdt et al, 1990
S. oralis 100 3.4x10-6 Reinholdt et al, 1990
B. melaninogenicus 62 3.4x10-6 5 4.5-7.5 Kilian and Reinholdt, 
1986
C. ochracea 48 9.1x10-6 II II
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have a slightly higher Mr than the type 1 enzyme (Simpson et al, 1988) which has 
been linked to different cleavage site positions within the precursor molecule 
(Halter et at, 1989). The enzymes appear to be active over a broad pH range (6-9; 
4.5-7.5 for B. melaninogenicus) but show substantial variations in their isoelectric 
points (IEP). Those isolated from N. gonorrboeae and H. influenzae have an lEP 
of 8.6 and 6.6 respectively, whereas those from 5. sanguis at^d B. melaninogenicus 
have respective IEPs of 5.45 and 5. Such differences explain the variations 
observed between purification protocols.
1.8.4 Enzyme classification
The classification of IgAl proteases has been based primarily on their 
sensitivity to diagnostic inhibitors from the serine, cysteine, metallo and aspartyl 
protease class. The inhibition of bacterial IgAl proteases is presented in Table 1.4.
IgAl proteases from S. sanguis, S. pneumoniae and C. ocbracea all 
appear to be metallo enzymes as they are inhibited by low concentrations (5­
10 mM) of ethylenediaminetetraacetic acid (EDTA) and other metal chelating 
agents. For S. sanguis, activity is recovered by dialysis with either calcium, 
magnesium, manganese or zinc ions (Labib et al, 1978, Plaut et al, 1974b). 
Sequencing of the iga gene from S. sanguis has identified a putative zinc-binding 
motif which is characteristic for metallo proteases from gram-negative and gram­
positive bacteria (Gilbert et al, 1991). Furthermore, site-directed mutagenesis of 
amino acid residues in this region has resulted in a catalytically inactive enzyme, 
further supporting the proposal that the streptococcal IgAl protease is a metallo 
enzyme.
In Bacteroides species, the IgAl proteases are also sensitive to the metallo 
protease inhibitor bathocuprine disulphonate (BCDS) (Frandsen et al, 1987), but 
are clearly inhibited by compounds that interact with sulfhydryl groups, such as 
iodoacetamide and p-chlorcmercuribenzcate (PCMB) (Mortensen and Kilian, 
1984a). These enzymes have therefore been defined as metal-ion dependent 
cysteine proteases (Frandsen et al, 1987).
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Table 1.4 Inhibitors of bacterial IgAl proteases
Species Inhibitor type I50 Reference
N. gonorrhoeae Metailo EDTA 10 mM 
125 mM
+
+/?
Plaut et al., 1975
Kilian et al., 1983a,
BCDS 30 mM + Simpson et al., 1988
phenanthroline 35 mM + d I
PCMB 90 mM + » ii
Serine PMSF 2 mM Blake and Swanson,
TLCK/TPCK 1 mM - 1978
DFP 6 x 10'4 M + Bachovchin et al., 1990
N. meningitidis Metailo EDTA 50 mM 
125 mM
+
+,?
Plaut et al, 1975
Kilian et al, 1983a
H. influenzae Metailo EDTA 125 mM +/? Kilian, 1981, Kilian et
BCDS 10 mM 
20 mM
+
+
al, 1983a
Bleeg et al, 1985
Serine DFP 6 x 10’4 M + Bachovchin et al., 1990
S. sanguis Metailo EDTA 5 mM ++ Plaut et al, 1978a
phenanthroline 500 pM + Labib et al, 1978
Cysteine Iodoacetamide 10 mM - ii ii
Cysteine PCMB 10 mM - ii ii
Serine PMSF 10 mM - ii ii
DFP 6 x10’4M - Bachovchin et al., 1990
S. mitior/
S. pneumoniae
Metailo EDTA 5 mM + Kilian et al, 1983a.
Bacteroidessp. Metailo EDTA 125 mM +/? Kilian et al., 1983a
BCDS 10 mM + ii ii
Serine SBTI 1 mg.ml'1 - Mortensen and Kilian,
PMSF 1 mg.ml'1 - 1984a
Aspartyl Pepstatin 1 pg.ml'1 - ii ii
Cysteine HgClb 10 pM ++ ii ii
PCMB 10 pM ++ ii ii
DTNB 10 pM + ii ii
Capnocytophaga Metailo EDTA 6 mM + Kilian, 1981
sp. BCDS 10 mM + Kilian et al, 1983a
Cysteine Iodoacetamide 1 mM - Kilian, 1981
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Classification of the IgAl proteases from N. gonorrhoeae and 
H. influenzae has been more controversial. Early reports classified these enzymes 
as metallo proteases (Plaut et al, 1975, Blake and Swanson, 1978) although 5-fold 
higher concentrations of EDTA were required for enzyme inhibition compared 
with streptococcal IgAl proteases (Kornfeld and Plaut, 1981). Kilian et al, (1980) 
reported that the IgAl proteases from H. influenzae and N. meningitidis were 
completely insensiitive to EDTA but later reported that all IgAl proteases were 
inhibited by the metallo enzyme inhibitor BCDS (Kilian et al, 1983a). The type 1 
enzymes from N. gonorrhoeae are more sensiltive to low concentrations of cysteine 
and metallo protease inhibitors than their type 2 counterparts (Simpson et al., 
1988). More recently, the inhibition of N. gonorrhoeae and H. influenzae type 1 
and type 2 IgAl proteases by diisopropyl fluorophosphate (DFP) and peptidyl 
boronic acids, which act as serine-protease transition state analogues, has 
suggested that these enzymes are serine proteases (Bachovchin et al, 1990). These 
workers identified a possible consensus sequence for a chymotrypsin-like serine 
protease (GDS*GGPL) in the iga genes isolated from these species. Site-directed 
mutagenesis of the serine residue (S*) to a threonine residue in the iga gene from
H. influenzae has resulted in enzyme inactivation and lends further support to the 
proposal that these IgAl proteases are members of the serine protease class 
(Poulsen et al, 1992).
I. 9 THE DIVERSITY OF IGAI PROTEASES
Although IgAl proteases share a common function, the differences in 
substrate specificity and biochemical properties, both within and between 
bacterial species, suggests that these enzymes are highly diverse. Such diversity is 
further emphasised by complementary immunochemical and genetic comparisons 
of IgAl proteases and their respective iga genes.
1.9.1 Immunochemical analysis
The preparation of neutralising antibodies to partially or totally purified 
preparations of IgAl proteases has been reported by a number of workers. IgAl
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proteases from N. gonorrhoeae, N. meningitidis, H. influenzae and
5. pneumoniae all appear to be strongly immunogenic (Kilian et al, 1983a, 
Stafford and Plaut, 1982, Blake and Eastby, 1991) but there has been some 
difficulty in raising neutralising antisera to the enzymes from 5. sanguis, S. oralis, 
Bacteroides or Capnocytophaga species (Kilian and Reenholdt, 1986, Frandsen 
et al, 1987). In these cases, a highly purified and concentrated preparation has 
been required for the inoculum (Frandsen et ai, 1987) or neutralising antiserum 
has been obtained from patients with an active bacterial infection (Reinholdt et al, 
1990).
1.9.2 Genetic analysis
Genomic libraries of chromosomal DNA from N. gonorrhoeae,
H. influenzae and S. sanguis have been used to express the genes encoding the 
IgAl protease enzymes (iga genes) (respectively; Koomey et al, 1982, Bricker 
et al, 1983, Gilbert et al, 1988). Positively-expressing clones were identified by 
the digestion of radiolabelled IgAl bound to either a nitrocellulose (Halter et al, 
1984) or Sephadex-containing agarose (Gilbert and Plaut, 1983) overlay. The 
region of the gene encoding the active enzyme was determined by deletion 
analysis (Halter et al, 1984) or transposon mutagenesis followed by gene 
expression in mini or maxi cells (Bricker et ai, 1983, Grundy et al, 1987), Gilbert 
et al, 1988). The complete sequence of the iga genes from N. gonorrhoeae (type 
2, Pohlner et al, 1987), H. influenzae (typc 1; Poulsen et al, 1989, 1992) and 
S. sanguis (Gilbert et al, 1991) have been published.
The relationship between different iga genes has been established by 
physical mapping, hybridisation studies or direct sequence comparison.
1.9.3 Intra-species variability
a) H. influenzae
H. influenzae demonstrates considerable polymorphism with respect to 
IgAl protease specificity type, antibody inhibition type and iga gene structure. 
Using a battery of antisera raised against nine prototype H. influenzae IgAl
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proteases, a minimum of fifteen inhibition types have been identified which show 
an association with capsular serotype and substrate specificity (Kilian et al,
1983b), (see Section 1.8.3). All serotype b strains belong to inhibition type 1, 
which on further examination using additional neutralising anti-sera and inhibition 
titrations, have been subdivided into four inhibition groups (I-IV) (Poulsen et al, 
1992). Restriction enzyme analysis of H. influenzae iga genes has revealed 
characteristic restriction enzyme patterns (RFL pattern) which correlate well with 
each of the eighteen inhibition types (Poulsen et al, 1988).
To examine in more detail the molecular basis for the serological variation 
within H. influenzae IgAl proteases, iga genes encoding four serologically distinct 
enzymes have been cloned and sequenced (Poulsen et al, 1989, 1992). A 
comparison of the deduced amino acid sequences has revealed long stretches of 
conservation divided by short regions of high variability. Between strains, these 
are organised in a mosaic-like structure with different combinations of identity 
within the variable regions. This may be explained by horizontal genetic exchange 
occurring between strains of this species via transformation and subsequent 
homologous recombination events.
b) N. gonorrhoeae
A similar mechanism of inter-strain transformation has been proposed for 
N. gonorrhoeae, as nucleotide sequence comparisons of three type 2 and one type 
1 iga genes have revealed a mosaic-like organisation of variable regions (Halter 
et al, 1989). Since restriction enzyme analysis has shown a high level of 
nucleotide conservation between type 1 genes, extensive polymorphism may be 
confined to type 2 iga genes, where eight different RFL groups have been 
identified (Mulks et al, 1987) (see Section 1.8.3). Genetic differences have been 
linked to alterations in precursor molecule autocatalytic sites which lead to 
variations in the size of mature gonococcal IgAl proteases (Halter et al, 1989).
To examine if such polymorphisms have serological implications, 
inhibition studies using a single neutralising antisera have been performed by 
these workers. Although gonococcal strains revealed considerable antigenic 
diversity, the association of inhibition types with genetic differences has not been
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as well defined as for H. influenzae (Halter et al, 1989). However, using 
monoclonal antisera, differential inhibition can been demonstrated between type 1 
and type 2 enzymes (Blake and Eastby, 1991)
c) N. meningitidis
Neutralising antisera raised against three selected strains of 
N. meningitidis has divided IgAl proteases from this species into five different 
inhibition types (Lomholt et al, 1992). These can be grouped according to IgAl 
specificity type (a, b and c are type 1 enzymes, d and e type 2), but there is no 
correlation with the capsular serogroups or protein serotype of the strains. 
Examination of the iga gene region by restriction endonuclease analysis has 
revealed a high degree of genetic polymorphism which, unlike H. influenzae, 
could not be related to the inhibition or protease cleavage types. Extensive iga 
sequence comparisons have not been performed but it has been suggested that in 
N. meningitidis frequent inter strain recombination occurs, similar to that 
proposed for N. gonorrhoeae and H. influenzae (Lomholt et al, 1992).
d) Other species
S. sanguis has been divided into two or three inhibition types, which 
correlate directly with other biological and serological properties of the isolates 
(biovar 1, 2 and 3 are found in type 1 and biovar 4 in type 2) but the genetic basis 
for this has not been examined (Kilian and Reinholdt, 1986, ^^ein^<^^dt et al, 1990). 
Two different inhibition groups have been identified within S. razY's biovar 1 
(Rei:nholdt et al, 1990, Kilian and Remholdt, 1986) but all strains of S. oralis 
belong to one inhibition type only. There is little antigenic heterogeneity within 
Bacteroides and Capnocytophaga species (Frandsen et al, 1987).
From this preliminary evidence it appears that the antigenic and genetic 
variability within the neisserial or H. influenzae IgAl proteases is greater than 
within other species, although such detailed examinations have not been 
performed for these species. If the variation observed is due to immunologic 
selection pressure (Kilian and Poulsen, 1992), this suggests that the oral IgAl 
protease-producers {Streptococcus, Bacteroifes and Capnocytophaga species) are 
not exposed to significant levels of neutralising antisera in vivo. The difficulty in
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obtaining neutralising antisera to these IgAl proteases supports such a theory and 
may be explained by hidden active-site epitopes in the enzymes.
1.9.4 Intra-genus variability
Within the genus Haemophilus, IgAl proteases of H. aegyptius isolates are 
inhibited by neutralising antisera from H. influenzae inhibition groups 1 and 2 
(Kalian and Thomsen, 1983). Although it has been documented that these two 
species are genetically similar (Leidy et al, 1965) homology between the iga genes 
has yet not been examined.
Hybridisation studies have also indicated a high level of sequence 
homology between iga genes within the two neisserial species (Koomey and 
Falkow, 1984) but, as expected, restriction enzyme analysis has revealed a degree 
of restriction site polymorphism, particularly at 5' terminal regions of the gene 
(Rahr et al, 1985). Koomey and Falkow, (1984) suggested that iga genes encoding 
neisserial enzymes of the same specificity type shared a greater degree of 
homology than those coding enzymes of the different specificity type. This is 
supported by immunochemical studies where antisera raised against 
N. gonorrhoeae type 2 IgA protease inhibited the meningococcal type 2 but not 
type 1 enzymes (Stafford and Plaut, 1982). Other workers have raised antisera that 
cross-react with all type 1 ' and type 2 neisserial strains in a Western blot (Blake and 
Eastby, 1991).
For the genus Streptococcus, cross-neutralising tests using antisera towards 
IgAl proteases from S. pneumoniae, S. sanguis and S. mitior/S. oralis (Kilian 
et al, 1983a, Reinholdt et al., 1990) has suggested that they are all mutually 
exclusive. This is supported by genetic hybridisation data which found no 
homology between the iga gene from S. pneumoniae and S. sanguis. Since these 
IgAl proteases share an identical substrate sperificity and enzyme mechanism, this 
is perhaps a surprising result. The overall level of DNA relatedness between these 
species, however, is only 20-30%; there is more similarity between the genomes of 
S. orals, S. mitis and S. pneumoniae and an analysis of their iga genes may show 
higher levels of conservation (Reinholdt et al, 1990).
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An extensive study of antigenic relationships between Bacteroides species 
demonstrated considerable interrelationships; antisera raised against IgAl 
proteases from B. buccae, B. capillusand B. pentosaceus caused complete mutual 
enzyme inhibition, from B. veroralis and B. oralis showed partial inhibition while 
enzymes from B. oris, B. buccalisand denticolawcrc antigenically distinct 
(Frandsen et al., 1987). For Capnocytophaga species, anti-IgAl protease antisera 
from C. ochracea and C. sputgena produced reciprocal enzyme inhibition while 
the IgAl protease from C, gingivalis was partially inhibited by antisera from 
C. sputgena.
1.9.5 Cross-genera interrelationships
The inhibition of IgAl protease activity in B. oralis by antisera raised 
against three species of Capnocytophaga is the only evidence of shared active site- 
related antigens between genera (Frandsen et al, 1987). Although inhibition tests 
using neutralising antisera raised against the IgAl protease from N. gonorrhoeae 
and H. influenzae suggest that the enzymes are mutually exclusive (Stafford and 
Plaut, 1982, Kilian et al, 1983a), a gonococcal-specific monoclonal antibody has 
been produced which cross reacts with the IgAl protease from H. influenzae by 
Western blotting (Pohlner et al, 1991). This relationship is supported by sequence 
analysis, where H. influenzae and N. gonorrhoeae iga genes show over 60% 
homology (Poulsen et al, 1989).
1.9.6 Evolution of IgAl proteases
The high degree of sequence homology between IgAl proteases from the 
two distantly related genera Haemophilus and Neisseria, suggests that the iga 
genes have evolved from a common source by divergent evolution (Kilian and 
Reinholdt, 1986). On the other hand, the clear diversity found among IgAl 
proteases has led Kilian and Poulsen (1992) to propose more recently that the 
enzymes from H. influenzae, N. gonorrhoeae and 5. pneumoniae have evolved 
from three independent lines. Whatever their evolutionary path, the fact that IgAl
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proteases show great variation in biochemical, antigenic and genetic characteristics 
while maintaining a common function attests to their biological significance.
1.10 THE BIOLOGICAL SIGNIFICANCE OF IGAI PROTEASES
Since all IgAl protease-producing bacteria colonise mucosal epithelia, 
where IgA is the major immunoglobulin, it has naturally been suggested that the 
role of the enzyme is to interfere with the specific host defences provided by IgA. 
The evidence implicating IgAl proteases as important bacterial virulence factors 
will be discussed in the following section.
1.10.1 Subclass specificity
The inability of IgAl proteases to digest IgA2 was for many years a 
fundamental problem in justifying a role for these enzymes in bacterial 
pathogenicity, particularly since S-IgA may contain up to 50% IgA2 (Grey et al., 
1968, Delacroix et al, 1982). A more recent analysis using specific anti-isotypic 
antibodies and refined immuno-histochemical techniques, however, has revealed 
that the proportion of IgA2-secreting immunocytes can vary considerably between 
different mucosal tissues (Kett et al, 1986). Thus, in certain sites favoured by IgAl 
protease-producing organisms, such as the upper respiratory tract or salivary 
glands, antibodies of the IgAl isotype predominate. Even more significantly, 
perhaps, the major anti-bacterial in antibody in gingival fluid and secretion such as 
saliva has been found to be IgAl (Brown et al, 1991, Ahl and Reenholdt, 1991) 
which suggests that the physiological function as well as the relative distribution of 
IgA may vary between the different subclasses. In this regard, Mestecky et al, 
(1990) have reported that salivary antibodies specific for proteins or glycoproteins 
are primarily of the IgAl subclass but antibodies specific for lipopolysaccharide 
belong mainly to the IgA2 subclass. This may be of significance when considering 
the role of IgAl proteases in enhancing bacterial adhesion (Section 11.1.5) since 
IgAl antibodies are likely to predominate in the humoral response towards 
glycoprotein adhesin molecules.
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1.10.2 Protease positive organisms
It is striking that all IgAl protease-producing bacteria share predilection 
for human secretory sites and all, under some circumstances, can invade the 
mucosal barrier and cause systemic disease. In most cases, these bacteria do not 
appear to be opportunistic pathogens but produce infections in otherwise healthy 
hosts.
The clearest assotiation between IgAl protease activity and disease is in 
the case of bacterial meningitis, where the three major protagonists,
N. gonorrhoeae, H. influenzae and S. pneumomae, all elaborate the enzyme. 
Within the genera Neisseria and Haemophilus, IgAl protease production is 
confined to pathogenic species and those species that exist as commensals within 
the human nasopharynx, such as N.flava, N. sicca and H. parainfluenzae do not 
elaborate enzyme activity (Mulks and Plaut, 1978). This pattern is not maintained 
within the genus Streptococcus, however, where the highly pathogenic Lancefield 
group A streptococci or group B P haemolytic species such as S. pyogenes or 
S. agalactiae are negative for IgAl protease activity. Although S. sanguis and 
S. oralis are IgAl protease-producers, the third major etiologic agent of dental 
caries, S. mutans, is devoid of enzyme activity.
Within each species, a direct correlation between IgAl protease activity 
and pathogenicity has also not been established. In N. gonorrhoeae, both piliated 
infectious forms (colonial types 1 and 2) and non-piliated non-infectious forms 
(types 3 and 4) elaborate an IgAl protease enzyme. Likewise, over 90% of 
S. pneumoniae and H. influenzae isolates are positive for the enzyme but only a 
proportion of these are associated with disease and many appear to be harmless 
members of the upper respiratory tract (Mulks, 1985). It is possible that the level of 
IgAl protease activity varies between pathogenic and non-pathogenic isolates in 
these species, but seim-quantitative in vitro studies have suggested this is not the 
case (Kornfeld and Plaut, 1981). The relative levels of IgAl protease activity in 
vivo, however, remain to be determined.
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1.10.3 IgA protease activity in vivo
IgAl protease activity in vivo was first suggested by the detection of intact 
Fca fragments in the intestinal fluids of patients with liver dysfunction (Mehta, 
1973). Since then, enzyme activity or specific IgAl protease digestion products 
have been identified in vaginal secretions of women with gonococcal infection, 
(Blake et al, 1979), in cerebrospinal fluid from patients with H. influenzae 
meningitis (Insel et al, 1982), in nasopharyngeal secretions from children with 
respiratory disease (90tensen and Kilian, 1984) and in incipient dental plaque from 
healthy individuals (Ahl and Reinhoidt, 1991).
Indirect evidence of in vivo enzyme activity is provided by the presence of 
inhibitory anti-IgAl protease antibodies in human secretory IgA and in serum 
(Kobayashi et al, 1987b, Gilbert et al, 1983). Enzyme-neutralising activity has 
been localised to the Fab fragments of S-IgA (Kobayashi et al, 1987b) and to the 
IgG fraction of serum (Gilbert et al, 1983), confirming that the inhibition is not 
due to competing IgA substrate or to plasma protease inhibitors such as a 
antitrypsin and a macroglobulin. Although antibody titres found in patients 
recovering from neisserial infections are generally higher than from uninfected 
individuals (Gilbert et al, 1983, Mulks et al, 1980c), there is no indication that 
anti-IgAl protease activity protects against further infection (Mulks, 1985, Plaut, 
1983). Furthermore, a recent study has reported that commensal carriage of 
meningococci is as efficient in antibody stimulation as active menigococcal disease 
(Brooks et al, 1992). These workers suggest that IgAl protease-production may 
not be a function of disease, but a more detailed examination of the IgG 
subclasses stimulated during disease and carriage states is required before the 
significance of this finding is known.
To directly assess the role of IgAl proteases in disease necessitates the 
identification of a suitable host for in vivo pathogenicity studies. Since the 
enzymes are highly specific for human IgAl, traditional murine models are not 
appropriate for such investigations. A single report identifying an IgAl protease in 
H. pleuropneumoniae specific foo porane I gA has not bben ssh^ssanhti^teei by 1 ater
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enzymatic or genetic studies (Mulks et al, 1982). In addition, IgAl proteases found 
in isolates of S. sanguis colonising M. fiscularis and animal strains of 
S. pneumoniae are only spe<^ilfic for human IgAl (Kilian and Holmgren, 1981, 
Proctor and Manning, 1990). It has therefore been necessary to confine such 
investigations to in vitro model systems.
1.10.4 IgAl protease activity in vitro
a) Tissue culture models
Using human fallopian tube organ cultures, Cooper et al, (1984) have 
reported that the rate of attachment, damage and invasion of N. gonorrhoeae IgAl 
protease-negative mutants was indistinguishable from that produced by their wild- 
type isogenic counterparts. These workers obtained similar results using isogenic 
strains of H. influenzae in human nasopharyngeal organ cultures (Farley et al, 
1986) and concluded that bacterial IgAl proteases were not responsible for the 
pathogenic effects observed in vitro. It is not possible to draw conclusions from 
such experiments concerning the role of the enzymes in vivo, since specific anti­
bacterial S-IgA was not present in either of the model systems.
In assessing the function of IgAl proteases in bacterial pathogenicity, in 
vitro studies have concentrated on the effect of enzyme activity on S-IgA functions.
b) IgA functional models
On of the best documented functions of S-IgA is the prevention of 
microbial attachment to cell surfaces (Section 1.6.2). There are numerous reports 
which suggest that IgAl proteases can abrogate this function. The enzymes can act 
on free or antigen-bound IgAl (Plaut et al, 1977) and Mulks et al, (1980c) have 
demonstrated that IgAl protease-digestion of specific S-IgA counteracts its ability 
of to reduce the adherence of N. gonorrhoeae to human epithelial cells. Likewise, 
the capacity of adhesin-specific S-IgA to impede the adherence of oral streptococci 
to saliva-coated hydroxyapatite is neutralised by the action of IgAl proteases 
(Reinholdt and Kilian, 1987, Hajishengallis et al, 1992). It was originally proposed 
that this effect was due to a loss in binding capacity of IgAl following enzyme 
treatment (Plaut et al, 1977) but Mansa and Kilian (1986) demonstrated that the
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resulting Faba digestion fragments retained antigen-binding properties. Their 
ability to prevent bacterial adhesion, however, was severely compromised, which 
may have been due to a reduction in microbial agglutination resulting from the 
loss in antibody valency. Alternatively, removal of the relatively hydrophilic Fc/SC 
portion of S-IgA may have allowed adhesion via hydrophobic interactions, as 
described in Section 1.6.2. This is supported by the observation that in some 
circumstances assodation with Faba fragments actually increases the adhesion of 
streptococci to hydroxyapatite beads (Reinholdt and Kilian, 1987 and 
Hajishengallis et al, 1992). Thus, rather than prevent adhesion, Faba fragments 
appear to mediate adhesion, presumably via their hydrophobic properties.
An additional consequence of retained Faba fragment binding is that 
antigenic sites may be protected from recognition by intact functional antibody 
molecules or immunocompetent cells. A similar process of 'fabulation' has been 
described for a number of protozoa including Tetrahymena pyriformis (Eisen and 
Tallan, 1977). By elaborating an enzyme that selectively cleaves IgAl, IgAl 
protease-producing bacteria may have evolved a more efficient means of escaping 
the immune system than by producing an enzyme that causes more extensive 
degradation of IgA.
The specific digestion of IgAl may also interfere with any Fc-dependent 
immune-complex elimination. Although such Fc effector functions appear to 
predominate in the systemic compartment (Section 1.6.3), they may nevertheless 
play an important role in secretory immunity. Moreover, Bacteroides and 
Capnocytophaga species are exposed to gingival fluid, containing predominantly 
serum IgA and in an invasive infection, the action of bacterial IgAl proteases on 
serum IgA may be significant.
Although knowledge of this area is sparse, it has been demonstrated that 
the inhibition of chemotaxis by serum IgA is reduced by the action of gonococcal 
IgAl proteases (Van Epps et al, 1980) and that released Fc fragments may also act 
as polyclonal B cell mitogens (Berman et al, 1979). The increase in PMN and 
monocyte infiltration and polyclonal lymphocyte activation may serve to increase 
the inflammatory response in mucosal tissues and precipitate tissue damage. Such
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effects may be significant in the case of destructive periodontitis, which is 
characterised by the inflammation of gingival mucosa leading to extensive 
periodontal breakdown (Kilian et al, 1983a).
1.10.5 A hypothetical model for the role of IgAl proteases in disease
On the basis of in vivo and in vitro observations, Kilian and Remholdt, 
(1987) have described a hypothetical model for the development of invasive 
infection by bacteria elaborating an IgAl protease (Fig. 1.8).
By this model, it is proposed that when a host is colonised by IgAl 
protease-producing bacteria, antigen-specific antibodies (including anti-IgAl 
protease antibodies) are elicited. Since the enzyme is neutralised and the bacteria 
are not coated by protective Faba fragments, commensal carriage ensues. The 
specific immune response confers protection against subsequent attacks by the 
same bacteria. If, however, specific antibodies are already present in the host, from 
say a previous encounter with a similar but IgAl protease-negative species, 
colonisation with an IgAl protease^producer will result in digestion of these cross­
reacting antibodies. The pathogen becomes coated with protective Faba- 
fragments before an effective immune response to the IgAl protease is elicited and 
the bacteria may become invasive. In addition, IgAl digestion may extend to 
specific antibody directed against closely colonising but IgAl protease-negative 
organisms, thereby promoting the establishment of other potential pathogens. In 
this regard, S. gordonii (IgAl protease-negative) coated with IgAl Faba fragments 
has been identified following incubation of the bacteria with whole saliva (Ahl and 
Reinholdt, 1991).
Although there is no confirmation that these reactions occur in vivo the 
model provides an answer to some previously unexplained clinical observations, 
particularly with respect to infant meningitis (Kilian and Reinholdt, 1987). It also 
serves to reiterate that a disease process is a complex interrelationship between 
the host immune response and bacterial virulence propertiies. Thus conflicting 
evidence as to the role of IgAl proteases in bacterial pathogenicity does not 
necessarily discount a function for the enzyme in this process but may
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Fig. 1.8 Hypothetical model of invasive infection due to IgAl protease-producing 
bacteria. (Taken from Kilian and Reinhoidt, 1987).
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result from a lack of knowledge regarding the different factors operating in disease
onset.
1.10.6 Alternative functions for IgA proteases
The identification of susceptible substrates other than IgAl it has
suggested that IgAl proteases may perform functions additional to IgAl digestion. 
Thus, the enzymes are likely to be responsible for autocatalytic processing and 
extracellular release (Pohlner et al, 1987) as well as for the processing of a 
number of other bacterial components (Shoberg and Mulks, 1991). Since synthetic 
peptides based on the autocatalytic processing sites are more suitable enzyme 
substrates than those based on the IgAl hinge region, the enzymes may primarily 
be required for the former function. The identification of IgAl-protease bacteria in 
animals whose S-IgAl is resistant to IgAl protease activity supports this 
suggestion. If it is indeed the case that the digestion of IgAl is merely a fortuitous 
by-product of enzymes with alternative functions, it nevertheless remains likely 
that for colonisation of mucosal surfaces, IgAl protease-expressing bacteria have a 
selective advantage over their IgAl protease deficient counterparts.
_ :.... ...... O. ■k-Cicmri > y
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SECTION C
THE IGA1 PROTEASE OF U. UREALYTICUM
1.11 GENERAL PROPERTIES
1.11.1 Isolation
Over fifty strains representing the genera Mycoplasma, Ureaplasma, 
Acholeplasma and Spiroplasma have been examined for IgAl protease activity but, 
within the class Mollicute, enzyme expression appears to be limited exclusively to 
the genus Ureaplasma. IgAl proteases have been identified in all 14 human 
serotypes of U. urealyticum and in over 50 clinical isolates obtained from a variety 
of mucosal sites (Kilian et al., 1984, Robertson et al., 1984, Stemke et al., 1984, 
Kapatais-Zoumbos et al., 1985). Ureaplasmas isolated from cases of NGU and from 
asymptomatic controls are positive for IgAl protease activity (Robertson et al., 
1984).
For the bovine ureaplasma, U. diversum, two strains have been identified 
as IgAl protease-negative, but the type strain from this species (A417) appears to 
extensively degrade both human and bovine IgA (Kilian and Freundt, 1984). This 
effect has not been reproduced by other workers and Kapatais-Zoumbos et al., 
(1985) found that human, murine and porcine IgA was resistant to cleavage by 
strain A417. The digestion of bovine IgA was reported as inconclusive. IgAl 
proteases expressed by ureaplasma isolates from non-human primates, feline, 
canine, ovine or avian hosts do not digest human IgA (Stemke et al., 1984, 
Kapatais-Zoumbos et al., 1985). Two strains of canine ureaplasmas (D1M-C and 
D11N-A), however, cleave canine IgA. The species specificity of U. urealyticum 
IgAl proteases is confirmed by the inability of the human ureaplasma IgAl 
protease to digest porcine, murine or canine IgA.
1.11.2 Assaying for the enzyme
To detect the presence of the IgAl protease from U. urealyticum, crude 
cellular suspensions are incubated with IgA (18 h, 37 °C), and the supernatants
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examined for digestion products by immunoelectrophoresis or SDS-PAGE. By 
immunoelectrophoresis (with anti-S-IgA antisera) of the digestion mixture, two 
separate precipitation lines are produced, differing in electrophoretic mobility 
from intact IgAl. Using specific antisera to different portions of the IgA molecule, 
these species have been identified as Faba and Fca fragments (Kilian et al., 1984, 
Robertson et al., 1984, Kapatais-Zoumbos et al., 1985). SDS-PAGE analysis 
(reducing conditions) of the digestion products has estimated the relative 
molecular mass of the a chain fragments to be 29 kDa (Faba) and 33.5 kDa (Fca) 
(Kilian et al., 1984) and as 28-29 kDa (Faba) and 33 kDa (Fca) (Kapatais-Zoumbos 
et al., 1985). Using SDS-PAGE under non-reducing conditions, partial digestion 
products (110-115 kDa) and a single band representing co-migrating Faba and Fca 
fragments (50 kDa) have been identified (Robertson et al., 1984). In this report, 
[125I] IgAl replaced unlabelled IgAl and digestion products were identified by 
autoradiography rather than by staining with Coomassie blue.
1.11.3 Characterisation
Human serum IgAl is a substrate for the ureaplasma IgAl protease but 
human IgG, IgM, IgA2 and azocasein are resistant to digestion (Robertson et al., 
1984, Kilian et al., 1984). In general, ureaplasma cell harvests have been used a 
source of IgAl protease, but Kilian et al., (1984) have detected activity in 
concentrated cell-free supernatants by immunoelectrophoresis. The IgAl protease 
is not be inhibited by up to 25 mM EDTA (Robertson et al., 1984).
These preliminary studies have established that the IgAl protease of 
U. urealyticum specifically digests IgAl into intact Faba and Fca fragments, is 
possibly released into the growth medium and does not appear to be a metallo 
enzyme. Identification of the enzyme in ureaplasmas isolated from asymptomatic 
controls as well as from NGU patients suggests that it does not correlate directly 
with virulence, but does not discount the IgAl protease from being one of a 
number of virulence determinants for this organism. In this respect, serum IgA 
specific for U. urealyticum has been identified in patients with NGU (Brown et al.,
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1983) but changes in S~IgA levels in response to ureaplasma infections have not 
been examined to date.
1.12 AIMS OF THE THESIS
The main aim of this thesis is to extend these preliminary studies and to 
further characterise the IgAl protease from U. urealyticum. This would not only 
add to the limited knowledge available on the enzymatic functions operating in 
this simple life-form, but may, in the long-term, serve as a basis for understanding 
the role of the IgAl protease in ureaplasma pathogenicity. Information on the 
ureaplasmal enzyme may also contribute to the field of bacterial IgAl proteases in 
general. Thus, further comparisons between enzymes from different genera may 
provide a better understanding of their diversity, functions, and ultimate 
significance.
In order to achieve these goals, a primary aim should be to improve the 
assays previously developed for identifying IgAl protease activity in 
U. urealyticum. Once this is achieved, it should be possible to characterise the 
enzyme in terms of its site of production, substrate speccficity and enzyme 
classification. To further characterise the IgAl protease, purification would be 
desirable, particularly if this enables the production of a specific anti-IgAl protease 
antibody. Not only would this aid enzyme detection but it would allow 
comparative immunochemical studies between the ureaplasmal and the bacterial 
IgAl proteases to be performed. Isolation and sequencing of the iga gene from 
U. urealyticum would serve to support and expand all of these findings, as has 
been possible for the IgAl protease from N. gonorrhoeae.
In Chapter 1, progress made in developing an enzyme assay and 
characterising the IgAl protease from U. urealyticum will be presented. Attempts 
to purify the enzyme and to identify the iga gene in U. urealyticum are covered in 
Chapters 2 and 3 respectively.
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Chapter 2:
Characterisation of the IgAl protease 
from U. urealyticum
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SECTION A
MATERIALS AND METHODS
All chemicals and solvents described were AnalaR grade. Apart from gel 
electrophoresis buffers, which were freshly prepared, all other buffers were 
sterilised by autoclaving or, if stated, by filtration using 0.2 pm filters. H2O refers to 
sterile double-deionised water obtained from a Milli Q water purification system 
(ELGA).
2.1 INITIAL DEMONSTRATION OF IGA1 PROTEASE ACTIVITY
2.1.1 Source and cultivation of bacteria
Ureaplasma urealyticum (U. urealyticum) strains of serotypes 1 (T7), 4 
(11860), 6 (12253), and 8 (T 960) were gifts from D. Taylor-Robinson (Clinical 
Research Centre, Harrow, UK); serotype 7 strain (27819) was obtained from the 
American Type Culture Collection, and strains of serotypes 2 (T 23), 3 (DKF 3), 5 
(NIH 5), 9 (9-Vancouver), 10 (10-Western), 11 (11-JsL 2), 12 (12-JsL 5), 13 (13-JsL 
6), and 14 (14-JsL 11) were gifts from J. Robertson (University of Alberta, 
Edmonton, Canada). All strains were cultured and harvested as described 
previously (Thirkdl et al, 1989a). Briefly, ureaplapmss were grown in a sterile 
medium containing 70% (v/v) PPLO broth (Difco), 20% horse serum (NBL), 2.5% 
(w/v) fresh yeast extract, 0.1% (w/v) urea, 0.005% (w/v) phenol red and penicillin 
G (1000 I U.mh1) (Glaxo) at a starting pH of 6.0. Cultures were incubated without 
shaking at 37 °C until a pH of 7.6 was reached (at which stage cell numbers have 
been shown to be maximal, Myles, 1990), harvested by centrifugation (25,000 x g, 
20 min, Beckman J2-21 centrifuge) and the pellets washed three times in 
Dulbecco's phosphate buffered saline 'A' (PBS), (Dulbecco and Vogt, 1954). The 
washed pellets were resuspended in PBS (5 ml per 10 1 culture) to give a final 
protein concentration of approximately 5 mg.id-1, estimated by the method of 
Lowry et al, (1951). These preparations were used fresh or after aliquoting and
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storage at -70 °C. Unless otherwise stated, these cellular suspensions from 
U. urealyticum serotype 8 were as used a crude source of IgAl protease.
N, gonorrhoeae (27631/91, a type 2 IgAl protease-producing strain from 
the IB serogroup) was kindly provided by H. Young, (Department of Bacteriology, 
University of Edinburgh) and grown overnight (37 °C, 5% CO2) in sterile nutrient 
broth medium (Oxoid No. 2) containing 10% (w/v) glucose, 10% (w/v) horse 
serum, 10 mg.mW V factor (NAD or NADP) and 4 mg.ml-1 haemin. Cultures were 
harvested by centrifugation (25,000 x g, 20 min) and the supernatant used as a 
source of extracellular IgAl protease activity. The remaining pellet was washed 3 
times in PBS, resuspended in 5 ml PBS (from a 11 culture) and used as a source of 
cell-associated IgAl protease.
2.1.2 Solubilisation of IgAl protease from U. urealyticum
Fresh ureaplasma harvests (100 pi) were pelleted from suspension by 
centrifugation (50,000 x g, 10 min, Beckman TL-100 centrifuge) and resuspended 
to their original volume in PBS:0.5% (v/v) Nonidet P-40 (NP40) (Sigma). After 
solubilisation (30 min, 4 °C), samples were centrifuged as before and the 
supernatant used as a crude source of solubilised IgAl protease.
2.1.3 Source of IgA
Secretory IgA (S-IgA) from human colostrum was obtained from Sigma 
and purified human IgAl from Calbiochem. Purified human serum IgA2 was 
kindly provided by M. Kerr, (Department of Pathology, Ninewells Hospital). All 
were reconstituted in PBS at 1 mg.mW and stored as aliquots at -20 °C.
2.1.4 ^i-iabelling of IgAl
Purified. IgAl was radio-labelled by the addition of 0.5 mCi [125I] (Na^l, 
100 mCi.ml’1; Amersham International) to 20 pi of IgAl (1 mg.ml‘1 in PBS). The 
reaction was initiated at 20 °C with 20 pi chloramine T in PBS (0.2 mg.im-1) and 
terminated after 2 min with 20 pi sodium metabisulphite (0.3 mg.ihh1 in PBS) and 
an additional 40 pi PBS. Unbound label was removed by spin-coiumn 
chromatography using 'medium' Sephadex G50 (Pharmacia) swollen in PBS.
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[I25i] IgAl Was diluted in PBS to give 0.02 mg protein.rml1 (containing
approximately 10^ cpm.ml-1). The preparation was stored as aliquots at -20 °C.
2.1.5 Digestion reactions
5 pi of ureaplasma cell suspension (~25 pg) was incubated with either
15 pi S-IgA (1 mg.ml"1 in PBS) or 3 pi [125I] IgAl (in an additional 12 pi PBS) for
16 h (37 °C). Samples at zero incubation time or of IgA alone in 20 pi PBS were 
always included as controls. Digestion was terminated by centrifugation
(12,000 xg, 5 min, Beckman microcentrifuge) and supernatants were assayed for 
the products of IgAl protease digestion by SDS-PAGE followed by PAGE blue 83 
staining or immunoblotting (for S-IgA) or by autoradiography (for [125I] igAl).
2.1.6 Preparation of SDS-Polyacrylamide gels
The method of SDS-polyacrylamide gel preparation was adapted from that 
described by Russell and Blair, (1977). Bio-Rad Mini Protean System gel rigs were 
as;^<^ia^Jled and used according to the manufacturer's instructions. 12.5% (w/v) 
separating gels were prepared by mixing 2 mi acrylamide: bis-acrylamide 
(50: 0.235 [w/v] stock solution), 3 ml 1 M Tris-HCl, pH 8.6, 80 pi 10% SDS, 2.3 ml 
H2O and degassed for 15 min. 5 pi of TEMED and 40 pi of freshly prepared 10% 
ammonium persulphate were added to the separating gel mixture and poured 
between two sets of gel casting plates, leaving a 2 cm gap at the top of the gel. The 
running gel was overlaid with H2O and allowed to set for at least one hour. The 
overlay was removed prior to addition of the top stacking gel which contained 
0.4 ml acrylamide: bis-acrylamide (50: 1.3 (w/v) stock solution), 0.5 ml Tris-HCl, 
pH 6.8, 40 pi 10% (w/v) SDS, 0.5 ml H2O, 40 pi 10% (w/v) ammonium persulphate 
and 8 pi TEMED. An appropriate comb was inserted before setting of the stacking 
gel.
2.1.7 Sample preparation and electrophoresis.
Samples were denatured in 1/3 their volume of '4 x denature mix', (8% 
(w/v) SDS, 20% (v/v) p-mercaptoethanol (Sigma), 10% (v/v) glycerol and 0.1% 
(w/v) bromopheno! blue) by boiling for 2 min. After cooling and centrifugation
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(5 min, 12,000 x g), supernatants were loaded into pre-formed wells and separated 
by applying a voltage of 150 V for 1 h using 0.19 M glycine, 0.025 M Tris, 0.1% 
(w/v) SDS (should be at pH 8.6) as the electrophoresis buffer. Molecular weight 
markers (BRL or Sigma) were loaded when required.
2.1.8 Staining with PAGE blue 83
Gels were stained for 30 min in 0.3% (w/v) PAGE blue 83 (Sigma), 46% 
(v/v) methanol and 7.5% (v/v) acetic acid and destained in 25% (v/v) methanol, 
7.5% (v/v) acetic acid. When required, gels were dried on a vacuum gel drier 
(ATTA) for 1-2 h (80 °C).
2.1.9 Immunoblotting.
Electrophoretic transfer of proteins from polyacrylamide gels to 
nitrocellulose sheets (Gelman) was carried out on an Ancos model A semi- dry 
dectroblotter according to the manufacturer's instructions (Ancos). Eighteen 
pieces of 3 MM Whatman filter paper and one sheet of nitrocellulose were cut to 
the same size as the gel. A 'sandwich', consisting of 6 sheets of filter paper soaked 
in anode buffer 1 (0.3 M Tris-HCl, pH 10.4, 20% [v/v] methanol) covered by 3 
further pieces of filter paper soaked in anode buffer 2 (0.025 M Tris-HCl, pH 10.4, 
20% [v/v] methanol) and overlaid by a single sheet of nitrocellulose paper soaked 
in H2O, was positioned on the lower graphite plate. The gel was rinsed with H2O 
and placed on top of the nitrocellulose, taking care not to trap air bubbles. The 
sandwich was completed with 9 pieces of filter paper soaked in cathode buffer 
(0.025 M Tris-HCl, 40 mM 6-aminoaexanoic acid, 20% [v/v] methanol, pH 9.4) and 
compressed gently using a glass rod to remove air bubbles. After attaching the 
upper electrode, the gel was blotted for 1 h at 8 mA.cm-2.
Pre-stained molecular weight markers (Sigma) confirmed successful 
transfer and nitrocellulose sheets were blocked with 10%(w/v) Marvel (Cadbury) 
in PBS for 2 h (20 °C). After rinsing briefly with PBS, the sheet was incubated with 
a 1/1000 dilution of sheep anti-human IgA (Scottish Antibody Production Unit, 
SAPU) in 5% (w/v) Marvel: PBS for 2 h or overnight (20 OC). Unbound antibody
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was removed by washing once with PBS (10 min), twice with PBS:0.5% (v/v) NP40 
(10 min each wash) and once more with PBS alone (10 min). The nitrocellulose 
was incubated with a 1/500 dilution of peroxidase-linked donkey anti-sheep 
antibody (SAPU) in 5% (w/v) Marvel: PBS for 2 h (20 °C). The nitrocellulose was 
washed as above, incorporating an additional final wash in PBS alone, and stained 
for antibody binding. The staining solution contained 60 mg 4-chloro-l-naphthol 
(Sigma) dissolved in 20 ml methanol and made up to 100 ml with PBS. 60 pi H2O2 
(BDH) was added immediately before use. Staining was complete in 15-20 min 
and excess H2O2 was removed by rinsing the nitrocellulose in PBS.
2.1.10 Autoradiography
After SDS-PAGE, gels were fixed (30 min in 10% [w/v] trichloroacetic acid, 
40% [v/v] methanol), dried, and exposed to Fuji X-ray film with a Philips fast 
tungstate intensifying screen. Autoradiograms were developed using a Kodak 
automatic developer and, when quantitative information was required, scanned 
using a Shimadzu Dual wavelength densitometer.
The extent of IgAl digestion was estimated using the following calculation 
(Simpson et al, 1988):
peak area of Fca/Faba fragments 
peak area of intact a chain + peak area of Fca/Faba fragments
2.2 ALTERNATIVE ASSAYS FOR DETECTING IGAI PROTEASE ACTIVITY.
2.2.1 Quantitative rocket immunoelectrophoresis
Protease-treated S-IgA and suitable control samples, as prepared in Section 
2.1.5, were subjected to quantitative rocket immunoelectrophoresis (RIEP) 
according to the method of Lassster et al, (1989). 1% (w/v) agarose (Sigma, type 1) 
in Barbital buffer (25 mM sodium barbital, 5 mM barbital, 4 mM sodium azide, 
pH 8.6) were dissolved at 100 °C and cooled to 56 °C in a water bath. Sheep anti­
human IgA (SAPU) was incorporated at 5 pl.ml'1 and the agarose was poured onto 
standard RIEP plates. 10 pi of protease-treated samples, control samples and S-IgA
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standards (0.1-1 mg.ml’1) were electrophoresed in Barbital buffer for 18 h at 80 V. 
Agarose gels were washed in 0.15 M NaCl (2 x 10 min), H2O (2 x 10 min), dried 
between Whatman no. 1 filter paper for 15 min and stained with PAGE blue 83 
(0.5% [w/v] in 45% [v/v] ethanol, 10% [v/v] acetic acid). Destaining was in 30%
(v/v) ethanol, 15% (v/v) acetic acid and the gels were allowed to air-dry'.
2.2.2 High performance liquid chromatography (HPLC)
Samples for HPLC analysis were prepared by incubation of S-IgA with 
ureaplasma harvests or PBS alone, as described in Section 2.1.5, and by 
resuspending the resultant supernatant (1:5 by volume) in 0.5 M NaCl. 2 ml 
samples (representing 250 pg S-IgA in PBS:0.4 M NaCl) were loaded onto a 
Dupont gel filtration Zorbax column (GF 250) linked to an LKB HPLC system. 
Proteins were eluted in a mobile phase of PBS: 0.4 M NaCl at a flow rate of 
1 ml.min- 1 and detected spectrophotometrically at 226 nm. The localisation of 
intact and digested IgA a chain in 0.5 ml fractions was confirmed by SDS-PAGE (of 
50 pi samples) followed by immunoblotting, as outlined previously (Section 2.1.9).
2.2.3 Continuous spectrophotometry using IgA: 10% PEG
30 pg of S-IgA (from a stock of 4 mg.ml-1 in 0.1 M Tris-HCl, pH 7.2) were 
combined in a cuvette with PEG 6OOO (10% [w/v] in 0.1 M Tris-HCl, pH 7.2) to give 
a final volume of 6OO pi. A turbid suspension was produced immediately (Bleeg 
et al., 1985). Following addition of 20 pi ureaplasma IgAl protease preparations 
(either as crude cellular preparations or solubilised extracts from Tris buffef:0.5% 
NP40 treatment), the change in turbidity was measured at 400 nm for 1 h (37 °C), 
using the time course programme on a Perkin-Elmer, Lambda 5 UV/visible 
spectrophotometer. Controls containing Tris buffer alone or Tris buffer:0.5% NP40 
to replace of ureaplasma cells or solubilised ureaplasma preparations, respectively, 
were included.
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2.3 BIOCHEMICAL CHARACTERISATION
2.3.1 Effect of pH on IgAl protease activity
Ureaplasma cell suspensions (5 pi) were diluted (1/5 by volume) in a 
citrate-phosphate-borate buffer solution ranging from pH 2-pH 10. (2 ml volumes 
of stock buffer solution [0.03 M citric acid, 0.03 M phosphoric acid, 0.06 M boric 
acid, 0.34 M NaOH] were brought to the required pH with 0.1 M HC1 and adjusted 
to a final volume of 10 ml). After addition of S-IgA (15 pi) and exact
pH determination, samples were incubated for 16 h (37 °C) and assessed for 
digestion products by SDS-PAGE and immunoblotting, as outlined in Section 2.1.9.
2.3.2 Effect of Inhibitors on IgAl protease activity.
The serine protease inhibitors: phenylmethylsulphonyl fluoride (PMSF), 
3,4-dichloroipocoumarin (3,4-DCI), aprotinin, soy bean trypsin inhibitor (SBTI), 
chymostatin, di-isopropyffluorophosphate (DFP), tosyl eannylalanyl chloromethyl 
ketone (TPCK), tosyl lysyl caloromethyl ketone (TLCK), elastinal; the metallo 
protease inhibitor: ^W-phenanthroline; the aspartyl inhibitors: bromophenacyl 
bromide, pepstatin; and the cysteine protease inhibitors: cystatin, leuecptin, L- 
trans-neoxysuccinyl-leucylamide-(4-guanidlno)-butann (E64) were all obtained 
from Sigma. Ethylenediaminotetraacetic acid (EDTA, metallo protease inhibitor) 
and iodoacetic acid (IAA, cysteine protease inhibitor) were from BDH. All 
inaib>it^c^I^s were reconstituted and used at concentrations recommended by Bond 
(1989), as summarised in Table 2.1 (page 118).
Uresplasma cell suspensions (5 pi made up to 25 pi with PBS) were pre­
incubated for 30 min (37 °C) with 5 pi of inhibitor, prepared to give the effective 
concentrations described in Table 2.1. After addition of S-IgA (15 pi) and further 
incubation (16 h, 37 °C), the extent of digestion in the presence of inhibitor was 
estimated by immunoblotting, as outlined previously (Section 2.1.9). Control 
incubations containing the corresponding volumes of appropriate buffer or solvent 
were included.
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2.4 DETERMINATION OF SUBSTRATE SPECIFICITY
2.4.1 IgA digestion
15 pi of IgAl, IgA2 and S-IgA (each at 1 mg. mb1 in PBS) were incubated 
with 5 pi ureaplasma cell suspension in PBS for 16 h, 37 °C, as described in 
Section 2.1.5. Digestion was terminated by centrifugation (12,000 x g) and 
supernatents were assayed for the products of digestion by immunoblotting, as 
described in Section 2.1.9.
2.4.2 Determination of cleavage site in S-IgA
N-terminal sequencing of Fca, fragments, following their electroblotting 
and excision from polyvinylidene difluoride membranes (Matsudaira, 1987), was 
performed in the authors presence by B. Dunbar (SERC Protein Sequencing Unit, 
Aberdeen University).
90 pi S-IgA was incubated with 30 pi ureaplasma cell suspension for 16 h 
(37 °C) and digestion products collected in the cell-free supernatant following 
centrifugation (12,000 xg, 5 min). To enable detection of free sulfhydryl groups 
(cysteine residues) in the Fca fragments, the supernatant was dried onto the 
surface of an Eppendorf tube by rotary evaporation and subsequently 
pyridylehylated using a mixture of 4-vinylpyridine and tributylphosphine vapours 
(3 h, 80 °C), as described by Amons, (1987). The reaction product was treated with 
gel electrophoresis sample preparation buffer containing 1% (w/v) SDS (Laemmli, 
1970) and run as three tracks on SDS-PAGE (12.5% [w/v] acrylamide) using a 
Mighty Small II apparatus (Hoefer Scientific Instruments Ltd.) as described in 
Applied Biosystems User Bulletin No. 25. In this instance, piperazine diacrylamide 
was used as a gel crossdinker instead of bis-acrylamide. The gel was electroblotted 
on to Immobilon-P membrane (Millipore) and stained with 0.1% (w/v) Coomassie 
blue (Serva) in 50%(v/v) aqueous methanol. Fca fragments were excised with a 
scalpel. The first nine N-terminal amino acids of the excised band were sequenced 
by Edman degradation with an Applied Biosystems Model 477A pulsed-liquid
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sequencer equipped with a 120A on-line PTH analyser, using the manufacturer's 
BLOTT 1 cycle.
2.4.3 Digestion of IgA a chains.
1 SIgA in 6 M guanidine:0.6 M Tris-HCl, pH 8.6 was reduced with
0.14 M p-mercaptoethanol (2 min, 100 °C, followed by 3 h, 20 °C) and 
subsequently alkylated with 0.15 M iodoacetamide (67 pi of a 2.1 M solution in 1 M 
NaOH) for 30 min in the dark (20 °C). To obtain isolated IgA a chains, 200 pi of 
the reduced and alkylated S-IgA (representing -200 pg S-IgA) was separated by 
gel filtration using a Superose 6 column linked to a Pharmacia FPLC system. The 
column was eluted with 6 M guanidine at a flow rate of 0.3 ml.min.--, monitored 
spectrophotometrically at 226 nm and 1.2 ml fractions collected. Fractions 
corresponding to elution peaks were analysed by SDS-PAGE (12.5% (w/v), non­
reducing conditions) followed by silver staining, (Bio-Rad silver stain kit). Those 
fractions containing IgAa chains were pooled from three separate runs, dialysed 
extensively against PBS and concentrated to a final volume of 100 pi using a 
microconcentrator (Amicon, P30).
To test whether isolated IgAa chains were cleaved by the IgAl protease 
from U. urealyticum, 20 pi aliquots of the preparation (-20 pg) were incubated 
(16 h, 37 °C) with 5 pi ureaplasma cell suspension. As controls, incubation in the 
absence of ureaplasma cells, incubation for zero time and incubation using intact 
S-IgA as the substrate (25 pg in PBS) were included. Samples were examined for 
digestion products by SDS-PAGE and immunoblotting, as outlined in Section 2.1.9.
2.4.3 Synthetic peptide substrates
A synthetic peptide, which had been shown to be a substrate for the type 
2 IgAl protease from N. gonorrhoeae (QVood and Burton, 1991), was prepared to 
contain the following sequence of amino acids, with C terminal acetylation:
Ac-Val -Val -Al a - Pro- Pro-Ser- Pro-GI n -Al a -Asn- N H 2
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The peptide was synthesised by solid phase fiuorenyl methoxycarbonyl 
(Fmoc) polyamide chemistry in a continuous-flow system using a semi-automated 
Pepsyntaesiser II (Cambridge Research Biochemicals, CRB). Individual amino 
acids were introduced from a mar^i^^all^^Jfilled syringe barrel and all the operations 
of single residue addition and deprotection were under the control of a 
microcomputer (CRB software using an Apple lie computer) with the possibility 
of manual override when required. Detailed operating instructions are provided by 
the manufacturer (CRB) and additional information on the theoretical and practical 
aspects of solid-phase peptide synthesis are described by Atherton and Shepard, 
(1989).
a) Reagents
The pepsin KB resin (0.1 m, equivalents.g‘1), Fmoc pentafluorophenyl 
ester derivatives of amino acids were from milligen wher^e^as O-rings and filters 
were obtained from CRB. Dimethylformamide (DMF), ethanol, methanol, 
acetoirntrile and trifluoroacetic acid (TFA) were all HPLC grade from Rathburn. 
Piperidine was purchased from Applied Biosystems and ethanedithiol, anisole, 
tertiary amyl alcohol (TAA) and 4-dimetaylaminopy^idlne (DMAP) from Aldrich, 
Diethyl ether (DEE) and acetic acid (AA) were obtained from May and Baker and 
the molecular sieves and other chemicals from Sigma. All solvents were of the 
highest grade to avoid contamination with aqueous or amine compounds. To 
prevent the accumulation of dimethylamine in DMF, which can react with the 
amino acid Fmoc protecting groups, the solvent was stored in the presence of 
heat-activated molecular sieves at 20 °C for a number of weeks. To prevent 
blockage of the Peppynthesiset lines and valves, DMF was filtered before use 
(0.2 pm nylon filter, Anachem).
b) Synthesis reactions
Prior to peptide synthesis, the main lines of the synthesiser were washed 
manually (10 min) with DMF (Bottle A) and the flow rate adjusted to 3 ml.min."O. 
Bottle B contained DMF: 20% (v/v) piperidine in DMF. 1 g of pepsin KB resin was 
washed in 3 x 10 mi of DMF, packed into a 5 x 1 cm column and attached to the
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Pepsynthesiser by linking the appropriate lines. The operating programme is
shown below:
Pepsynthesiser operating programme:
Step Time (min)
1 flow A 5
2 Flow B 10
3 Flow A 15
4 call (load amino acid) -
5 Flow S 5
6 recirculate 25
7 call -
8 recirculate 25
9 flow S 1
10 Flow A 5
11 recirculate 0.5
12 Flow A 5
13 call -
14 repeat -
The programme was initiated at step 3, a 15 min wash prior to loading the 
first derivatised amino acid. Each amino acid (present in five-fold excess, as 
calculated by the CRB programme) was reconstituted in DMF (2 ml) and 
centrifuged (12,000 x g, 3 min) to remove insoluble particles. For the initial 
coupling reaction, the catalyst DMAP (12 mg in 200 pi DMF) was loaded 
immediately prior to the first residue (step 4) and this catalyst/amino acid step was 
repeated, omitting the deprotection step, to ensure effective coupling. After 
recirculation for 1.5 h (manual override) and rinsing the loading syringe (step 9), 
uncoupled amino acids were washed from the column (steps, 10, 12 and 2) before 
removal of the Fmoc protection group ('deprotection') by 20% piperidine in DMF
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(step 3). The lines were washed with DMF (15 min, step 4) and the cycle repeated 
until the N-terminal amino acid had been coupled and de-protected.
The continual flow of the system allowed peptide synthesis to be 
monitored spectrophotometrically at 320 nm (Cecil spectrophotometer) by placing 
an 8 pi flow cell downstream from the reaction column. Changes in absorbance 
were recorded on a chart recorder at a chart speed of 0.1 mm.min/1 with a full 
scale deflection (FSD) of 2. The Fmoc protecting groups absorb strongly in the UV- 
range which enabled the stages of amino acid coupling and deprotection to be 
observed.
Once synthesis was complete, the peptide was N-terminally acetyiated, 
amino acid side-chain protecting groups were removed (de-blocking) and 
ammonia (NH3) treatment of the resin released the peptide amide, as described
below.
c) Acetylation
For acetylation, the peptide was treated with a 5 M excess of acetic 
anhydride in DMF with O.1M equivalent of pyridine (0.5 mM acetic anhydride,
0.05 mM pyridine made up in 2 ml DMF) by using the recirculation programme 
(1.5 h), followed by washing with DMF (15 min).
The resin was removed from the column and washed through a scintered 
glass funnel with DMF, T-amyl alcohol (TAA), acetic acid (AA), and Di-ethyl ether 
(DEE) using 'wash protocol 1'.
Wash protocol 1:
1 x DMF 25 ml
1 x TAA 10 ml
1 x AA 10 ml
1 xTAA 10 ml
2 x DEE 25 ml
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d) De-blocking
The resin was transferred to a round-bottom flask and mixed with de­
blocking solvents; 40 ml TFA, 1 ml anisole, 1 ml etasnediol for 3 h (20 °C). Using a 
scintered glass funnel, the resin was washed with 3 x 5 ml TFA followed by 'wash 
protocol T
e) Cleavage
To produce a C-terminal amide group, the peptide was cleaved from the 
resin by liquid ammonia, following the method of 'Waters' (Millipore UK Ltd.).
This was kindly performed by J. Walton (Department of Chemistry, University of 
St. Andrews).
Initially the resin was washed following 'wash protocol 2' and 
subsequently dried under vacuum to remove all traces of ether.
Wash protocol 2:
4xTAA 10 ml
4 x DMF 10 ml
4 x 10% (v/v) isoproeylethylamLine in DMF 10 ml
2 x DMF 10 ml
2 x DAA 10 ml
Glacial acetic acid (0.4 ml) was added to 1 g resin in a pressure vessel and 
the mixture cooled by immersion in dry ice. Following addition of liquid ammonia 
(10-20 mi), the vessel was sealed and gradually warmed to 20 °C, by evaporation 
of the dry ice. After 16 h, the vessel was recooled with dry ice (30-60 min), the top 
pressure valve removed, and the ammonia allowed to evaporate. The dried 
peptide/resin mixture was washed in TFA, the peptide-containing solvent filtered 
free from resin and the TFA removed by rotary evaporation. Crystals of peptide 
were resuspended in 5 ml water and lyophiHsed. A stock solutions of peptide 
(20 mg. ml-1 in PBS) was stored at -20 °C.
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a) Assessment of synthetic peptide as a substrate for U. urealyticum
IgAl protease.
15 pi of the peptide (300 pg in PBS) was incubated with 5 pi crude 
ureaplasma cell suspension (16 h, 37 °C). The reaction was terminated by the 
addition of 0.1% (v/v) TFA (30 pi) followed by fi^t^i^ation through 0.2 pm filters 
(Millipore). The filtrates (50 pi) were loaded in 0.1% (v/v) TFA (Buffer A) onto a 
reverse-phase column (Ultrasphere-ODS, Altex) which was attached to a Gilson 
802 HPLC system. Separation was achieved with a gradient of 0.1% (v/v) TFA in 
acetonitrile (Buffer B), as directed by the 'peptides' programme from a linked 
Apple He computer-.
Peptides programme
Time (min) %B
5 0
5 0
30 50
35 100
35.1 0
45 0
The flow rate was 1 mimin'1, eluting peptides were monitored 
spectrophotometrically at 226 nm and recorded using a Shimadzu chart recorder 
set with an FSD of 0.2.
b) Preparation of crude IgAl protease from N. gonorrhoeae.
A crude preparation of IgAl protease was obtained from N. gonorrhoeae, 
according to the method of Gilbert et al., (1983). Harvest supernatants were 
precipitated with 60% ammonium sulphate and following 3 x lh dialysis in 50 mM 
Tris-HCl, pH 8.1, were separated by gel filtration chromatography using the 
Superose 6 column linked to a Pharmacia FPLC system. Fractions containing IgAl 
protease activity were identified by incubation with S-IgA followed by
immunoblotting, as described previously (Sections 2.1.5, 2.1.9). 40 |il samples of 
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spent media (from before and after concentration with ammonium sulphate) and 
single colonies of N. gonorrhoeae resuspended in 15 pi PBS were examined for 
IgAl protease activity by incubation with S-IgA and immunoblotting.
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SECTION B 
RESULTS
2.6 INITIAL DEMONSTRATION OF IGA1 PROTEASE ACTIVITY
2.6.1 SDS-PAGE and immunoblotting
Previous reports identifying an IgAl protease in U. urealyticum were 
corroborated; overnight incubation (37 °C) of human S-IgA with urnaelasmn cell 
suspensions resulted in partial digestion of S-IgA to produce Faba and Fca 
fragments. These were detected as two separateey-migrating protein bands of 
relative molecular mass (Mr) 33 kDa and 28 kDa by SDS-PAGE of digestion 
mixtures followed by staining with PAGE blue 83 (Fig. 2.1a, lane 3). Enzyme 
activity was specific to the urnaelasmn preparations, since incubation of S-IgA in 
the absence of ureaplasma suspensions or for zero time resulted in no detectable 
digestion products (Fig. 2.1a, lanes 1 and 2).
The additional protein bands seen in lanes 2 and 3 of Fig. 2.1a represent 
urnnelasmn proteins. To clearly differentiate between these proteins and S-IgA 
digestion products and to improve the serasittvity of the detection system, the gels 
were Western-blotted and probed with sheep anti-human IgA (a chain) antibody 
followed by a peroxidase-linked anti-paeee IgG antibody and a final colour­
developing reagent step (immunoblotting). By this method, the Faba and Fca 
fragments were visualised as a single band clearly separate from the undigested a 
chain (Fig. 2.1b, lane 3). Alternatively, if l°25I] igAl replaced S-IgA, digestion 
products were identified (by SDS-PAGE followed by autoradiography) as a single 
band of slightly higher Mr than the radiolabelled light chain (Fig. 2.1c, lane 3).
Although these SDS-PAGE-based methods allowed unequivocal detection 
of IgAl protease activity in ureaplapmn samples, they provided only semi­
quantitative information and, for routine analysis, were time-consuming. In order 
to rapidly detect and quantify IgAl protease activity a number of other assay 
systems were therefore examined.
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a) PAGE Blue-steininn b) immunoblotting c) autoradiography
12 3 12 3 12 3
Fig. 2.1 Digestion of human secretory IgA (S-igA) by U. urealyticum IgAl 
protsass.
S-IgA (15 |ig in PBS) was incubated (37 °C) in the absence of ureaplasma cell 
suspension for 16 h (lane 1), with 5 |il ureaplasma cell suspension for 0 h (lane 2) 
or with 5 |il ureaplasma. cell suspension for 16 h (lane 3), as described in Section 
2.1.5. Digestion products were separated by SDS-PAGE (12.5%, reducing 
conditions) and identified by:
a) staining with PAGE blue 83 (Se<cion 2.1.8),
b) immunoblotting with sheep anti-human IgA a chain antibody followed by 
peroxidase-linked donkey anti-sheep antibody (Section 2.1.9),
c) autoradiography, where 3 pi [125U IgAl replaced S-IgA (Section 2.1.10).
Fabcc/Fca fragments (28 kDa and 33 kDa, respectively) are indicated by the 
arrows. Additional protein bands in Fig. 2.1a, lanes 2, and 3 are ureaplasma 
proteins.
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2.7 ALTERNATIVE ASSAYS FOR DETECTING IGAI PROTEASE ACTIVITY
2.7.1 Rocket immunoelectrophoresis
In quantitative rocket immunoelectrophoresis (RIEP), as described by 
Lassiter et al, (1989), S-IgA digests are subjected to electrophoresis through 
agarose that contains anti-IgA antibody. At optimal antigeinantibody 
concentrations, a rocket-shaped precipitin line is formed. Digested samples should 
produce a larger rocket area than undigested controls, as the smaller cleaved 
fragments migrate faster in an electric field than intact substrate but still retain 
reactivity with anti-IgA antisera. As can be seen in Fig. 2.2, although ureaplasma- 
digested samples (lane 4) produced slightly larger rocket areas than undigested 
controls (lane 5), the antibody:antigen precipitation did not seem to have reached 
completion, even after electrophoresis for 18 h. Increasing electrophoresis times, 
altering running buffer composition, or varying anti-IgA antibody concentrations, 
failed to produce more definitive results. In addition, the long electrophoresis 
times made detection of digestion products slower than by SDS-PAGE.
2.7.2 Continuous spectroscopy
The monitoring of IgAl protease activity by continuous 
spectrophotometry, fij"st reported by Bleeg et al, (1985), is based on the 
observation that IgA spontaneously forms spherical micro particles (<1 mm 
diameter) when added to solutions of 10% PEG. These create a turbid suspension 
which has a detectable absorbance at 400 nm (A400) that remains constant for a 
number of hours. Addition of an IgAl protease to the system results in a decrease 
in turbidity since Faba and Fca fragments are soluble in 10% (w/v) PEG (in Tris 
buffer). The rate of decrease of turbidity is therefore an immediate measurement of 
enzyme activity'.
In the present study, it was initially confirmed that the A400 of the 
S-IgA:PEG suspension was proportional to S-IgA concentration but that even at 
maximum recommended levels of S-IgA (50 mg.ml-1), the A400 only rose to 0.082.
106
a) 5 gl.ml'1 anti-IgA antibody
1 2 3 4 5
b) 2.5 p.iiirnl"1 anti-IgA antibody
1 2 3 4 5
Fig. 2.2 Detection of IgA digestion products by rocket immunoelectrophoresis.
S-IgA (15 pg in PBS) was incubated (16 h, 37 °C) with either 5 |il ureaelssms cell 
suspension (lane 4) or PBS (lane 5). Samples were electrophoresed in 1% agarose 
containing anti-IgA antibody at 5 pl.ml° (a) or 2.5 pl.ml‘° (b), as described in 
Section 2.2.1. Immunoprecipitation rockets were visualised by PAGE blue 83 
staining.
Lanes 1-3 contain IgA standards of protein concentration: 1 mg.rm*1, 0.5 mg.ml'° 
and 0.1 mg.ml'i respectively.
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Fig. 2.3 IgAl protease activity measured by continuous spectrophotometry.
The initial turbidity (Ai00) of a reaction mixture containing 30 jig S-IgA in 0.1 M 
Tris-HCl, pH 7.2:10% PEG was recorded for an initial period of 20-30 min (i), as 
described in Section 2.3. The changes in A^q were recorded (ii) following addition 
of 20 pi ureaplasma cell suspension in 0.1 M Tris-HCl, pH 7.2 (a), 20 pi ureaplasma 
extract, solubilised with 0.1 M Tris-HCl, pH 7.2: 0.5% NP40 (b), and 20 pi 0.1 M 
Tris-HCl, pH 7.2: 0.5% NP40 (c).
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This was in agreement with the results of Bleeg et al., (1985), who found that the 
A400 did not rise above 0.95. In contrast to these workers, however, a substantial 
decrease in turbidity was not detected in the presence of IgAl proteases and, 
following addition of ureaplasma suspensions, the A400 it1 fact increased from 
0.075 to 0.33 (Fig. 2.3). Over a period of 1 h this fell to 0.29 and after overnight 
incubation, followed by re-mixing, the A400 was 0.203. Although this suggested 
only minimal S-IgA digestion, it was shown by immunoblotting that the 
ureaplasmal IgAl protease extensively digested S-IgA in the presence of 10% 
(w/v) PEG: Tris buffer.
The spectrophotometric assay therefore seemed incapable of detecting 
this digestion but it is possible that the ureaplasma cells had interfered with the 
formation of the two-phase system. Absorbance by cellular suspensions certainly 
may have been responsible for the observed increase in A400. To overcome this, 
soluble ureaplasma extracts, from Tris buffer:0.5% (v/v) NP40 treatment, replaced 
cellular suspensions. These produced a minimal increase in A400 above 
background levels but after incubation for 1 h followed by overnight (37 °C), no 
decrease in turbidity was recorded (Fig. 2.7b). Addition of 0.5% (v/v) NP40 alone 
did not appear to alter the integrity of the PEG:S-IgA suspension (Fig. 2.7c). These 
preliminary results suggested that the technique was not suitable for assaying 
ureaplasma IgAl protease activity.
2.7.3 HPLC
Using an HPLC system, smaller digestion products can be separated from 
larger undigested substrates by gel filtration chromatography and subsequently 
identified by spectrophotometric analysis of column eluates. By this method, 
ureaplasma-digested IgA eluted with an additional protein 'shoulder' (arrowed, 
Fig. 2.4c) not present in undigested controls (Fig, 2.4a,b). When the concentration 
of sample loaded onto the column was reduced (by loading 200 pi rather than 
2 ml) this 'shoulder' resolved as a separate peak (peak 2, Fig. 2,5a). Analysis of 
fractions by SDS-PAGE and immunoblotting confirmed that peak 1 represented
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Fig. 2.4 Detection of IgAl digestion products by gel filtration (HALC).
S-IgA (250 pg in PBS) was incubated with either 90 pi PBS for 16 h (37 °C) (a),
90 pi ureaplasma suspension for 0 h (b), or 90 pi ureaplasma suspension for 16 h 
(37 °C) (c). Filtered digests were diluted 1:5 in 0.5 M NaCl and 2 ml samples 
(250 pg S-IgA) separated on a Dupont GF 250 column (Zorbax) at a flow rate of 
1 ml.ran'1 using PBS: 0.4 M NaCl as the mobile phase, as described in Section 
2.2.2. Proteins were detected spectrophotometrically at 226 nm and collected as 
0,5 ml fractions.
The digestion peak is indicated by an arrow.
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Fig. 2.5 Analysis of digestion products identified in gel filtration (HPLC) assay.
a) Samples were prepared and analysed as described in Fig. 2.4 except that 200 |tl 
(25 pg S-IgA) was used in the separation rather than 2 ml. The individually 
resolved peak eluting at fraction 7.5 is indicated by an arrow (2).
b) Protein-containing fractions (50 pi from 0.5 ml) were analysed by SDS-PAGE 
(12.5%, non-reducing conditions) and immunoblotting, using sheep anti-human 
IgA a chain antibody followed by peroxidase-linked donkey anti-sheep antibody 
as described in Section 2.1.9.
Faba/Fca fragments are indicated by the arrow.
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intact S-IgA and that peak 2 represented digested S-IgA fragments (Fig. 2.5b). 
These protein peaks were detected with as little as 3 pg of digested S-IgA and 
within 10 minutes of sample loading. However, column clearance (with PBS:0.4- M 
Nad) for up to 30 min was required between each sample run and when large 
sample numbers were involved, the method became time-consuming and labour­
intensive. In addition, an HPLC machine was not available on a regular basis for 
such studies and it is for these reasons that a gel filtration-based assay system was 
not adopted as a means of identifying the ureaplasmal IgAl protease.
In the assessment of techniques for identifying IgAl protease activity, the 
immunoblotting method was used repeatedly to confirm the identity of putative 
digestion products. It rapidly became clear that, despite initial reservations about 
the method, immunoblotting was capable of unambiguous detection of IgA 
digestion products both reliably and reproducibly. Efforts were therefore 
concentrated on refining this assay system rather than investigating further the 
value of alternatives.
2.7.4 Refining immunoblotting techniques
By varying the concentration of S-IgA and ureaplasma cell suspension in 
the incubation mixture, it was found that digestion products could be detected 
with as low as 5 pg S-IgA when incubated with 2.5 pi ureaplasma suspension. For 
definitive identification of Faba/Fca fragments by immuncblctting, 15 pg of S-IgA 
combined with 5 pi of ureaplasma suspension (equivalent to 10 ml liquid culture) 
was used. This was an improvement on assays described by other workers where 
ureaplasma preparations equivalent to 100-200 ml of liquid culture were incubated 
with 100-400 pg of IgA substrate (Kapatais-Zoumbos et al, 1985, Kilian and 
Freundt, 1984). Low levels of product could be observed after two hours 
incubation but overnight incubation (16 h) was necessary before digestion 
products were unequivocally detected by immunoblotting (Fig. 2.6).
Agitation of the mixture during incubation did not improve the extent of 
digestion but multiple small volume digests (< 50 pi) gave proportionally more 
product than a single digest of larger volume. Incubation at 37 °C was optimal for
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a) Autoraaiograahy
b) Immunoblotting
Time (h) 0 2 4 6 8 16
Fig. 2.6 Time course of IgA digestion by U. urealyticum IgAl protease.
S-IgA (15 pg) or [125H IgAl (3 gg) were incubated with 5 pi ureaplasma cell 
suspension in PBS (37 °C, 0-16 h). The reaction was terminated by addition of '4 x 
denature mix' and samples were analysed by SDS-PAGE (12.5%) followed by 
autoradiography (for [125U IgAl samples) (a), or by immunoblotting with sheep 
anti-human IgA a chain antibody and peroxidase-linked donkey anti-sheep 
antibody (b), as described in Sections 2.1.10 and 2.1.9.
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the enzymatic reaction and, as expected, exposure of the protease to temperatures 
above 50 °C resulted in denaturation and loss of activity. Extreme acid (<pH 3.6) 
or alkaline (>pH 10.5) conditions had a similar effect but the enzyme appeared 
stable over a wide range of pH (pH 3.6-pH 10.5) (Fig. 2.7). The activity appeared 
strongest between pH 3.6-8.3 and therefore PBS at pH 7 was a suitable choice of 
buffer for the digestion mixture. Addition of divalent cations (Mg2+, Ca2+,
1-10 mM) to the reaction mixture did not activate or inhibit enzyme activity.
The replacement of 14 x 14 cm polyacrylamide slab gel apparatus with 
Bio-Rad 'mini gel' systems substantially lowered the cost and running time of the 
assay. In addition, the reduction of antibody incubation times in immunoblotting 
to 2 h and the use of a colour-developing reagent enabled digested samples to be 
analysed within 8 h. The use of l125I] IgAl as a substrate did not improve the speed 
of the assay but was marginally more sensitive (Fig. 2.6) and used less substrate 
than immunoblotting (0.04 pg rather than 15 pg). Due to the hazards associated 
with using radioactivity, however, P25I] IgAl was only used when quantitative 
measurements were required.
2.8 BIOCHEMICAL CHARACTERISATION
2.8.1 Inhibition studies
The effect of Inhibitors on enzyme activity is presented in Table 2.1. Of the 
range of compounds used that were diagnostic for the four classes of proteases, 
only a number of serine protease-spedfic inhibitors were effective in reducing or 
inhibiting ureaplasma IgAl protease activity. In particular, DFP and DCI (Fig. 2.8A 
and B) gave clear inhibition profiles and it was established that this effect was not 
due to inhibitor solvent. PMSF, another diagnostic inhibitor for serine proteases, 
reduced enzyme activity only inconsistently. This was not due to compound 
instability, since each inhibitor preparation reduced trypsin activity by 100% in a 
standard trypsin assay. It was noted that EDTA, even at 160 mM, had no effect on 
ureaplasmal enzyme activity (Fig. 2.8C).
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Fig. 2.7 Effect of pH on U. urealyticum IgAl protease activity.
15 M S-IgA (1 mg.rmli in PBS) was incubated with 5 pi ureaplasma cell 
suspensions at a range of pH values, as described in Section 2.3.1:
1 - 2.4 7* 8.3
2 * 3.6 8= 8.9
3-4.5 9= 9.9
4 - 5.6 10= 10.5
5-6.5 11= PBS alone
6 = 7.5 12 = no IgAl protease
Protein digests were analysed by SDS-PAGE (12.5%) and immunoblotting using 
sheep anti-human IgA a chain antibody followed by peroxidase-linked donkey 
anti-sheep antibody, as described in Section 2.1.9.
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Table 2.1 Inhibition of U. urealyticum IgAl protease activity.
Class Inhibitor Solvent Effective
conc.
Working
conc.
Inhibition
(+/-)
Serine PMSF propan-2-ol 0.1-1 mM 0.1 mM 
0.5 mM
1.0 mM 
(propanol)
+
3,4-DCI DMSO 5-100 pM 10 pM
50 pM
100 pM 
(DMSO)
+
+
++
Aprotinin H2O equimolar 
with protease
100 pM
500 pM
1 mM
SBTI 25 mM 
phosphate, 
pH 7.0
equimolar 
with protease
100 pM
500 pM
1 mM -/+
DFP propan-2-ol 100 pM 10 pM
100 pM
1 mM
10 mM 
(propanol)
++
44—
4—4
Chymostatin DMSO 10-100 pM 10 pM
100 pM 
(DMSO)
Elastinal H2O 10-100 pM 10 pM
100 pM -
TPCK methanol 10-100 pM 100 pM 
(MeOH)
-
TLCK 1 mM HCl, 
pH 3.0
10-100 pM 100 pM
(100 pM 
HCl)
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Table 2.1 contd.
Class Inhibitor Solvent Effective
conc.
Working
conc.
Inhibition
(+/-)
Metallo EDTA
1,10 Phenan­
throline
H2O 
(pH 8.6)
Methanol
10 mM
1-10 mM
1 mM
5 mM
25 mM
5 mM 
(MeOH)
-
Aspartyl Pepstatin A Methanol 1 pM 1 pM 
(MeOH)
-
Bromophenacyl
-bromide
Methanol 0.6 mM 0.5 mM 
(MeOH)
-
Cysteine Cystatin 25 mM 
phosphate, 
pH 7.5, 20% 
glycerol
equimolar
with
protease
10 pg.ml-1 
100 pg.ml-1 
(phos.)
-
Iodoacetamide H2O 10-100 pM 100 pM
10 pM
(H2O) -
E64 25 mM 
phosphate, 
pH 7.5
1-10 pM 1 pM
10 pM 
(phos.) -
Cysteine
/Serine
Leupeptin H2O 10-100 pM 100 pM -
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Fig. 2.8 The effect of inhibitors on U. urealyticum IgAl protease activity.
Ureaplasma cell suspensions (5 pi in 25 pi PBS) were pre-incubated (30 min, 37 °C) 
with 5 pi inhibitor (a-c) and following addition of 15 pg S-IgA, for a further 16 h 
(37 °C). Controls of inhibitor solvent alone were included where appropriate. The 
extent of inhibition was determined by immunoblotting of digest supernatants 
using sheep anti-human IgA a chain antibody and peroxidase-linked donkey anti­
sheep antibody, as described in Section 2.1.9. The Inhibitors used were:
a) Di-isopropylfluorophosphate in isopropanol at 10 mM, 1 mM, 0.1 mM and 
0.01 mM (lanes 3-6). Lane 1, IgA alone (no IgAl protease), lane 2, isopropanol 
alone.
b) 3,4-Dichloroisocoumarin in DMSO at 100 pM, 50 pM, 10 pM (lanes 1-3). Lane 4, 
DMSO alone.
c) EDTA (pH 8.6) at 20 mM, 100 mM, 160 mM (lanes 1-3). Lane 4, PBS alone, lane 5, 
IgA alone (no IgAl protease).
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2.8.2 Serotype distribution
An IgAl protease was expressed by all fourteen serotypes of 
U. urealyticum (Fig. 2.9) and by using the method of Simpson et al., (1988) 
(Section 2.1.10), it was calculated that the extent of digestion was not identical for 
each serotype. Higher enzyme activity was found in serotypes 1, 7, 8,10, and 13 
and the lowest activity was found in serotypes 6, 9 and 12. Standardising 
ureaplasma protein concentrations for each serotype Is subject to considerable 
error, however, and differences In levels of IgAl protease activity between 
serotypes are therefore only presented as a possibility.
The analysis also suggested that each serotype expressed an IgAl protease 
of identical substrate specificity to serotype 8, since the digestion products were of 
apparently identical Mr. In other bacteria, multiple IgAl protease-types are clearly 
identified by SDS-PAGE of digested IgA. This is due to the extensive glycosylation 
in the hinge region of the molecule, which enables fragments differing by only a 
few amino acids to be detected by differences in their migration rates.
2.9 SUBSTRATE SPECIFICITY
2.9.1 Determination of cleavage site
Fig. 2.10A demonstrates that IgAl but not IgA2 was susceptible to 
cleavage by the ureaplasma IgAl protease. The partial digestion observed with 
S-IgA was therefore probably due to the fact that this is composed of a mixture 
IgAl and IgA2. The small amount of intact IgAl remaining after digestion 
suggested that even this isotype may be partially resistant to the ureaplasma IgAl 
protease. Equally it could represent a small amount of undigested IgA2 
contaminating the preparation or could be due to an inadequate time of 
incubation to promote total digestion.
The resistance of IgA2 to the action of the IgAl protease suggests that the 
ureaplasma enzyme cleaves within the hinge of IgAl, since the absence of thirteen
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Fig. 2.9 IgAl protease activity in 14 serotypes of U. urealyticum.
3 |tl [125I] IgAl w'as incubated for 16 h (37 °C) with PBS (lane X) or with 5 |lI of 
each serotype (lanes 1-14). Digests were examined by 12.5% SDS-PAGE (reducing 
conditions) followed by autoradiography, as described in Section 2.1.10.
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A)
a) lgA2 b) IgAl c) S-IgA
—IgAa
_Fab/
Fca
1 3 1 3 1 3
Fig. 2.10 Digestion of IgA by U. urealyticum IgAl protease.
A) 15 p1 aliquots of IgA2 (a), IgAl (b) and S-IgA (c), each at 1 mg.ml'1 in PBS were 
incubated with 5 |il ureaplasma cell suspension in PBS, 16 h, 37 °C (lane 1), 5 pi 
ureaplasma cell suspension, 0 h (lane 2), or with PBS alone, 16 h, 37 °C (lane 3). 
Digestion products were analysed by 12.5% SDS-PAGE (reducing conditions) and 
immunoblotting using sheep anti-IgA (a chain) antibody followed by HrP-labelled 
anti-sheep antibody, as described in Section 2.1.9.
B) Isolated S-IgA a chain fragments (20 pg), (panel a) and 25 pg S-IgA (in PBS) 
(panel b), were incubated (16 h, 37 °C) with 5 pi PBS (lanes 1 and 3) or with 5 pi 
U. urealyticum cellular suspensions (lanes 2 and 4).
Molecular weight markers are to the left of the figure. Possible digestion products 
are indicated by arrows.
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amino acids in this region is the major structural difference between IgA2 and 
IgAl. This was confirmed by determining the point of scission in the IgAl a chain. 
N-terminal amino acid sequencing of the Fca portion of digested S-IgA 
reproducibly gave the following sequence:
-Thr-Pro-Ser-Pro-Ser-Cys-Cys-His-Pro-
The designation of the two cysteine residues was only possible after 
pyridylethylation of the Fca fragment, since under normal conditions of Edman 
degradation, cysteine residues cannot be identified. Comparison with the known 
amino acid sequence of human IgAl (Putnam et al, 1979) revealed that cleavage 
had occurred between residues 235 and 236, a site located in the second repeat of 
the octapeptide within the hinge region of the a chain (Fig. 1.6). This was one of 
the two previously predicted cleavage sites for U. urealyticum (Kapatais-Zoumbos 
et at, 1985) and is the confirmed cleavage site of the Type 2 IgAl proteases from 
N. gonorrboeae, N. meningitidis and H. influenzae (Plaut et at, 1975, Mulks et at, 
1980a, Kilian et al, 1980).
2.9.2 Synthetic peptide substrates
Having identified the site of digestion for the ureaplasma IgAl protease, it 
was then possible to design a synthetic peptide that may have served as more 
useful substrate for assaying enzyme activity than human S-IgA or IgAl. Since the 
IgAl proteases of N. gonorrhoeae (type 2) and U. urealyticum cleave the same site 
in the IgAl hinge region, one of the 10-residue synthetic peptides that had been 
susceptible to digestion by the neisserial IgAl protease (Wood and Burton, 1991) 
was synthesised.
The purified peptide molecule eluted as two distinct peaks by reverse- 
phase HPLC. There was no alteration in peak size or mobility following incubation 
with crude ureaplasma extracts, suggesting that no digestion had occurred 
(Fig. 2.11, panel c). The pH of the reaction mixture (pH 7 in PBS) was favourable 
for IgAl protease activity, but there may have been a number of other reasons why 
there was no cleavage of synthetic substrate. To confirm the integrity of the
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a) TFA alone b) Peptide in TFA
A226nm
c) Peptide + ureaplasma 
cells, 16 h incubation
d) Peptide + ureaplasma 
cells, 0 h incubation
Fig. 2.11 Analysis of synthetic peptide by reverse-phase HPLC.
15 pi (300 pg in PBS) of the synthetic peptide Ac-V-V-A-P-P-S-P-Q-A-N-NH2 in 30 pi TFA (0.1%) was analysed by reverse-phase
chromatography (HPLC) using using a gradient of 0-50% TFA (0.1%) in 30 min (panel b), as described in Section 2.4.3. A sample of 15 pi PBS 
in 30 pi 0.1% TFA was included as a control (panel a). To assess digestion of the peptide by U. urealyticum IgAl protease, 300 pg of peptide 
(in 15 pi PBS) was incubated (37 °C) with 5 pi crude ureaplasma cell suspension for either 0 or 16 h. After addition of 30 pi TFA (0.1%), the 
digest mixture was examined by reverse-phase HPLC, as before (panels c and d).
time (min)
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peptide, an attempt was made to prepare the type 2 IgAl protease from 
N. gonorrhoeae to test under the same conditions. No enzyme activity was 
detected in neisserial pellets or spent medium using the immunoblotting method 
(data not shown) and further purification of the IgAl protease was probably 
necessary before it could be used for this purpose. It is also possible, but very 
unlikely, that the bacterial strain used did not produce an IgAl protease.
As an alternative, peptides based on the hinge region of IgAl could have 
been synthesised, although such compounds had not proved to be effective 
substrates for other IgAl proteases (Table 1.2). As a preliminary to such work, it 
was shown that isolated IgA a chains (obtained by reduction and 
carboxymethylation of IgA followed by gel filtration) were partially digested by the 
ureaplasma IgAl protease (Fig. 2.10). It appeared that digestion was less specific 
than with intact IgA and a number of cleavage products were detected. Elucidation 
of these digestion sites may serve as a basis for future synthetic substrate design.
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SECTION C 
DISCUSSION
It was confirmed that U. urealyticum produces a classical IgAl protease 
which cleaves IgAl, but not IgA2, into Faba and Fca fragments. There were a 
number of features of this process, however, that hindered progress in enzyme 
characterisation. The most fundamental of these was the length of time required to 
demonstrate the presence and levels of IgAl protease activity. Incubation times of 
over ten hours were required before digestion products were identified and the 
detection methods themselves were time-consuming and only semi-quantitative.
Comparable incubation times have been reported by other workers 
examining ureaplasma IgAl protease activity (Kilian et al, 1984, Kapatais- 
Zoumbos et al, 1985). Robertson et al, (1984) found that optimal degradation 
occurred after 42 h (36 °C). Crude preparations of other bacterial IgAl proteases 
frequently require incubation with substrate for up to 16 h (Labib et al, 1978, 
Mulks and Knapp, 1987, Frandsen et al, 1987, Tsuji et al, 1989) but digestion 
times for partially purified or purified enzymes have been reported as low as 
30 min (Plaut et al, 1974b, Blake and Swanson, 1978, Mortensen and Kilian,
1984a, Halter et al, 1984). The specific activity of the IgAl protease preparation 
was undoubtedly higher in these cases and each reaction contained a minimum of 
100 pg IgAl substrate (Mulks et al, 1980b). In the present study, where 
commercial S-IgA (colostrum) was used as a substrate, such concentrations were 
prohibitively expensive. If clinical material had been available, a high titre of 
monoclonal IgAl could have been obtained from the serum of patients with a 
plasma cell neoplasm (Plaut, 1983). For enzyme characterisation, however, 
colostral S-IgA may represent the natural substrate for the ureaplasma IgAl 
protease more closely than serum IgAl.
It is not known how ureaplasma IgAl protease activity in vitro compares 
with the activity in vivo, but it seems likely that in vitro reaction conditions are 
suboptimal, since if IgAl digestion is to be of benefit to U. urealyticum in vivo, a 
more rapid substrate digestion would be expected. There may be a number of
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factors which operate in vitro to reduce enzyme activity. The reaction
temperatures used (37 °C) matched those found in vivo and although the pH of 
the reaction buffer (pH 7.4) did not absolutely reflect the pH of the vagina or 
urinary tract (pH 5 and pH 6 respectively), it was shown that such differences in 
pH did not significantly influence enzyme activity. Divalent cations similarly did 
not affect IgA proteolysis but Blake and Eastby (1991) routinely included 10 mM 
CaClz and 10 mM MgCl2 into gonococcal IgAl protease reaction mixtures, 
suggesting that this IgAl protease is activated by metal ions. It is possible that the 
ureaplasma IgAl protease was simply not as active in cells grown in artificial 
culture medium or that the medium used was suboptimal for expression. The 
presence of large quantities of IgAl in vivo may stimulate IgAl protease 
production in ureaplasmas, but it is generally regarded that IgAl protease 
production in other bacteria is constitutive.
The serum component of ureaplasma growth medium, which frequently 
co-harvests with ureaplasma cells, may have contained inhibitors to the IgAl 
protease. Bacterial IgAl proteases have demonstrated considerable resistance to 
common anti-proteases such as a-2-macroglobulin and a-1-antitrypsin (Plaut, 
1983) but the effect of similar serum-bound inhibitors on the ureaplasmal enzyme 
has not been examined. Since the enzyme may be membrane associated (Chapter 
3), the cell-bound serum components may have restricted substrate access. 
Alternatively, the substrate itself, S^_IgA, may contain antibodies inhibitory to 
enzyme activity (Kilian et al., 1980, Gilbert et al, 1983). There was no apparent 
difference between the rates of digestion of the commercially-obtained serum IgAl 
and the S-IgA used in this study. This was only judged on a visual basis by 
immunoblotting, however, and accurate quantitative measurements of IgAl 
protease activity were not performed.
Developing rapid and quantifiable detection methods for the ureaplasma 
IgAl proteases remains a principal requirement for research on this enzyme. 
Although rocket Immunoelectrophoresis has been used for the analysis of bacterial 
IgAl proteases (Lassiter et al, 1989, Kilian et al, 1983a) it was found that the 
technique was no faster to perform than SDS-PAGE and the results obtained were
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more ambiguous. It was not clear why the PEG-based spectrophotometric assay 
failed to detect ureaplasma IgAl protease activity. The preparations of relatively 
pure H. influenzae IgA 1 protease used in the original report by Bleeg et al, (1985) 
may have been more suitable than the crude IgAl protease samples obtained from 
U. urealyticum harvests. The separation of digestion products by HPLC and 
quantitation of digestion by measurement of peak areas demonstrated 
considerable potential as a quantitative method for assaying IgAl protease activity. 
The time and labour required for the analysis of large sample numbers rendered 
the technique impractical for the purposes of this investigation. If an HPLC 
machine had been available on a regular basis, these problems may have been 
overcome by using higher flow rates and by the installation an auto-injector.
For future work, a number of other options should be considered for the 
quantification of ureaplasma IgAl proteases. ELISA-based methods have been 
described for the measurement of gonococcal and streptococcal enzyme activity 
(Blake and Eastby, 1991 and Reinholdt et al, 1990). As described in Chapter 1 
(Section 1.7.6), the recent identification of a Cen A-IgAl hybrid molecule which is 
susceptible to cleavage by the IgAl proteases from N. gonorrhoeae and 
H. influenzae (Miller et al, 1992) may have applications for the assay of these 
enzymes. It is likely that the ureaplasma IgAl protease would also cleave this 
molecule, since preliminary evidence suggests that the enzyme shares a substrate 
specificity with the Neisseria and Haemophilus type 2 IgAl proteases.
To examine the IgAl substrate specificity of U. urealyticum IgAl protease, 
Fca digestion products were subjected to limited N-terminal amino acid 
sequencing. By comparison with the published sequence for IgAl (Putnam et al, 
1979), the point of scission was identified as the Pro235-Thr236 hinge region 
peptide bond, identical to the site cleaved by the type 2 IgAl proteases from 
N. gonorrhoeae and H. influenzae. The homogenous mixture of amino acids 
obtained from N-terminal sequencing suggested that the enzyme cleaved at only a 
single bond only within the hinge region of IgAl. As was found for other bacterial 
IgAl proteases digesting this site, the Pro-Thr peptide bond in the sister 
octapeptide of the hinge region was resistant to attack. Although the precise
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reason for this is unclear, it has been suggested that bacterial IgAl protease are 
conformation-dependent rather than sequence-specific enzymes (Section 1.7.6). 
This has been supported by the fact that synthetic peptides based on the IgAl 
hinge region were not substrates for the gonococcal IgAl type 2 IgAl protease but 
peptides of similar (but not identical) sequence, based on the autocatalytic 
cleavage sites within the precursor molecule of the gonococcal IgAl protease, 
were readily digested by the enzyme (Pohlner et al, 1987).
The specificity determinants for the ureaplasma IgAl protease may also be 
conformational, but a preliminary examination found that one of the synthetic 
peptides digested by the gonococcal enzyme (peptide B) was not susceptible to 
digestion by the ureaplasma enzyme. There may be a number of explanations for 
this, other than the peptide simply not being a suitable substrate for the enzyme. 
The identification of two peptide peaks from reverse-phase chromatography 
suggested that synthesis was only partially complete and one peak may represent 
a truncated version of the peptide. If this had interacted with the active site, 
digestion of the completed peptide may have been inhibited. For further 
experiments, it would be essential to purify the synthetic peptide and confirm its 
composition by amino acid analysis or protein sequencing. Before it is dismissed 
as a synthetic substrate for U. urealyticum, it should also be demonstrated that the 
peptide is susceptible to digestion by the neisserial IgAl protease. This would 
require further enzyme purification than was achieved in this preliminary study 
and detailed protocols have been described by Plaut (1988) and Halter et al, 
(1984).
The production of multiple digestion products following incubation of the 
ureaplasmai IgAl protease with reduced and alkylated IgAa chains also suggest 
that substrate recognition may be different for the ureaplasmai enzyme. Using a 
similar approach, Kilian et al, (1980) established that the H. influenzae type 1 
enzyme only digested the single hinge-region peptide bond in isolated a chains. It 
is necessary to confirm the result obtained with U. urealyticum and if the N- 
terminai amino acid sequence of each fragment can be elucidated, the substrate 
requirements of the IgAl protease may be defined more clearly. Furthermore,
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synthetic peptides based on these sequences could serve as alternative substrates 
for the ureaplasmal enzyme.
To further clarify the substrate specificity and, more broadly, the function 
of the IgAl protease, it would be of interest to establish whether ureaplasma 
proteins are substrates the enzyme, as has been demonstrated in N. gonorrhoeae 
(Shoberg and Mulks, 1991). Proteins isolated from the single ureaplasma isolate 
found to be devoid of IgAl protease activity (Robertson et aL, 1984) may be of use 
in investigating a role for the enzyme in protein-processing. It is not clear whether 
autocatalytic cleavage of the IgAl protease occurs during processing in 
U. urealyticum, since the enzyme produced by this organism appears to be cell- 
associated (discussed in Chapter 3).
An examination of IgAl digestion products from all fourteen serotypes of 
U. urealyticum suggested that the substrate specificity for each enzyme was 
identical to that established for serotype 8. Although Faba and Fca fragments 
differing by only a few amino acids by are clearly identified by SDS-PAGE, 
observed migration patterns may nevertheless be misleading. For example, the 
action of streptococcal glycosidases on hinge region carbohydrate has produced 
distinct IgAl degradation patterns from IgAl proteases with identical substrate 
specificity (Reinholdt et aL, 1990). The precise cleavage sites of ureaplasma 
serotypes will therefore only be confirmed following N-terminal amino acid 
sequencing of individual digestion products. From these preliminary studies, 
however, it appears that U, urealyticum is unlike H. influenzae, N. gonorrhoeae 
and N. meningitidis where two IgAl protease spetificity types have been 
identified (Section 1.7.4).
The different levels of IgA digestion products obtained from apparently 
identical ureaplasma cell preparations (in terms of protein concentration) 
suggested that some serotypes express higher levels of IgAl protease activity than 
others. This may have been due to experimental design rather than real differences 
in serotype activity, since the estimation of ureaplasma cell concentrations did not 
take into account the levels of medium-protein contamination present in each 
serotype preparation. Although each serotype was grown to the same titre, this
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method does not accurately determine the number of live ureaplasma cells used in 
each assay.
Quantitative differences in IgAl protease production both within and 
between other bacterial species have generally not been reported. Male, (1979) 
found that the 5. pneumoniae IgAl protease was more active than its 
H. influenzae counterpart and suggested that this may have been due to exposure 
of the IgAl cleavage site by pneumococcal glycosidases. The effect of differential 
anti-IgAl protease antibody activity in the S-IgA preparation was not taken into 
account in this study, however. For N. gonorrhoeae, the disease-associated piliated 
bacteria have been shown to produce more enzyme per diplococcal unit than 
non-piliated isolates (Blake and Swanson, 1978), but it was stressed by these 
workers that the quantitation of bacterial numbers per culture was subject to 
inaccuracy. As far as the involvement of IgAl protease in disease is concerned, 
semi-quantitative estimations have identified no differences in enzyme act^i/vity 
between isolates associated with infected or non-infected sites (Kornfeld and 
Plaut, 1981). For U. urealyticum, it has been established that the enzyme is present 
in isolates from diseased as well as healthy individuals (Robertson et al, 1984) but 
quantitative measurements of enzyme activity were not performed in this study. It 
would be of interest to establish whether the IgAl protease-negative isolate of 
U. urealyticum has different pathogenic properties from the IgAl protease-positive 
organisms; at present there is no definitive correlation between bacterial IgAl 
protease expression and virulence although type 2 enzymes show a stronger 
association with disease than type 1 enzymes (Section 1.7.5).
Using a range of class-specific inhibitors, the IgAl protease from 
U. urealyticum appeared to be a member of the serine protease class as it was 
inhibited by the two diagnostic serine protease inhibitors DFP and 2,4-DCI (Bond, 
1989). It was not clear why an early demonstration of inhibition by PMSF was later 
unreproducible. Although PMSF is more unstable and less reactive than DFP, it 
clearly inhibited trypsin in a standard trypsin assay. The type 2 IgAl protease from 
N. gonorrhoeae has also demonstrated insensitivity to concentrations of up to 
2 mM PMSF (Blake and Swanson, 1978, Simpson et al, 1988) but has been
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assigned to the serine-protease class following inhibition with DFP and transition 
state analogues (peptidyl boronic acids) and by site-directed mutagenesis of the 
putative active site (Bachovchin et al, 1990, Poulsen et al., 1992). The inhibitory 
effect of DFP and peptidyl boronic acids on the H. influenzae IgAl protease has 
also suggested that this enzymes is a serine protease (Bachovchin et at, 1990). 
Following their sensittvity to metal chelators, reported by some but not by all 
workers, it has been proposed that these two enzymes may be metal-dependent 
(Kilian et at., 1983a). The IgAl protease from U. urealyticum was insensitive to 
EDTA but the effect of BCDS, which according to Kilian et al, (1983a) is inhibitory 
to all IgAl proteases, was not examined.
The mechanism of enzyme activity may be defined more clearly if a 
purified ureaplasma IgAl protease was available. A pure enzyme could also be 
used to generate specific antisera for rapid IgAl protease detection and for 
comparative immunological studies with other bacterial IgAl proeeases. For these 
reasons, efforts were concentrated upon purification of the ureaplasma IgAl 
prorensc.
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Chapter 3:
Purification of the IgAl protease
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SECTION A
MATERIALS AND METHODS
3.1 THE SOURCE OF U. UREALYTICUM IGA1 PROTEASE
3.1.1 Location of IgAl protease activity in ureaplasma cultures.
Two identical ureaplasma liquid cultures (20 ml) were grown to very late 
log-phase, as described in Section 2.1.1. A 10 pi aliquot of growth medium from 
each culture was sampled before and after harvesting. Of the resultant ureaplasma 
pellets, one was resuspended in PBS to the original culture volume (20 ml) and the 
second was resuspended in PBS to 1/2000 x original culture volume (10 pi). (This 
was equivalent to resuspending a 10 1 harvest into 5 ml). 5 pi of each sample was 
tested for IgAl protease activity, as described in Section 2.1.5.
3.1.2 Concentration of spent medium from ureaplasma growth culture.
To concentrate the spent medium, a 1 ml sample was reduced to 50 pi 
(20 x concentration) using a microconcentrator (Amicon, P1O, 3000 x g). The 
concentrated sample (15 pi) was analysed for IgAl protease activity by incubation 
with S-IgA and immunoblotting, as described in Sections 2.1.5 and 2.1.9.
3.1.3 Fractionation of spent medium by ammonium sulphate precipitation.
Solid ammonium sulphate was slowly added to ureaplasma culture 
supernatants (50 ml, 4 °C) to give a 20% saturated solution (Harris and Angal, 
1989). After gentle stirring (30 min., 4 °C), precipitated proteins were collected by 
centrifugation (10,000 xg, 4 °C) and resuspended in a minimum volume of 
distilled water (1 ml). The ammonium sulphate concentration in the remaining 
supernatant was increased to 30% saturation and the process repeated at 10% 
concentration intervals until precipitates from a range of concentrations (20%- 
100% saturation) were obtained. These were dialysed extensively with PBS (4 °C) 
and 30 pi samples assayed for IgAl protease activity by immunoblotting or 
autoradiography, as described in Sections 2.1.9 and 2.1.10.
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3.1.4 Solubilisation of IgAl protease from ureaplasma cell harvests
A number of different solubilisation buffers (Table 3.1, page 144) were 
analysed for their ability to release the IgAl protease from ureaplasma cell 
harvests. HEPES buffer (N-[2-hydroxyethyl] piperazine-N'-[2-ethane sulphonic 
acid]), NP40 (Nonidet-P40), Tween 20 (polyoxyethylene sorbitan monolaurate), 
CHAPS (3-[(3-cholamicopropyl) dimethyl ammonial-1-propane sulphonate), Brij 
35, Brij 78 and W1 (polyoxylene ether) were obtained from Sigma. Triton X-100 
(TX-OOO) was from National Diagnostics, SDS (sodium dodecyl sulphate) from 
BDH and Zw3-12 (Zwittergent) from Calbiochem.
For a general assessment of each solubilisation buffer (Table 3. 1 A), 
ureaplasma cell suspensions in PBS (prepared as described in Section 2.1.1) were 
divided into 100 pi aliquots and harvested by centrifugation (50,000 x g, 10 min,
4 °C). The pellets were thoroughly resuspended in 100 pi ice-cdd solubilisation 
buffer and placed on ice (30 min). The solubilised extract was collected by 
centrifugation and 10 pi aliquots were assayed for IgAl protease activity, by 
incubation with IgA and immunoblctt:ing, as described in Sections 2.1.5 and 2.1.9.
To examine the effect of repeated solubilisation steps, 100 pi aliquots of 
ureaplasma cell suspensions in PBS were solubilised as above. After 30 min on ice 
a 10 pi aliquot (representing the original sample) was removed and the remaining 
suspension was separated by centrifugation (50,000 x g, 10 min, 4 oc). The 
supernatant, which contained solubilised ureaplasma cell protein (Sup. 1), was 
decanted and the insoluble pellet resuspended in 90 pi solubilisation buffer. A 
10 pi sample (representing pellet 1) was removed and following centrifugation, as 
before, the resolubilised cellular material (Sup. 2) and the remaining pellet (which 
had been resuspended in 80 pi buffer), were collected. The solubilised extracts 
and resuspended pellets (10 pi) were assayed for IgAl protease activity by 
incubation with S-IgA and immunoblotting, as described in Sections 2.1.5 and 
2.1.9. Crude ureaplasma suspensions in PBS alone were included as controls for 
each immunoblotting assay.
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3.1.5 InMbitioo of IgAl proteeasaativity u uing sseeific aatissra
As a preliminary to purification experiments, a number of uncharacterised 
monoclonal antibodies, produced from three separate hybridoma fusions and a 
polyclonal antiserum, all raised against U. urealyticum serotype 8 (Precious et al, 
1987) were tested for their ability to inhibit IgAl protease activity. Ureaplasma 
cellular suspensions (5 pi, prepared as in Section 2.1.1) were pre-incubated (37 °C, 
30 min) with each monoclonal antibody (1/250 dilution in PBS) or a polyclonal 
antisera (1/250 dilution in PBS) prior to incubation with S-IgA and analysis of 
digestion products by immunoblotting, as described in Section 2.1.5 and 2.1.9.
3.2 PURIFICATION PROTOCOLS
3.2.1 Pilot studies
The purification studies were performed using a Pharmacia FPLC system, 
as detailed in the manufacturers handbook (FPLC portfolio, Pharmacia). All buffers 
were filtered before use with 0.2 pm membranes (Anachem).
In initial pilot studies, 125 pi of ureaplasma cell suspension (representing 
250 ml late log-phase culture; -0.6 mg protein, prepared as described in Section 
2.1.1) was solubilised twice (30 min, 4 °C) in 200 pi Buffer A (50 mM Tris-HCl, 
pH 8.0: 0.05% NP40) as described in Section 2.2.4. The resulting supernatants were 
pooled and filt^er^ed using 0.2 pm membranes (Anachem).
A 9 pi aliquot was removed and stored as a pre-load and 300 pi of the 
remainder (or the equivalent of 250 pg solubilised ureaplasma protein) was loaded 
on to the purification column, as described below.
a) Ion exchange chromatography
Separation by ion exchange chromatography utilised a Mono Q (anion) or 
Mono S (cation) column equilibrated with 50 mM Tris-HCl, pH 8.0:0.05% (v/v) 
NP40 (Buffer A). Proteins were selectively eluted (1 mhmin.'1) with NaCl by 
increasing the concentration of Buffer B (50 mM Tris-HCl, pH 8.0:0.05% (v/v)
NP40, 1 M NaCl), by a rate controlled by programme 1 or 2 (see below). The
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eluted proteins were measured spectrophotometrically (280 nm) and collected as 
1 ml fractions, until the recorded elution profile had reached the initial base line.
Elution programme for ion exchange chromatography:
%B Programme 1
(steep)
Programme
(shallow)
0 5 min 5 min
50 15 min 35 min
100 20 min 40 min
100 25 min 45 min
0 25 min 45 min
0 30 min 50 min
b) Gel filtration chromatography
In gel filtration chromatography, proteins were separated at 0.5 ml.min-1 
on a Superose 6 column equilibrated with 50 mM Tris-HCl, pH 8.0: 0.05% (v/v)
NP40. As before, eluted proteins were detected spectrophotometrically at 280 nm 
and 1 ml fractions were collected.
c) Identifying IgA! protease activity
To identify IgAl protease activity, 30pl of each fraction or a suitable 
volume of preload sample (~10 pi) were incubated with 4 pi S-IgA (4 mg. mb1,
16 h, 37 °C). Digestion products were detected by SDS-PAGE and immunoblotting, 
as described in Section 2.1.6 and 2.1.9. The volume of preload sample was chosen 
to approximate the dilution of IgAl protease enzyme that was produced by the 
separation step. For example, if the enzyme was loaded onto the column in 300 pi 
and eluted in a single fraction of 1000 pi, assuming 100% recovery, 30 pi of the 
fraction should have contained the same level of enzyme activity as 9 pi preload 
sample. The preload sample thereby enabled a qualitative assessment of the levels 
of enzyme activity maintained in the purification process. The protein content of 
active fractions was examined by SDS-PAGE followed by PAGE-blue 83 or silver-
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staining. Where necessary, the fractions were concentrated by freeze-drying or 
precipitation in a final concentration of 10% (w/v) trichloroacetic acid (TCA).
3.2.2 Two-step analyses
When two purification columns were used in succession, 1.0 ml 
ureaplasma harvest (representing 2 1 log-phase culture, -10 mg protein) was 
solubilised twice in 1.5 ml Buffer A. The solubilised preparations were filtered 
(0.2 pm nylon fi^t^r^s, Anachem) prior to loading onto an ion exchange column, as 
above. Active fractions were identified (as above), combined and concentrated to 
a volume of 200 pi using a microconcentrator (Amicon P1O, 3000 x g) and loaded 
on to the gel fi^t^r^ation column, as above.
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SECTION B 
RESULTS
3.3 SOURCE OF U. UREALYTICUM IGA1 PROTEASE
The bacterial IgAl proteases purified to date have been isolated from 
spent culture medium. As a preliminary to U. urealyticum IgAl protease 
purification experiments, it was important to establish whether the spent culture 
medium was a more abundant source of enzyme than harvested ureaplasma cells.
3.3.1 The cellular location of the IgAl protease
There was no evidence of extracellular IgAl protease activity in the 'spent' 
medium from ureaplasma liquid cultures following incubation of an aliquot of 
'spent* medium with S-IgA and analysis of digestion products by SDS-PAGE and 
immunoblotting (Fig. 3.1, lane 3). Furthermore, no activity was detected in the log- 
phase culture medium prior to harvest (lane 1), presumably as a consequence of 
dilution. Following centrifugation and resuspension of ureaplasma cells in PBS at 
1/2000 original culture volume, a cell-associated activity was clearly identified 
(lane 2). In addition, when the ureaplasma cells were subsequently resuspended 
to their original volume in PBS (lane 4), enzyme activity was again undetectable by 
this method, confirming that dilution of cells was indeed a consideration. Thus, the 
failure to identify any extracellular IgAl protease activity in ureaplasma 'spent' 
culture medium may simply be due to the enzyme being present at too low a 
concentration to be detected by this assay.
Following the method outlined by Kilian et al, (1984), 'spent' medium 
was concentrated x 20 by positive pressure ultrafiltration using a 
microconcentrator (Amicon P1O) and assayed for IgAl protease activity, as above. 
The presence of a large number of medium components in the concentrated 
samples so distorted the electropherograms that detection of intact IgA and any 
specific digestion products was not possible. Because of this, 
immunoelectrophoresis was not attempted. The masking effect of the medium
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Fig 3.1 Localisation of IgA protease activity in U. urealyticum liquid cultures.
Two identical ureaplasma cultures (20 ml) were grown to log-phase, as described 
in Section 2.1.1. 10 |il aliquots of growth medium were sampled before (S1) and 
after (S3) harvesting of ureaplasma cells. The resultant pellets were resuspended in 
either 10 pi or 20 ml of PBS and 10 pi aliquots of each were sampled (S2 and S4 
respectively). The samples were analysed for IgAl protease activity by incubation 
with S-IgA and immunoblotting, as described in Section 2.1.9.
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proteins could not be overcome by replacing S-IgA with [125Il IgAl and examining 
for intact substrate and digestion products by autoradiography.
In an attempt to reduce the contamination by medium proteins, 
ureaplasma spent medium was fractionated by ammonium sulphate precipitation. 
Although there was no evidence of IgAl protease activity in any of the ammonium 
sulphate fractions (Fig. 3.2A), it was possible that this was again due medium 
protein interference with the detection system, since the IgAa chain was masked 
in the immunoblot. The addition of crude IgAl protease preparations to each 
sample in the assay indicated that even if digestion products are present, in some 
fractions (30%-60%) these will be masked by the high concentration of 
contaminating medium proteins (Fig. 3.2b). It was therefore not possible to 
determine by these methods whether U. urealyticum produced an extracellular 
IgAl protease. It was clear, however, that 'spent' culture medium did not contain 
large quantities of IgAl protease activity and for the purposes of enzyme 
purification, cell harvests represented the most abundant source of U. urealyticum 
IgAl protease enzyme.
3.3.2 Solubilisation of the IgAl protease
Prior to purification studies, it was necessary to solubilise the cell- 
associated ureaplasmal enzyme. Of the large number of solubilisation systems that 
were examined (Table 3.1), it was found that the non-ionic detergents such as 
Tween 20, NP40 and TX-1OO, at concentrations as low as 0.05% (v/v), were best 
able to solubilise and maintain ureaplasma IgAl protease activity. The detergents 
were effective in a variety of different buffers (Tris, PBS, HEPES), although for 
some detergents (Tween, NP40), the presence of 1 M NaCl appeared to marginally 
reduce the level of enzyme activity in the solubilised preparation. For all the 
systems examined, a proportion of the IgAl protease enzyme remained cell- 
associated after the first round of solubilisation (Fig. 3.3, Table 3.1B). Repeated 
detergent treatment was able to solubilise a portion but not all of this cell- 
associated activity. By measuring protein concentrations, it was estimated that a
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Fig. 3.2 Fractionation of U. urealyticum 'spent* medium by ammonium sulphate 
precipitation.
a) U. urealyticum spent medium was precipitated by increasing concentrations of 
ammonium sulphate (20%-100%, saturation), as described in Section 3.1.3. Each 
fraction was dialysed extensively with PBS (4 °C) and 30 pi samples assayed for 
IgAl protease activity by incubation with S-IgA and immunoblotting.
b) To examine the effect of concentrated spent medium proteins on the detection 
of IgA digestion products, ureaplasma cell suspensions (5 pi) were included in 
each incubation reaction and the digests were analysed by immunoblottir^g. 
Reactions containing IgA alone (1) and IgA +% pi ureaplasma cell suspensions (2) 
were included as controls.
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Table 3.1 Solubilisation of U. urealyticum IgAl protease
A)
Solubilisation buffer IgAl protease 
activity in 
supernatant
Solubilisation buffer IgAl protease 
activity in 
supernatant
h2o - PBS: 0.5% CHAPS ++++ (34%)
PBS + (9%) PBS: 0.5% CHAPS:
0.5 M NaCl
++++ (43%)
PBS: 0.5 M NaCl + (12%) PBS: 0.5 % 2w3-12 - (34%)
PBS: 0.05% NP40 ++++ PBS: 0.5 % Zw3-12:
0.5 M NaCl
- (33%)
PBS: 0.1% NP40 ++++ PBS: 0.5% SDS -
PBS: 0.5% NP40 ++++ (25%) PBS: 0.5% SDS:
0.5M NaCl
-
PBS: 0.5% NP40:
0.5 M NaCl
+++ (30%) 50 mM HEPES, pH 7.5 +
PBS: 0.5% TX-1(O ++++ (25%) 50 mM HEPES:
0.5 M NaCl
+
PBS: 0.5% TX-100:
0.5 M NaCl
++++ 00%) 50 mM HEPES:
0.5% NP40
++++
PBS: 0.5% Tween 20 ++++ (28%) 50 mM HEPES: 1 M 
NaCl
4
PBS: 0.5% Tween 20: 
0.5 M NaCl
+++ 09%%) 50 mM HEPES: 0.5 M 
NaCl: 0.5% NP40
++++
PBS: 0.5% BRIJ 35 ++ (19%) 50 mM Tris-HCl, pH 8: 
0.5% NP40
++++
PBS: 0.5% BRIJ 78 +++ (23%) 50 mM Tris-HCl, pH 8: 
0.5% NP40: 0.1 M NaCl
++++
PBS: 0.5% W1 ++ ' (20%) 15 mM Tris-HCl, pH
7.5: 0.5% NP40: 1 M 
NaCl
++++
(* -% of total protein solubilised, calculated by D, Smith, University of
St. Andrews).
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B)
IgAl protease activity
Solubilisation buffer Original
sample
Sup. 1 Pellet 1 Sup. 2 Pellet 2
PBS ++++ + ++++ + +++
PBS: 0.05% NP40 ++++ ++++ ++++ ++++ ++++
PBS: 0.1% NP40 ++++ ++++ 4—4++ ++++ ++++
PBS: 0.5% NP40 ++++ ++++ ++++ ++++ +++
PBS: 0.5% BRIJ 35 ++++ ++ ++++ + +++
PBS: 0.5% BRIJ 78 +++ +++ +++ + ++++
PBS: 0.5% W1 +++ 4—- +++ + +++
50 mM HEPES, pH 7.5 ++++ + ++++ - ++++
50 mM HEPES: 0.5 M
NaCl
++++ + ++++ + ++++
50 mM HEPES: 1 M NaCl ++++ + ++++ + ++++
50 mM HEPES: 0.5 M
NaCl: 0.5% NP40
++++ ++++ ++++ ++++ + + + +
50 mM Tris-HCl, pH 8: 
0.5% NP40
++*4" 4- ++++ ++++ +++ ++++
50 mM Tris-HCl, pH 8: 
0.5% NP40: 100 mM NaCl
++++ +4-4-*- ++++ +++ ++++
15 mM Tris-HCl, pH 7.5: 
0.5% NP40: 1 M NaCl
++++ ++++ ++++ +++ +4-4-4-
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Fig. 3.3
a) PBS: 0.5% NP40 b) PBS: 0.5% Brij 35
—IgAa
..... _ Faba/
Fca
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Fig. 3.4
Fig. 3.3 Solubilisation of U. urealyticum IgAl protease with PBS: 0.5% NP40 
and PBS: 0.5% Brij 35.
Ureaplasma cellular suspensions were solubilised (2 x) with PBS: 0.5% NP40 and 
0.5% Brij 35, as described in Section 3.1.4. 10 pJ samples of the original solubilised 
preparation (O), protein-containing supernatents (SI, S2) and the remaining pellets 
(Pl, P2) were examined for IgAl protease activity by incubation with S-IgA 
followed by immunoblotting, as described in Sections 2.1.5 and 2.1.9. Incubations 
containing IgA alone (Cl) and 5 pi of the original cellular harvest (C2) were 
included as controls.
Fig. 3.4 The effect of anti-U. urealyticum serotype 8 antibodies on IgAl 
protease activity.
Cellular ureaplasma suspensions (5 pi) were pre-incubated with a range of 
uncharacterised monoclonal antibodies (1-13) and a polyclonal antisera (P), 
originally raised against U. urealyticum Serotype 8, as described in Section 3.1.5. 
The level of inhibition was estimated by incubation with S-IgA followed by 
immunoblotting, as described in Sections 2.1.5 and 2.1.9. Incubation in the absence 
of antiserum (C) was included as a control.
maximum of 40% ureaplasma protein was solubilised by each treatment (Table
3.1 A). While sonication (3 x 10 sec) of ureaplasma suspensions in PBS alone 
resulted in a degree of enzyme release, in detergent-solubilised preparations, 
sonication did not appear to increase the overall level of enzyme activity. Likewise, 
repeated freeze-thawing (10 x) of the cellular suspension was not as effective in 
enzyme release as detergent treatment (data not shown). These results appear to 
give more evidence that the IgAl protease in U. urealyticum may be membrane- 
associated.
3.3.3 Inhibition of IgAl protease activity using specific antisera.
The monoclonal antibodies used were specific for U. urealyticum proteins 
by ELISA but are described as 'uncharacterised' since they have failed to identify 
specific ureaplasma proteins by Western blotting (experiments performed by B. 
Precious and A. Myles, University of St. Andrews). None of the monoclonal 
antibodies tested inhibited IgAl protease activity, which suggested that none were 
specific for the active site of the enzyme (Fig. 3.4). Furthermore, no inhibition was 
seen with an anti- U. urealyticum rabbit polyclonal antisera, at dilutions as low as 
1/250 in PBS.
In these examinations, a number of physical properties of the solubilised 
IgAl protease were established which were important for the design of 
purification experiments. As mentioned previously, the enzyme was stable in a 
large number of detergent and buffer systems. It appeared to be resistant to 
repeated freeze-thawing and remained stable at 4 °C or 20 °C for over 8 h. Enzyme 
activity was not reduced by filtration (0.2 pm fil^^ei*, Anachem) and could be 
detected by the immunoblotting assay at dilutions of up to 1/120 in PBS,
3.4 PURIFICATION PROTOCOLS
3.4.2 Pilot studies
To purify the ureaplasma IgAl protease, a number of pilot studies were 
used to establish which chromatographic techniques allowed fractionation and
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recovery of the enzyme. In subsequent experiments, the level of purification 
achieved by a series of these separation steps was examined,
a) Anion exchange chromatography
by anion exchange chromatography (Mono Q) demonstrated
that in 50 mM Tris-HCl, pH 8.6, the ureaplasma IgAl protease bound to the Mono 
Q column and was eluted by a salt concentration of approximately 0.38 M NaCl. 
(Fig. 3.5). The activity of the eluted enzyme in 30 pi of the 1 ml fraction (where it 
had been diluted ~1:3.3 by volume) was substantially less than in 9 pi of the 
preload sample. This suggested that a proportion of the enzyme activity had been 
lost in the single purification step. As the IgAl protease had been solubilised from 
ureaplasma cells using 0.05% (v/v) NP40, this non-ionic detergent was included at 
the same concentration in the equilibrating and eluting buffers.
Fig. 3.6 demonstrates that 0.05% (v/v) NP40 appeared to stabilise the 
enzyme and the total amount of IgAl protease activity found in 30 pi of fraction 11 
and fraction 12 (each 1 ml) was almost identical to that found in the 9 pi preload.
In subsequent purification steps, 0.05% (v/v) NP40 was included in all the 
chromatography buffers. The absorbance properties of NP40 at 280 nm, however, 
produced erratic elution profiles which in some cases prevented the identification 
of peaks corresponding to IgAl protease activity.
An examination of the selective elution of the IgAl protease enzyme from 
the Mono Q column using a shallower salt gradient (from 0 M NaCl to 0.5 M NaCl 
in 30 min rather than 10 min) highlighted this problem (Fig. 3.7). As the 
concentration of Buffer B was raised, the base line of the recorder trace increased 
at the same rate. Although the equilibration and elution buffers contained the same 
concentration of NP40 (0.05%, [v/v]) it was clear that small differences in detergent 
concentration were producing large differences in absorbance readings at this 
wavelength. If the solubilisation, equilibration and elution buffers were derived 
from the same original stock, this effect was reduced but not completely 
eliminated.
It is clear from Fig. 3.7 that the shallower elution gradient improved the 
separation of proteins by anion exchange chromatography but the level of IgAl
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Fig. 3.5 Anion exchange chromatography of U. urealyticum IgAl protease
Ureaplasma proteins were solubilised in Buffer A (50 mM Tris-HCl, pH 8.6; 0.05% 
NF40), as described in Section 3.1.4. 300 pi (-250 pg) were separated by anion 
exchange chromatography (1 ml.min’l) using a steep gradient of 1 M NaCl in 
Buffer A (0-0.5 M in 10 min, 0.5-1 M in 5 min). Eluted proteins were measured 
spectrophotometrically at 280 nm (FSD 0.02) and collected as 1 ml fractions. To 
identify IgAl protease activity, 30 pi samples and 9 pi preload (F, F' represents 
preload activity after ultrafiltration) were incubated with S-IgA and analysed for 
digestion products by immunoblotting, as described in Section 2.1.9. The arrow 
and asterisks indicate the position of active fractions.
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Fig. 3.6 Anion exchange chromatography of U. urealyticum IgAl protease using 
0.05% NP40 in the equilibration and elution buffers.
Ureaplasma proteins were solubilised in Buffer A (50 mM Tris-HCl, pH 8.6: 0.05% 
NP40), as described in Section 3.1.4. 300 |il (-250 pg) were separated by anion 
exchange chromatography (1 ml.min"1) using a steep gradient of 1 M NaCl in 
Buffer A (0 M-0.5 M in 10 min, 0.5 M-1 M in 5 min). Eluted proteins were measured 
spect^ophctomet^ically at 280 nm (FSD 0.02) and collected as 1 ml fractions. To 
identify IgAl protease activity, 30 pi samples and 9 pi preload (P, P’ represents 
preload activity after ultrafiltration) were incubated with S-IgA and analysed for 
digestion products by immunoblotting, as described in Section 2.1.9. The arrow 
and asterisk indicate the position of active fractions.
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Fig. 3.7 Anion exchange chromatography of U. urealyticum IgAl protease using 
a shallow gradient of NaCl.
Ureaplasma proteins were solubilised in Buffer A (50 mM Tris-HCl, pH 8.6: 0.05% 
NP40), as described in Section 3.1.4. 400 pi (250 pg) were separated by anion 
exchange chromatography (1 ml.rmn'1) using a shallow gradient of 1 M NaCl in 
Buffer A (0 M-0.5 M in 30 min, 0.5 M-1 M in 5 min). Eluted proteins were measured 
spectrophotometrically at 280 nm (FSD 0.02) and collected as 1 ml fractions. To 
identify IgAl protease activity, 30 pi samples and 12 pi preload (P) were incubated 
with S-IgA and analysed for digestion products by immunoblotting, as described in 
Section 2.1.9. The arrow and asterisk indicate the position of active fractions.
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protease activity recovered from the Mono Q column was substantially less than 
when a steeper NaCl gradient had been used (Fig. 3.6). The enzyme had also 
eluted at approximately 0.28 M NaCl rather than 0.38 M NaCl. It is possible that 
under these elution conditions, the IgAl protease was separated from a putative 
stabilising factor which both conferred a charge to the molecule and was essential 
for maximum enzyme acltivity.
b) Gel filtration chromatography
An initial study examining the purification of the IgAl protease by gel 
filtration chromatography demonstrated that the ureaplasma enzyme could be 
recovered from a Superose 6 column (see Fig. 3.8). It was not possible to detect an 
elution peak corresponding to IgAl protease activity since the chromatographic 
trace was apparently off-scale at this point. This phenomenon was found 
reproducibly and may and have been caused by the NF40-containing buffers. As 
with ion exchange, enzyme activity was reduced by a single gel filtration step, 
although in this case it may have been because the activity was distributed 
between four separate fractions. In addition, the level of enzyme activity was at the 
limit of the detection system. For this reason, subsequent purification attempts 
used a higher concentration of solubilised ureaplasma proteins.
3.4.3 Two-step analyses
To examine the purification of the IgAl protease enzyme by cation- 
exchange chromatography (Mono S), harvested cells from a 5 1 ureaplasma culture 
were solubilised in 0.05% (w/v) NF40, as described in Section 3.1.4. In initial 
experiments, the sample was eluted with 50 mM Tris-HCl, pH 8.6, 1 M NaCl, 0.05% 
(v/v) NF40, the buffer that had been used for anion exchange chromatography. As 
expected, the IgAl protease did not bind to the Mono S column under these 
conditions but eluted in fractions 2, 3, and 4 (Fig. 3.9). This step served to separate 
the enzyme from a proportion of ureaplasma proteins that bound to the column 
(not all visible from the recording trace) without removing the enzyme from the 
putative stabilising factor that appeared to be necessary for maximum enzyme 
activity. The fractions were pooled, concentrated 30 x by ultrafiltration and
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Fig. 3.8 Gel filtration chromatography of U. urealyticum IgAl protease
Ureaplasma proteins were solubilised in Buffer A (50 mM Tris-HCl, pH 8.6: 0.05% 
NP40), as described in Section 3.1.4. 400 pi (400 pg) were fractionated using a 
Superose 6 column (0.5 ml.min'1) with Buffer A as the mobile phase. Eluted 
proteins were measured spectrophotometrically at 280 nm (FSD 0.02) and 
collected as 0.5 ml fractions. To identify IgAl protease activity, 30 pi samples and 
24 pi preload (P) were incubated with S-IgA and analysed for digestion products 
by immunoblotting, as described in Section 2.1.9. The asterisks indicate the 
position of active fractions. Protein peaks corresponding to IgAl protease activity 
(arrowed) are not visible, due to negative absorbance reading at this position.
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Fig. 3 9 Cation exchange chromatography of U. urealyticum IgAl protease
Ureaplasma proteins were solubilised in Buffer A (50 mM Tris-HCl pH 8.6; 0.05% 
NP40), as described in 3.1.4. 2 ml (1.25 mg) were separated using a Mono S
column (1 ml.min’i) with a steep gradient of 1 M NaCl in Buffer A (0 M-0.5 M in 
10 min, 0.5 M-1 M in 5 min). Eluted proteins were measured
spectrophotometrically at 280 nm (FSD 0.05) and collected as 1 ml fractions. To 
identify IgAl protease activity, 30 pi samples were incubated with S-IgA and 
analysed for digestion products by immunoblotting, as described in Section 2.1.9. 
The arrow and asterisks indicate the position of active fractions.
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separated by gel filtration using the Superose 6 column. The IgAl protease activity 
eluted in fractions 18 and 19 but when their activity was compared to the pre-load 
sample, only a small proportion of enzyme activity appeared to have been lost by 
this separation (Fig, 3.10). When these fractions were concentrated by TCA (10% 
lw/v]) precipitation and examined by SDS-PAGE, however, it was clear that the 
level of purification achieved had been minimal (Fig. 3.11).
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Fig. 3.10 Gel filtration chromatography of U. urealyticum IgAl protease 
following elution from cation exchange column.
IgAl protease-active fractions from cation exchange chromatography were pooled 
and concentrated by ultrafiltration. 200 |il were separated using a Superose 6 
column (0.5 mimin'1) with Buffer A (50 mM Tris-HCl, pH 8.6: 0.05% NP40) as the 
mobile phase. Eluted proteins were measured spectrophotometrically at 280 nm 
(FSD 0.05) and collected as 1 ml fractions. To identify IgAl protease acltivity, 30 pi 
samples and 6 pi preload (P, P' represents preload activity after ultrafiltration) were 
incubated with S-IgA and analysed for digestion products by immunoblotting, as 
described in Section 2.1.9. The asterisks indicate the position of active fractions. 
Protein peaks corresponding to IgAl protease activity (arrowed) are not visible.
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Fig. 3.11 The protein content of IgAl protease-active fractions from cation 
exchange and gel filtration chromatography.
IgAl-protease active fractions (650 pi) from a cation exchange column (lane 1) and 
a gel filtration column (fractions 18 and 19, lane 2 and 3) were concentrated by 
TCA precipitation (10%[w/vl) and analysed by SDS-PAGE (12.5%) followed by 
staining with PAGE-blue 83, as described in Sections 2.1.6-2.1.8. Molecular weight 
markers are to the left of the figure
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SECTION 0 
DISCUSSION
Contrary to a single publication reporting extracellular IgAl protease 
production by U. urealyticum (Kilian et al, 1984), it was not possible to detect the 
enzyme activity in ureaplasma 'spent' medium. The harvested ureaplasma cells, 
however, contained relatively high levels of IgAl protease activity. This was the 
reverse of the situation found with other bacterial IgAl proteases. For
5. pneumoniae, N. gonorrhoeae and 5. sanguis, virtually all the IgAl protease 
activity has been isolated from cell-free supernatants and only minimal quantities 
are associated with the cell pellets (Blake and Swanson, 1978, Plaut et at, 1978b, 
Mulks, 1985). Mulks (1985) estimated that in N. gonorrhoea# type 2, the cell- 
associated levels were less than 2.5% of the total IgAl protease activity and Blake 
and Swanson (1978) reported that IgAl protease activity in sonicated gonococcal 
pellets was virtually non-existent. Apart from a recent report identifying a 
proportion of cell-bound IgAl protease activity in H. influenzae (Pohlner et al, 
1991), one of the few unifying features of all bacterial IgAl proteases is their 
extracellular location (Kilian and Remholdt, 1986). It was important therefore to 
establish whether the enzyme from U. urealyticum was also secreted into the 
extracellular environment.
The inabiility to detect even cell-bound IgAl protease activity in 
ureaplasma liquid cultures prior to harvesting highlighted the importance of 
dilution effects on IgAl protease detection. Thus, an extracellular enzyme may 
have been present in the 'spent' medium but at levels too low to be identified by 
the assay system used. Concentration of 'spent' medium by ultrafiltration resulted 
in additional problems, since high levels of serum proteins interfered with the 
detection of enzyme digestion products by SDS-PAGE, even when using 
radiolabelled substrate. Differential fractionation of spent medium using 
ammonium sulphate did not allow detection of IgAl protease activity since all 
fractions contained high concentrations of medium proteins and these may _ have 
masked Faba/Fca digestion products.
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For other bacterial IgAl proteases, such difficulties in identifying cell-free 
IgAl protease activity have not been reported, either because the levels of 
extracellular enzyme are higher in these cases or because bacterial growth 
medium is not as complex as the ureaplasma growth medium. Horowitz and Gal 
(1991) have recently described a method of growing U. urealyticum in media 
dialysed-free of serum components. Attempts to cultivate ureaplasmas by such a 
method in this laboratory have not proved successful, mainly due to 
contamination problems (D Smith, personal communication). If the nutrients 
required for ureaplasma growth are able to pass through a semi-permeable dialysis 
membrane, it may be more convenient to grow U. urealyticum on solid media 
covered by sterile dialysis membranes, as described for the growth of 5. sanguis 
(Higerd et al., 1977). Under these conditions, bacterial products of high molecular 
weight, such as the IgAl protease are separated from large proteins in the medium 
agar and the enzyme may then be harvested by rinsing the dialysis membrane into 
a sm^ll volume of buffer and removing bacteria by centrifugation.
Alternatively, SDS-PAGE could be replaced by an assay which 
incorporates the removal of growth medium components before quantifying the 
extent of IgAl digestion. ELISA-based methods (Reinholdt and Kilian, 1983, Blake 
and Eastby, 1991) and those exploiting IgA receptors on type 4 group A 
streptococci (Lindahl et al., 1981) allow the digested substrate to be separated 
from growth medium components by immunological methods.
It would be even more convenient to establish the presence of 
extracellular IgAl protease activity directly by selectively removing the enzyme 
from the 'spent' medium. If a specific antibody was available, the IgAl protease 
could have been removed by affinity chromatography or immune precipitation. 
However, neither a rabbit polyclonal antiserum or a number of previously 
uncharacterised monoclonal antibodies raised against U. urealyticum appeared to 
react with the IgAl protease active site, as indicated by their failure to inhibit 
enzyme activity. This suggests that the active site of the ureaplasma enzyme, or 
regions associated with the active site, were not immunogenic to the rabbit host. A 
number of other IgAl proteases have failed to elicit an immune response in host
159
animals, even when administered in a partially purified state (Kilian and Reinholdt, 
1986, Frandsen et al, 1987). For 6. mitior, a high titr^e of neutralising antiserum 
could only be obtained from a patient with 5. mz/x'or-associated endocarditis. 
Patients demonstrating a good serological response to U. urealyticum may 
likewise be a source of anti-ureaplasma IgAl protease antiserum, but such patients 
were not available for this study.
An antibody raised against another IgAl protease with similar substrate 
specificity or classification, such as the type 2 IgAl proteases from Haemophilus or 
Neisseria could have been used. This approach did not seem feasible, since 
antibody inhibition tests have suggested that antigenic relationships between IgAl 
protease active sites do not exist between genera (Kilian et al, 1983a). However, 
Pohlner et al., (1991) have recently isolated a monoclonal antibody that reacts with 
both H. influenzae and N. gonorrhoeae IgAl proteases by Western blotting. It 
would be of value to examine whether this antibody also cross-reacts with the 
ureaplasma enzyme, since an examination for extracellular enzyme activity by 
Western blotting may then be possible.
One other consideration is that the ureaplasmal IgAl protease is released 
extracellularly but that the soluble enzyme is either degraded by hydrolytic 
enzymes or that it aggregates in the growth medium and therefore co-pellets with 
ureaplasma cells upon harvesting. Although problems with extracellular IgAl 
protease degradation have generally not been reported by workers in this field, 
there are two instances where precautions have been taken to reduce the action of 
degradative enzymes. Lindler and Stutzenberger (1983) incorporated p- 
chloromercuribenzoate (PCMB) into the growth medium of 5. sanguis (at 31 °C) to 
inhibit non-specific streptococcal proteases and Simpson et al, (1988) grew type 1 
N. gonorrhoeae at 35 °C to reduce cell lysis and increase extracellular enzyme 
yields. If these cultures were harvested in late log phase, IgAl protease activity 
was only found in the cellular fraction, suggesting that the cell-bound enzyme was 
more resistant to cellular hydrolytic enzymes than its extracellular counterpart 
(Smpson et al, 1988). If the same is true for the ureaplasmal IgAl protease.
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harvesting of cells in early log-phase or the incorporation of general protease 
inhibl^t^c^r^s may increase the levels of IgAl protease found in the medium.
Aggregation of extracellular IgAl proteases has been reported for 
H, influenzae grown in human milk (Plaut et al, 1992). It is thought that S-IgA 
specific for the H. influenzae IgAl protease causes this effect since it can be 
abrogated by the addition of an IgAl protease from S. sanguis. Although specific 
anti-IgAl proteases are unlikely to be present in the horse serum contained within 
ureaplasma growth medium, there may be other components that encourage 
aggregation. The release of the enzyme from cell pellets following detergent 
treatment, however, suggests that the IgAl protease is more than loosely 
associated with ureaplasma cells and may indeed be membrane-bound. The 
minimal amount of enzyme activity released on cellular sonication may represent 
membrane fragments too small to be harvested by centrifugation. Isolation of 
purified ureaplasma membranes, or localisation of enzyme activity using 
immunogold-labelled specific antibodies, for example, is required before the site 
of enzyme activity is confirmed.
If none of these approaches reveal extracellular IgAl protease activity in 
ureaplasma 'spent' medium, it may be concluded that U. urealyticum expresses a 
cell-associated enzyme only. In this case, the mechanism of transport and 
processing of the ureaplasma Ij^l protease is likely to be different from that 
described in N. gonorrhoeae (Section 1.8.1). Either a totally different transport 
mechanism is involved, or the final stage of enzyme release from the 
transmembrane P portion of the precursor IgAl protease molecule does not occur 
in this organism. This could be due to a lack of susceptible cleavage sites in the 
precursor molecule or because of a different substrate specificity for the 
ureaplasma enzyme. The apparent failure of the IgAl protease to digest one of the 
synthetic peptides based on the autoproteolytic sites found in N. gonorrhoeae 
tentatively supports the latter theory but, as discussed in Chapter 2, this is only one 
of many explanations for this negative result. To gain insight the IgAl protease 
transport mechanisms operating in U. urealyticum it may be necessary to 
sequence and express the iga gene.
I6l
Analysis of the iga gene from H. influenzae identified putative leader and 
helper sequences, analogous to those found in the N. gonorrhoeae iga gene 
(Grundy et al, 1987a) but only one of the predicted autoprotedytic cleavage sites 
was found to be susceptible to cleavage, suggesting that the mechanism of IgAl 
protease secretion in these two species is similar but not identical. In contrast, no 
such sequence motifs have been identified in the streptococcal IgAl protease and 
the mechanism of enzyme secretion in this organism is unclear. It may that a 
number of accessory genes or proteins are required, as is the case with other gram 
positive extracellular enzymes (Gilbert et al, 1991).
A cell-bound IgAl protease may also confer particular advantages to 
U. urealyticum for colonisation and establishment in vivo. In addition to 
interfering with the protective function of S-IgAl, the enzyme may combine with 
IgAl on the luminal surface of mucosal cells and aid ureaplasma adherence. It has 
been proposed that bacterial IgAl proteases may serve as adhesins Mulks (1985), 
but such a function only seems relevant for a cell-associated enzyme. Subsequent 
digestion of IgAl may of course reduce binding and the relative advantages of 
adhesion verses IgAl digestion are not clear. A cell-bound enzyme may also only 
act upon closely associated ureaplasma-specific secretory IgAl and digestion of 
S-IgA specific for neighbouring IgAl protease-negative microorganisms may not 
occur. The wide-spread effects of extracellular IgAl protease activity on the 
general mucosal flora, as proposed by Kilian and Reinholdt, (1987) (Section 
1.10.5), may therefore not be relevant in the case of ureaplasma colonisation.
Whatever the explanation for failing to identify the presence of 
extracellular IgAl protease activity in 'spent' culture medium, it was clear that for 
purification purposes the harvested ureaplasma cells served as a more abundant 
and convenient source of IgAl protease activity. To obtain a soluble preparation of 
the enzyme from ureaplasma cell harvests, however, was a problem not 
encountered in the purification of other bacterial IgAl proteases.
Ureaplasma preparations were partially solubilised by a number of ionic 
and non-ionic detergents but the enzyme was only stable in the latter, as had been 
found with the gonococcal IgAl protease (Blake and Swanson, 1978). Using an
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excess of solubilisation buffer or repeated re-extractions, it was not possible to 
solubilise more than 40% of the total ureaplasma protein. This does not necessarily 
imply that only 40% of the IgAl protease had been released from the cells, since 
the solubility of different ureaplasma proteins is likely to vary, but the high levels 
of enzyme activity remaining in cell pellets after solubilisation suggested that a 
proportion of the enzyme had indeed remained insoluble. Difficulties in 
solubilising ureaplasma cells have been found by other workers (D. Thirkell, 
personal communication) and this may be due to the compacting of cells 
produced by the high g forces used in centrifugation, or to a peculiar, but as yet 
unknown, membrane structure.
It is well documented that research on U, urealyticum is hindered by the 
low cell yields obtained from large volumes of expensive culture medium (O'Brien 
and Barile, 1983) and failure to obtain more than 40% of this protein in a soluble 
form renders purification of individual proteins virtually impossible. It is probably 
for this reason that only one ureaplasma protein has been purified to
homogeneity, the urease enzyme, and this was only possible by affinity 
chromatography using a specific anti-urease monoclonal antibody (Thirkell et al, 
1989b). As discussed earlier, a monoclonal antibody specific for the ureaplasma 
IgAl protease is not presently available and it was therefore necessary to resort to 
conventional methods for enzyme purification.
Only a limited number of purification strategies were attempted, since in 
every case there were difficulties in detecting eluted IgAl protease activity, 
particularly when more than one chromatographic step was used. Thus, the level 
of enzyme activity recovered from an anion exchange separation was reduced 
below detectable limits by a subsequent gel filtration step. Although a cation 
exchange separation in combination with gel filtration allowed recovery of 
enzyme activity, this was at the expense of purity, presumably because the IgAl 
protease eluted in the 'flow-through' of the cation exchange column, thereby 
producing minimal purification. Before assesssng other methods for IgAl protease 
purification, a number of fundamental problems in the whole process need to be 
addressed. These include the inadequate assay for the detection of enzyme activity
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in chromatographic fractions, the losses incurred at each purification step and the 
low levels of starting material obtained from ureaplasma harvests.
In the purification of other bacterial IgAl proteases, enzyme activity has 
generally been assayed by SDS-PAGE using [I25I] IgAl (Halter et al., 1984,
Simpson et al, 1988) or by ELISA (Mortensen and Kilian, 1984a, Blake and Eastby, 
1991), both of which rely on the detection of IgAl digestion products. As 
discussed in Chapter 2, the recent identification of alternative synthetic substrates 
for IgAl proteases may enable a cheap, more rapid and quantitative assay to be 
developed. Combined with protein estimations this would allow enzyme yields 
and specific activities to be monitored during the purification procedure. Although 
quantitative measurements of IgAl protease activity were not performed during 
preliminary attempts to purify the enzyme from U. urealyticum, it was clear that 
substantial losses in enzyme protein or activity were sustained in each 
chromatographic step.
A loss in enzyme activity may have been caused by the oxidation of free 
sulphydryl groups, particularly if this occurred within or close to the active site of 
the IgAl protease. Simpson et al, (1988) stored gonococcal IgAl protease extracts 
in Tris-acetate buffer (pH 7.5) containing 1 mM dithtothreitol (DTT) and Mortensen 
and Kilian (1984a) reported that 100 mM DTT prevented loss in activity of the IgAl 
protease from B. melaninogenicus. It may have been prudent to include such 
reducing agents into the purification buffers in this study. Alternatively, the 
enzyme may be susceptible to proteolysis, which could have been reduced by 
conducting chromatography at low temperatures (4 °C) or by the addition of a 
cocktail of protease inhibitors. EDTA (50-100 mM) has been included in a number 
of IgAl purification protocols to inactivate metal-dependent proteases (Simpson 
et al, 1988; Blake and Eastby, 1991; Mortensen and Kilian, 1984a). 10-20% (v/v) 
glycerol can also increase the s^l^ii^ty of proteins by reducing the 'water activity* of 
the buffer and thereby minimising denaturation losses (Harris and Angal, 1989). 
Halter et al, (1984) included 10% (v/v) glycerol in purification buffers used for the 
isolation of the type 2 enzyme from N. gonorrhoeae. However, when a sample of 
solubilised ureaplasma enzyme was stored under the same conditions as the
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preparation undergoing purification (20 °C in chromatographic buffer), there was 
no apparent loss in activity for several hours, suggesting that denaturation by 
oxidation or proteolysis was not occurring under these circumstances. It seemed 
more likely, therefore, that the process of purification was simply separating the 
IgAl protease from factors required to maintain its stability.
Inclusion of NP40 into equilibration and elution buffers appeared to 
increase the stability of the ureaplasma IgAl protease during purification in all 
systems. If the U. urealyticum IgAl protease is membrane bound, the non-ionic 
detergent may serve to shield hydrophobic portions of the enzyme and maintain 
its solubility in solution. Since NP40 only partially reduced the losses in enzyme 
activity it is possible that some dissociation between detergent and protein had 
occurred during the purification process, thereby inducing protein precipitation. It 
is also possible that the enzyme was simply more unstable in dilute protein 
solutions due to the dissociation of subunits or to adsorption onto container 
surfaces. The bacterial IgAl proteases characterised to date, however, do not 
appear to have a subunit structure and the inclusion of 0.05% (v/v) NP40 should 
have minimised adsorption losses. Alternatively, the substantial loss of ureaplasma 
IgAl protease activity incurred during gel filtration chromatography suggests that a 
low molecular weight ligand may be required for enzyme activity. Simpson et al, 
(1988) proposed a similar explanation for the ' loss of gonococcal enzyme activity 
following a gel filtration step. Reconstitution experiments with the eluted fractions 
may confirm such a requirement for the ureaplasma IgAl protease.
In addition to all these potential improvements, it is of perhaps of primary 
importance to increase the initial yield of IgAl protease from U. urealyticum. It is 
generally regarded, however, that IgAl proteases are highly active enzymes that 
are only released in small quantities (Plaut, 1983). Thus large staining cultures have 
only generated sufficient quantities of pure bacterial IgAl protease for 
immunochemical characterisation and detailed biochemical or structural studies 
have not been possible (Blake and Eastby, 1991). With the additional problems 
inherent in isolating a membrane-associated enzyme it seems likely that
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purification of the IgAl protease from U. urealyticum is not readily be possible, 
even if improvements are made in cultivation and cellular solubilisation.
For these reasons, efforts were directed towards isolation of the iga gene 
from £. urealyticum with a view to expressing the enzyme in larger quantities 
from transformed bacteria.
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Chapter 4:
Identification of the iga gene in 
U. urealyticum
SECTION A
MATERIALS AND METHODS
A number of basic cloning techniques were used routinely for the genetic 
analysis of U. urealyticum, many of which are based on methods described by 
Sambrook et al., (1989). These are described in general in Appendix I to the 
Materials and Methods, Section 4.4. Appendix II, Section 4.5, details the 
preparation of bacterial growth media. As in previous chapters, all buffers were 
sterilised by autoclaving and H2O refers to ste^^le double-deionised water obtained 
from a Milli Q water purification system (ELGA).
4.1 PREPARATION OF U. UREALYTICUM GENOMIC DNA LIBRARY
4.1.1 Source and cultivation of bacteria
U. urealyticum was grown according to the method described in Section 
2.1.1. Af. hominis (PG21) was obtained from D. Taylor-Robinson (Clinical 
Research Centre, Harrow, UK) and was grown in 70% (v/v) PPLO broth (Difco), 
incorporating 20% (v/v) donor horse serum (NBL), 10% (v/v) fresh yeast extract, 
0.01% (w/v) phenol red, 0.2% (w/v) L-arginine hydrochloride and 1000 U.mh1 
penicillin at a starting pH of 7.0. Cultures were incubated (37 °C) to pH 8 and 
harvested as previously described for U. urealyticum.
4.1.2 Isolation of genomic DNA
Freshly harvested pellets from 5 1 ureaplasma or mycop>^^sma cultures 
were resuspended in 2 ml TE buffer and solubilised with SOS (0.5 %, [w/v]), 
proteinase K (Gibco BRL, 100 jxg.mh1) and RNAase (Boehringer/Mannheim,
0.5 pg.ml'1) in a 10 ml polypropylene tube for 2 h (50 °C). After addition of a 
further 2 ml TE buffer, ureaplasma DNA was purified from the cellular digest by 
phenohchloroform extraction, using an adaptation of the method described in 
Section 4.4.1, that was suitable for the extraction of genomic DNA. Initially, the 
viscous solution was mixed (10 min) with an equal volume of phenol by gentle 
inversion of the tube. After centrifugation (2,000 x g, 10 min, 20 °C), the aqueous
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phase was transferred, with a wide bore pipette, to a fresh tube, extracted with an 
equal volume of phend:chloroform;isoamyl alcohol (25:24:1, by voi.) and 
separated by centrifugation, as above. Traces of phenol were removed from the 
resulting aqueous phase by re-extraction in an equal volume of 
chlcrcform:isoamyl alcohol (24:1, by vol.), and re-centrifugation. The final 
aqueous phase was precipitated in a fresh tube with 0.1 x vol. 3 M NaAc (pH 5.2) 
and 2.5 x vol. ethanol (-20 °C, 30 min). The ureaplasma DNA was visible as a 
white precipitate which was collected by 'spooling' onto a Pasteur pipette. After 
washing in 70% (v/v) ethanol and air drying, the DNA was resuspended in 100 pi 
sterile TE buffer and its purity/concentration estimated by spectrophotometry, as 
described in Section 4.4.2.
DNA from U. urealyticum sej^otype 1 was kindly provided by B. Precious 
(University of St. Andrews, UK).
4.1.3 Partial digestion of genomic DNA
An initial study, to determine the concentration of restriction enzyme 
necessary to partially digest U. urealyticum DNA, was based on a protocol 
described by Sambrook et al, (1989). 180 pi ureaplasma genomic DNA (33 pg, 
prepared as in Section 4.2,2 and stored at 4 °C), was combined with 100 pi EcoRl 
restriction enzyme buffer (10 x: 0.5 M Tris-HCl, pH 8, 0.1 M MgCb, 1 M NaCl) and 
H2O to give a final volume of 1 ml. After equilibration (2 h, 4 °C), with intermittent 
gentle stirring, the solution was dispensed into ice-cdd Eppendorf tubes; 60 pi 
(containing ~2 pg ureaplasma DNA) into tube 1 and 30 pi (containing ~1 pg 
ureaplasma DNA) into each of tubes 2-10. 10 U (1 pi) AcoRI restriction enzyme was 
added to tube 1 and serial 1/2 dilutions made to tube 10 by sequential mixing, 
removal and transfer of 30 pi. The samples were heated to 37 °C and incubated for 
1 h. The reaction was terminated by addition of EDTA (pH 8) to a final 
concentration of 10 mM and the digestion products examined by gel 
electrophoresis, using 0.3% (w/v) agarose on a l%(w/v) agarose support, followed 
by ethidium bromide staining, as described in Section 4.4.5.
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Under these conditions, 2.5 U AcoRl produced a suitable range of 
digestion fragments (2-10 kbp) and ten identical reactions containing 2.5 U AcoRI 
were prepared, as before, to make a stock of partially digested ureaplasma DNA. 
To ensure that the correct size range of fragments had been produced by this 
method, an aliquot of the digestion mix was analysed by gel electrophoresis. The 
remainder was pooled, phenohchiorofcrm extracted and the aqueous phase 
centrifuged through a gel filtration column (250 x g) (Pharmacia 400) to remove 
any small fragments of DNA (<400 bp). The DNA was concentrated by ethanol 
precipitation and resuspended in TE buffer at 0.1 pg.ml*1.
4.1.4 Ligation and packaging into % ZAP bacteriophage vector
The ligation and packaging of ureaplasma DNA into the X ZAP cloning 
vector and the subsequent transfection of host bacteria were performed using a X 
Zap Cloning Kit (X ZAP II, Gigapack II Plus). The protocols described were 
adapted from those provided by the manufacturer (Stratagene).
In the ligation reaction, 1.6 |il partially-digested ureaplasma DNA (0.16 pg) 
was combined with 1 pi pre-digested and phosphatase-treated X arms (1 pg), 0.9 pi 
H2O, 0.5 pi 10 x ligation buffer (5 M Tris-HCl, pH 7.5, 0.1 M MgCl2, 0.1 M DTT,
10 mM ATP, 250 pg.mh1 BSA) and 1 pi T4 DNA ligase (both from NEB). As a 
control, 1.6 pi (0.4 pg) of pRheoEcoRI test insert (2.8 kbp) replaced ureaplasma 
DNA. The reactions were incubated for 2 h at 14 °C.
For packaging, 4 pi of the ligation mix was added to ice-cold 'freeze thaw 
extract' followed by 15 pi 'sonic extract' (both extracts were provided in the 
Gigapack II Plus packaging kit). After brief centrifugation (1 sec, 1,200 x g^hie 
mixture was incubated for 2 h at 20 °C. The reaction was terminated by addition of 
500 pi SM buffer (86 mM NaCl, 8 mM MgSO/b 50 mM Tris-HCl, pH 7.5, 0.01% [w/v] 
gelatine) and 20 pi chloroform. The solution was centrifuged briefly to remove 
sediment (12,000 x g, 2 min) and the supernatant stored as 'packaging extract' at 
4 °C. As a control, 1 pi (~0.2 pg) of wild-type X DNA (cl857 Sam7) was packaged 
following the same protocol.
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The success of the ligation and packaging procedure was assessed by 
transfection of XLl-Blue cells with 'packaging extract', as described below.
XLl-Blue cells (TnlO (tebi) were grown from a 15% (v/v) glycerol stock 
on LB-tet agar plates (see Appendix II). A single colony was transferred to 50 ml 
LB broth containing 0.2% (w/v) maltose: 10 mM MgSO° and grown with agitation 
for 4-6 h (37 °C), or 16 h (30 °C), to an OD°oo of 0.45-0.55. The bacterial culture 
(10 ml) was harvested by centrifugation (1,000 x g, 10 min), resuspended in 
0.5 x vol. MgS04 and stored for up to 3 days (4 °C) until required ('plating 
bacteria'). Immediately before use, the 'plating bacteria' were diluted to an OD6oo 
of 0.5.
The 'packaging extract' was diluted in SM buffer (neat, 10"", 1O‘°) and 1 pi 
samples were pre-incubated (15 min, 37 °C) with 200 pi 'plating bacteria'. 3 ml 
aliquots of melted top NZYDT agar (see Appendix II) were equilibrated to 48 °C in 
a water-bath. Working quickly, 50 pi of 5-bromo-4 chloro-3-indolyl-p-D- 
galactoside (X-gal; 250 mg.ml"i in DMF), 15 pi of isopropylthio-p-galactoside 
(IPTG; 0.5 M in H2O, filter sterilised) and the 201 pi of phage-associated bacteria 
were mixed with the top agar and immediately poured onto pre-warmed NZYDT 
agar plates (see Appendix II). After incubation for 6-8 h, recombinant and wild- 
type phage appeared on the bacterial lawn as white and blue plaques respectively. 
If the titre of recombinants was greater than 1 x 10° pfu.pg arms-1, the library was 
amplified and screened for specific ureaplasma DNA inserts.
To amplify the library, 100 pi packaging extract (calculated to give ~50,000 
recombinant bacteriophage) was incubated with 600 pi plating cells (15 min,
37 °C). The phage-bound bacteria were combined with 6.5 ml aliquots melted top 
agar (48 °C) and immediately poured onto pre-warmed NZYDT plates (15 cm 
diameter). Following incubation (6-8 h, 37 °C), the plates were overlaid with 10 ml 
SM buffer and stored overnight with gentle shaking (4 °C). The bacteriophage 
suspension was removed, the plates were rinsed with a further 2 ml SM buffer and 
chloroform was added to 5% (v/v). After 15 min (20 °C), the cell debris was 
removed by centrifugation (4,000 x g) and the supernatant stored (4 °C) as 1 ml 
aliquots containing chloroform (0.3 %, [v/v]). The titre of the amplified library was
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estimated, as described above, except that the phage suspension was diluted from 
lO-5-'lO-6 in SM buffer.
4.1.5 Screening the Library
When screening for ureaplasma inserts, a suitable number of 
bacteriophage plates, each containing approximately 104 plaques, were prepared 
as described previously, except that X-gal and IPTG were omitted from the top 
agar. After growth for 6-8 h, when plaques should just have been touching, the 
plates were stored at 4 °C for 2 h (but no longer than 48 h) to prevent the top agar 
from sticking to the fil^ei-. Circular 'Hybond N' filters (Amersham) were placed on 
each bacteriophage plate and after 2 min at 20 °C, plaque transfer was complete. 
The orientation of the filter was recorded and duplicate plaque-transfers (4 min,
20 °C) were made where possible. Transferred phage DNA was denatured by 
placing the fil^^e^rrs, plaques-uppermost, on Whatman 3 MM paper soaked in 
denaturing buffer (1.5 M NaCl, 0.5 M NaOH) (2 min) and neutralised by 
transferring the filters to neutralising buffer (1.5 M NaCl, 0.5 M Tris-HCl, pH 8)- 
soaked 3 MM paper (5 min). After rinsing in wash buffer (0.2 M Tris-HCl, pH 7.5,
2 x SSC) (30 sec), the filters were dried (1 h, 20 °C) and fixed by UV irradiation 
(3 min).
The filters were probed with radiolabelled DNA by the method described 
for Southern blotting (Section 4.2.7).
4.2.1 Plasmid preparation
A derivative of pBR322, pIP503, containing the iga gene from 
N. gonorrhoeae (Pohlner et ai., 1987) was kindly provided by J. Pohlner (Max- 
Planck-Institut fur Biologie, Tubingen, Germany). The plasmid was propagated in 
E, coli strain HB1O1 (as below), where it could be selected by virtue of its 
ampicillin resistance gene (Fig. 4.1). The preparation of growth medium (LB) and 
appropriate antibiotics (LB-amp, LB-strep) for the growth and selection of HB1O1 
transformants is described in the Appendix II.
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PCR probe
1764 bp
1
3 kb probe
2890 bp
1.35 kb probe
1350 bp
Fig. 4.1 The production of iga probes from plP503
Plasmid pIP503 was constructed by the insertion of a 5 kb fragment, encoding the 
IgAl protease from N, gonorrhoeae (iga gene, shaded region), into the £coRI (0) 
and BamHl (375) restriction sites within pBR322 (Halter et al, 1984, Pohlner et al, 
1987). For the generation of iga gene probes from pIP503, an N-terminal portion 
of the gene was amplified using PCR primers corresponding to nucleotide bases 
184-213 (primer 1) and complementary to 1950-1921 (primer 2, reverse primer). 
Restriction enzyme digestion of the plasmid at Hzndlll and BglW sites generated 
two additional probes of approximately 1.35 -kb and 3 kb.
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4.2.2 Transformation of E. coli HB1O1
E col were made competent for plasmid transformation by the 'calcium 
chloride' method, based on the method described by Sambrook et al, (1989). 
Single colonies of strain HB1O1 from LB-strep plates were grown overnight with 
agitation in 1 ml LB-strep broth (37 °C). The culture was reinoculated into 50 ml 
LB-strep broth and grown, with agitation, to an OD6oo of 0.45-0.55 (1-2 h). The 
bacteria were transferred to a 50 ml polypropylene tube and chilled on ice (10­
15 min). Following centrifugation (1000 xg, 10 min) and complete removal of 
supernatant, the pellet was resuspended in 25 ml of ice cold 50 mM CaCh: 10 mM 
Tris-HCl, pH 8. and left on ice (15-30 min). After a final centrifugation step (as 
before) the pellet was drained free of supernatant and resuspended in 2-3 ml 
50 mM CaCl2:lO mM Tris-HCl, pH 8. The competent cells were stored at 4 °C and 
for maximum transformation efficiencies, used after 24 h.
For transformation, 10-50 ng plasmid DNA in a final volume of 100 pi (in 
H2O) was combined with 0.3 ml competent cells in ice-cold 'Sterilin' tubes (10 ml). 
After 30 min (on ice), the cells were 'heat shocked' at 42 °C for 90 sec and 
transferred to an ice bath for 1-2 min. To allow expression of antibiotic resistance, 
the transformed cells were grown in 0.7 ml LB broth (37 °C, 25 min), before 50­
100 pi aliquots were plated onto LB-amp agar (7 cm diameter). Control 
transformations, containing no DNA, were plated onto LB-amp and LB agar. After 
overnight incubation (37 °C), the presence of colonies on the test plates, but not 
the control LB-amp plates, indicated successful transformation.
4.2.3 Mini-preparation of plasmid DNA {'Mini prep')
To confirm the presence and nature of the transformed DNA, small-scale 
plasmid purification's ('mini-preps') were prepared by the 'alkali lysis method'. 
Single colony transformants were grown overnight (37 °C) in 2 ml LB-amp broth.
1 ml of each overnight culture was harvested by centrifugation (12,000 x g, 30 sec, 
4 °C) and following complete removal of the supernatant, the pellet was dispersed 
by vortexing in 100 pi ice-cold resuspension buffer (Solution 1: 50 mM glucose,
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25 mM Tris-HCl, pH 8, 10 mM EDTA, pH 8). 200 pi lysis buffer (Solution 2: 0.2 M 
NaOH, 1% [w/v] SDS) was added to disrupt the bacterial cell wall and following 
gentle mixing, genomic DNA was precipitated by addition of 150 pi ice-cold 
acetate buffer (Solution 3: 5 M potassium acetate, 11.5 ml glacial acetic acid,
28.5 ml H2O). After 5 min at 0 °C (ice), the copious white precipitate was removed 
by centrifugation (12,000 xg, 5 min, 4 °C), and the plasmid-containing supernatant 
decanted and re-centrifuged to remove final traces of genomic DNA. The 
supernatant was extracted with an equal volume of phenohchloroform and 
plasmid DNA recovered from the aqueous phase by ethanol precipitation and 
centrifugation, as described previously (Section 4.4.1). The pellet was resuspended 
by vortexing in 50 pi TE buffer containing 20 pg.iml1 DNAase-free pancreatic 
RNAase (Boehringer/Mannheim). Typically, 3 pi of this 'mini prep' DNA was used 
to confirm the nature of the plasmid by restriction endonuclease digestion 
(Mi'wdlll, Bgtll, see Fig. 4.1) followed by agarose gel electrophoresis (Sections 
4.4.3, 4.4.5).
pIP503 was stored within HB1O1 cells as agar plate cultures (renewed 
every month), frozen, glycerol stocks (15% [v/v] glycerol) and as purified DNA 
from a medium scale preparation, as described below. For the preparation of 
glycerol stocks, single colonies were grown overnight (37 °C) in 5 ml LB-amp 
broth. 0.85 ml aliquots were thoroughly mixed with 0.15 ml sterile glycerol and 
stored at -70 °C in screw-top Eppendorf tubes.
4.2.4 Medium scale plasmid preparation ('Medium prep')
A single colony transformant of HB1O1 was inoculated into 100 ml LB-amp 
(in a 500 ml flask) and grown overnight with agitation (37 °C). The log-phase 
culture was divided between two 50 ml 'Corex' tubes (2 x 30 ml) and the bacterial 
cells harvested by centrifugation (12,000 x g, 10 min, 20 °C). The pellets were 
washed in Solution 1, pooled and resuspended in 4 ml Solution 1 containing 
10 mg.rm'1 lysozyme and 20 pg.mh1 RNAase (Sigma). After 15 min at 20 °C, with 
intermittent vortexing, the cells were alkali-lysed with 8 ml Solution 2 and left at 
20 °C until the cloudy suspension cleared (~10 min). 6 ml Solution 3 was added
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and after immediate vortexing, the genomic DNA was allowed to precipitate 
(5 min., 20 °C). The plasmid-containing supernatant was separated from the 
flocculent precipitate by centrifugation (as above), followed by filtration through 
cheese-cloth. The filt^^i^ate was divided between two 'Corex' tubes and recovered by 
addition of an equal volume of isopropanol followed by centrifugation, as before. 
The pellet was dried under vacuum, resuspended in 5 ml TE buffer, containing 
DNAase-free RNAase (1 pg.ml"1), and incubated (37 °C) for 30 min. Plasmid. DNA 
was extracted with phenol:chloroform, as described in Section 4.4.1, except that 
an initial phenol-extraction step followed by centrifugation (12,000 x g, 10 min,
20 °C) preceded phenol: chloroform extraction and ethanol precipitation. The DNA 
pellet was dried under vacuum, resuspended in 3 x 200 pi of H2O, pooled and 
stored at -20 °C. The concentration of plasmid was determined 
spectrophotometrically at 260 nm and its integrity examined by agarose gel 
electrophoresis (Sections 4.4.2, 4.4.5).
Portions of the N. gonorrhoeae iga gene, for use as specific probes in 
hybridisation studies, were generated from pIP503 by either PCR or by restriction 
endonuclease digestion, as described in the following sections.
4.2.5 Preparation of DNA probes
For restriction endonuclease digestion, 2.5 pg of pIP503 was digested with 
Hindlll (20 U) and Bgfll (20 U) in 1 x KGB buffer, as described in Section 4.4.3 
(Fig. 4.1). For PCR, oligonucleotide primers corresponding to nucleotides 184-213 
(primer 1) and 1950-1921 (reverse primer 2) of the published iga gene sequence 
(Fig. 4.2) were synthesised as follows:
Primer 1 (left): 5'-G(ATTGGTGAGAGACGATGTCGATrATCAA-3'
Primer 2 (right): B'-GATCCAGTCGTTATTTTCTGCTACACCGTT-S1
Using 200 ng pIP503 DNA as a template and thermal cycler Programme A, 
the PCR reaction was performed as described in Section 4.4.4.
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Primer 1:
Primer 3:
Ng-iga 147
Hi-iga 3(50
NT-iga 1 ^*7
Hl-iga 350
Primer 4 4
Ng-iga 8 9 0
Hi-iga 1109
Ng-iga 994
Hi-iga 112 9
Primer 2:
Ng~iga 1895
Hi-iga 20 69
Ng-iga 1925
Hi-iga 2217
Ng-iga 2425
Hi-iga 2614
. . . S’-GGCATTGGTGAGAG
5'-GAG
CTTTCTTGCCTATGCCCTTACGCCATACTCAGAkGCGGCATTGGTGAGAG 19 6 
III I I I II I I II I III I I I I I I If I I I I I I I I I I 
TACTGTCGCCTACGCATTAACCCCTTATACAGAAGCCGCGTTAGTGAGAG 34 9
actatttctattatcaa .... ACTAATTCTattatcaaatattcctttt
acgatgtcgattatcaaatattccgtgactttgcagtaaaacaaaggcaaza 2 4 6 
II11111 11111 I I III 111111111 I 1111111 I II II III II 
actatttttattatcaaatattcctttatttttcatataataaatttaat 399
. . . cctctatctcct
cactttcgcaagatgcgttaacaaavttacggcgtgttgggcgatagcggc 939 
I I 11 I I I 111 I I 11 11111 I 11 II 1111 i 11 111
AGAGGTGATAAACCTTAAGCGTGCA-5
II III I I I I I I II I I I I I II ! I I I I I I III I II
tttc
I II I I I I I I I III III
cacatcttcttttatttctttcctact-5
11 I III I 111 I I 1111 II III I I I I
IIIII It II 11 I II I II II II II II I I II I 111
Fig. 4.2 Design of PCR primers for amplification of the iga gene from 
N. gonorrhoeae and U. urealyticum.
The iga sequences from N, gonorrhoeae (Pohlner et al, 1987) and H. influenzae 
(Pouisen et al, 1989) were aligned using the 'GAP' programme from the 'GCG' 
sequence analysis package. To amplify a portion of the iga gene from 
N, gonorrhoeae, primers were selected to give a ~2 kbp PCR product from the N- 
terminal region of the gene (primer 1 and reverse primer 2). In order to identify 
the iga gene within U. urealyticum, a region of high conservation between the iga 
genes from H. influenzae and N. gonorrhoeae (nucleotides 205-224) and a second 
region thought to code for the serine protease active site in these enzymes 
(nucleotides 928-948) were chosen for the design of primers 3 and 4. To aid 
cloning of amplification products, the primers incorporated an additional tail 
(underlined) containing the £coRl cleavage site (GAATTC). The region between 
nucleotides 2429-2464, encoding two cysteine residues, was originally proposed as 
the gonococcal IgAl protease active site (Pohlner et al., 1987).
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The plasmid restriction digests (~2.5 pg), or PCR amplification products 
(~5 pg), were electrophoresed in 1% (w/v) low melting-point agarose (SeaPlaque 
GTC, PMC BioProducts), as described in Section 4.4.5, except that NT-TBE (0.09 M 
Tris-borate, 0.2 mM EDTA, pH 8.0) replaced TBE buffer. DNA was visualised by 
UV irradiation (< 1 min), the required band excised with the minimum excess of 
agarose and transferred to a pre-weighed Eppendorf tube. After addition of H2O 
(3 ml per g of gel), the gel slice was melted (65 °C, 2 min) and either used 
immediately or stored at -20 °C. DNA fragments were radio-labelled directly from 
gel slices by random priming using a T7 Quick-Prime kit, according to the 
manufacturers instructions (Pharmacia). The equivalent of 200 ng DNA (<25 pi) 
was made up to a total volume of 37 pi with H2O, heated to 95-100 °C for 7 min 
and transferred to a water bath (37 °C) for a further 10 min. This was combined 
with 10 pi labelling buffer (provided with the kit and containing random 
oligonucleotides, dATP, dGTP, dTTP) and 2 pi [«32p] dCTP (3000 Ci.mmoh1). The 
reaction was initiated by addition of 1 pi T7 DNA polymerase and incubated at 
37 °C (5-15 min). Radiolabelling was terminated by addition of 0.2 M EDTA, pH 8 
(5 pi) and unincorporated nucleotides were removed by centrifugation through a 
'medium' Sephadex G50 (10 x 0.5 cm bed, height x diameter) column (500 x g,, 2 
min). The efficiency of labelling was estimated by precipitation of a portion of the 
eluted probe with 10% (w/v) TCA and the remainder was either used immediately 
or stored (-20 °C) for up to one week. Before use in hybridisation analysis, the 
double-stranded DNA was denatured (95 °C, 3 min) and snap-frozen (ice, 5 min) 
to produce a single-stranded probe.
4.2.6 Southern Blotting
DNA from U. urealyticum (1 pg), M. hominis (1 pg), and pIP503 (1-10 ng) 
was digested with suitable restriction enzymes (£coRI, Hindttl, BgKl, see results 
section) and analysed by agarose gel electrophoresis (0.7% [w/v]), followed by 
ethidium bromide staining. X.HindW markers were included for size comparisons. 
The gel was prepared for Southern blotting by an initial depurination step 
(immersion in 200 ml, 0.2 M HCl, 15 min, 20 °C), which introduced nicks into high
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molecular weight DNA and improved transfer. After rinsing with H2O, the double­
stranded DNA was denatured by soaking the gel in several volumes of denaturing 
solution (0.6 M NaCl, 0.2 M NaOH), for 2 x 20 min (20 °C) and neutralised by gel- 
immersion in several volumes of neutralising buffer (0.6 M NaCl, 1 M Tris-HCl, 
pH 8.0), 2 x 20 min (20 °C). The Southern blot was assembled by placing the gel 
on a wick of Whatman 3 MM paper, followed by a 'Hybond N' filter (Amersham) 
and a stack of absorbent paper (4-5 cm high), cut to the same size of the gel. The 
assembly was compressed using a 500 g weight placed on a glass plate, as detailed 
by Sambrook et al., (1989). The wick was in contact with a tank of 10 x SSC 
(saltisodium citrate buffer; 1.5 M NaCl, 0.15 M Na3C6H$C^7.2H20) and DNA was 
transferred from gel to filter by capillary action. Once transfer was complete (8­
16 h), as confirmed by ethidium bromide staining of the gel, the filter was rinsed, 
air-dried and UV irradiated (3 min) to immobilise bound DNA. For
prehybridisation, the filters were immersed in 15 ml (0.2 ml.cm-2) 'hybridisation' 
buffer (6 x SSC, 0.5% [w/v] SDS, 0.1% BSA, 0.1% Ficoll, 0.1% polyvinyl pyrollidine 
and 100 pg.m-1 denatured, sonicated, calf-thymus DNA, [Sigma]) and agitated in 
hybridisation chambers (Techne) for 1 h at the required temperature (42 °C- 
55 °C). This was replaced by a further 15 ml hybridisation buffer containing 
radiolabelled probe (2 x 109 cpm.pg-1, 10-20 ng ml.”1), prepared as described in 
Section 4.2.5) and the agitated at the same temperature (12-16 h). The filters
were washed using the following general protocol:
Wash 1: 6 X S^<^:0.1% (w/v) SDS 
(50 ml)
42 °C-55 °C 2 x 15 min
Wash 2: 2 x SSC:0.1% (w/v) SDS 
(50 ml)
42 oC-55 oc 30 min
Wash 3: 0.2 x SSC:0.1% (w/v) 42 oC-55 °C 10 min
SDS (50 ml)
The stringency of hybridisation and washing was varied by altering the 
temperature of the hybridisation reaction and by altering the temperature and salt
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concentration of the wash solution. Details of the stringencies used for individual 
experiments are presented in the results section.
The filters were blotted to remove excess liquid, wrapped in cling film and 
subjected to autoradiography for 1-5 days.
4.4 PCR-BASED ANALYSIS
4.3.1 PCR amplification of the iga gene from U. urealyticum
PCR primers 1 and 2, originally synthesised to amplify a portion of the iga 
gene from N. gonorrhoeae (see Fig. 4.2), were used to PCR-amplify a portion of 
the iga gene within U. urealyticum. Two additional primers (3 and 4), that flanked 
regions of conservation between the (ga genes from N. gonorrhoeae and 
H. influenzae (see Fig. 4.2), were also designed for this purpose. For ease of 
cloning, these contained additional bases (underlined) at their 5' termini adjacent 
to an iTcoRI site (GAATTC):
Primer 3 (left): 5'-GAGACGMTTCGAKATCAAATATTCCGTG-3'
Primer 4 (right): 5 ‘-GGACGTGAAHCCAAATAfGAlTGGAGAGCCfGAiCTATCGCC-S1
Primer 4 was degenerate, since at two sites a mixture of guanidine and 
adenine nucleotides were included in the synthesis reaction. These correspond to 
sites of non-conservation between the N. gonorrhoeae and H. influenzae iga gene 
(nucleotide bases 946 and 936) where a thymidine in H. influenzae replaces the 
cytidine in N. gonorrhoeae. Since the ureaplasma genome shows a strong A+T 
bias, it is more likely that a thymidine rather than a cytidine is present at this 
position.
PCR amplification was performed as described in Section 4.4.4, using 1 pg 
ureaplasma genomic DNA as a template and thermal cycler Programme B. 
Amplified products were purified by electrceluticn from 1.5% (w/v) agarose gels 
(Section 4.4.6) and reamplified using identical primers and thermal cycler 
Programme B. The products were purified once more from agarose gels and the
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purified DNA resuspended in a minimum volume of H2O (~20 ng.jpl'1). A 
proportion of this (100 ng) was radiolabelled with [a32p] ATP (Section 4.2.5) and 
used to probe Southern blots of DNA from U. urealyticum and M. hominis (35 °C,
2 x SSC:0.1% [w/vl SDS washes, as described in Section 4.2.6). If the amplified 
fragment was confirmed to be ureaplasma DNA, the remainder was cloned into 
the filamentous bacteriophage Ml 3 for the production of single-stranded DNA 
required for DNA sequencing.
4.3.2 Cloning of PCR products into M13
The preparation of PCR inserts for cloning into Ml 3 depended upon 
which primers had been used to generate the amplified fragments. Those 
produced from primers 3 and 4 were precipitated from the PCR reaction mixture 
(as described in Section 4.4.4) EcoRI-digested (1 h, 37 °C), purified by 
electroelution (Section 4.4.6) and resuspended in the minimum volume of H2O. 
Those amplified using primers 1 and 2 were Klenow-treated and 5' 
phosphorylated in preparation for blunt-ended ligation into Swcl-digested Ml 3, as 
detailed below. 100-200 ng of ethanol-precipitated PCR product (Section 4.4.4) 
was phosphorylated (30 min, 37 °C) with T4 polynucleotide kinase (NEB, 5 U) in a 
reaction containing 10 pi of 10 x kinase buffer (0.5 M Tris-HCl, pH 7.6, 0.1 M 
MgCl2, 50 mM DTT, 1 mM spermidine, 1 mM EDTA) and H2O made up to 50 pi.
To fill-in any recessed 3' termini, 5 U of the Klenow fragment from E. coli DNA 
polymerase I (NEB) and 0.5 mM of each dNTP (from a stock of 2 mM) was added 
to the phosphorylation mixture. After 15 min, 37 °C the reaction was terminated by 
heat inactivation (65 °C, 10 min) and the products purified by electroelution.
The M13 vector (RE M13mpl8, NBL) was prepared for ligation by 
digestion with either £coRI (10 U, 1 h, 37 °C) or Smal (10 U, 1 h, 30 °C), and 
linearised molecules were purified by electroelution. To prevent vector 
recircularitation during the ligation reactions, 1-2 pg linearised M13 was incubated 
(30 min, 37 °C) with 1 U of calf intestinal alkaline phosphatase (CIAP, 
Boehringer/Mannheim) and 2 pi of 10 x CIAP buffer (30 mM triethanolamine, 3 M 
NaCl, 1 mM MgCl2, 0.1 mM ZnCh, pH 7.6) in a final volume of 20 pi. The reaction
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was terminated by addition of 10 mM ethylene glycol-bis N, N, N', N'-tetra acetic 
acid (EGTA, pH 8) followed by transfer to 68 °C (45 min). Any remaining CIAP 
was removed by phenohchloroform extraction (Section 4.4.1) and following 
ethanol precipitation, vector DNA was resuspended a minimum volume of H2O.
a) Ligation of insert and vector
Prior to ligation, the concentration of vector and insert DNA was estimated 
by agarose gel electrophoresis and ethidium bromide staining. In the ligation 
reaction between cohesive termini, approximately 100 ng of vector DNA was 
combined with insert DNA (at molar ratios of 3:1, 1:1, 1:3,1:10; vectoninsert), 1 pi 
10 x ligase buffer (0.5 M Tris-HCl, pH 7.8, 0.1 M MgClr, 0.2 M DTT, 0.5 mg.im-1 
BSA, 100 mM ATP) and H2O in a total volume of 9 pi. To separate cohesive 
termini, the mixture was heated to 45 °C (5 min) and cooled on ice before addition 
of 0.1 Weiss unit T4 DNA ligase and incubation at 16 °C (2-4 h). For blunt-ended 
ligation, a total of 200 ng of vector was combined with insert DNA at the same 
molar ratios with 1 pi 10 x ligase buffer, 0.1 Weiss unit ligase enzyme in a final 
volume of 10 pi and incubated for 2-4 h (16 °C). 1-2 pi (10-20 ng) of each ligation 
mixture was used to transform competent E. coliJM10\ cells.
b) Preparation of competent E coli JM1O1 cells (Hanrahan method)
All of the solutions required for the production and transformation of
competent of JM1O1 cells (M9 minimum agar, SOB media, FSB solution, H agar, H- 
top agar) are described in Appendix II.
A single colony of E, coli strain JM1O1, grown on minimum agar, was 
dispersed by vortexing in 1 ml SOB:20 mM MgSO4 medium and transferred to 
50 ml SOB:20 mM MgSO4 in a 250 ml tissue culture flask. The bacteria were grown 
in an orbital shaker (37 °C, 200 rpm) to a density of 4-7 x 107 cells.iml1 (OD6oo = 
0.45-0.55, 3-5 h). Bacterial cells were cooled on ice in a 50 ml polypropylene tube 
(10 min) and collected by centrifugation (1000 x g, 4 °C, 10 min). Following 
complete removal of supernatant media, the pellet was resuspended gently in 
1/3 x original vol. ice cold transformation buffer (FSB) and left on ice (10 min). 
After a further centrifugation step (as before) the supernatant-free pellet was 
disrupted gently in 1/12.5 x original vol. FSB, DMSO was added to 3.5% (v/v) and
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the mixed suspension stored on ice (5-15 nun). A further 3-5% (v/v) DMSO was 
added and the solution stored on ice for an additional 5 min. Competent cells were 
dispensed (100 pi) into pre-cooled Eppendorf tubes, snap-frozen in an ethanol-dry 
ice bath and stored (-70 °C) until required.
To prepare 'plating cultures', a single colony of JM1O1 was selected from a 
minimum agar plate and grown in 100 ml LB broth for 6-8 h (37 °C) with agitation. 
The cells were cooled on ice and stored for up to one week (4 °C).
c) Transformations
For transformation, competent JM1 01 cells were thawed in a water bath 
(20 °C) and transferred to ice (10 min). 10-20 ng recombinant M13 DNA was 
mixed with 50 pi competent cells in ice-cold Eppendorf tubes and stored on ice 
(30 min). The tubes were transferred to a circulating water bath (42 °C) 'heat- 
shocked' for exactly 90 sec and immediately returned to ice (1-2 min). Following 
addition of 195 pi SOB, aliquots of the transformed bacteria (25 pi, 125 pi) were 
combined with 100 pi 'plating culture', mixed with 4 ml melted H-top agar (46 °C), 
containing freshly-added. X-gal (40 pi, 20 mg.ml'i in DMF), and IPTG (4 pi,
200 mg.ml"i), and immediately poured onto H agar plates. After 5 min, the plates 
were inverted and incubated overnight (8-12 h) to allow growth of the bacterial 
lawn and Ml 3 plaque-production. Blue plaques were formed by wild-type Ml 3 
and white/colourless plaques by recombinant Ml 3.
d) Isolation single-stranded DNA
Recombinant plaques (representing -101-108 pfu) were isolated using a 
Pasteur pipette, transferred to TE buffer (100 pi) and vortexed to release 
bacteriophage. For the preparation of M13 single-stranded DNA templates, 20 pi of 
the plaque suspension was combined with 2 ml LB broth containing 20 pi 'plating 
culture' and grown (6-8 h) with agitation (37 °C). 1 ml of the transfected culture 
was collected by centrifugation (12,000 xg, 5 min, 20 °C), to produce a bacterial 
pellet containing double stranded RF Ml 3 and a supernatant containing single­
stranded M13 bacteriophage (~10i2 pfu.ml'i). The supernatant was removed, 
centrifuged (as before), to remove traces of bacterial pellet and gently 
resuspended in 200 pi 2.5 M NaCl containing 20% (w/v) PEG 8000. After 15 min
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(20 °C), the bacteriophage particles were harvested by centrifugation (14,000 x g,
5 min, 4 °C) and after complete removal of PEG supernatant by recentrifugation, 
were resuspended by vigorous vortexing in 100 pi TE buffer. Bacteriophage DNA 
was recovered by phenol-extraction and ethanol-precipitation (as described in 
Section 4.4.1), except that the first extraction step was with phenol alone. 
Following resuspension in 20 pi TE buffer, the concentration of single-stranded 
DNA was estimated by agarose gel electrophoresis and ethidium bromide staining.
4.3.3 Sequencing reactions.
The single-stranded templates (1 pg) were sequenced by the dideoxy 
chain-termination reaction using a 'Sequenase' (Version 2.0) sequencing kit 
(United States Biochemical) and [alls] dATP (1000 Ci.mmol'1) (Amersham). 
Sequencing reactions were performed exactly as described by the manufacturers 
protocol. The radiolabelled fragments (2-3 pi) were loaded onto denaturing 
polyacrylamide gels (6% [w/v] acrylamide:bis; 19:1, 7M urea in 1 x TBE buffer), 
prepared using wedge spacers in a 'Sequi-Gen' nucleic acid sequencing gel 
apparatus, following the manufacturers instructions (Bio-Rad). Electrophoresis was 
carried out in 1 x TBE buffer at 10,000 V (55 °C) until the first blue dye front 
(xylene cyanoi) had migrated from the gel (4-6 h). The gels were dried on to 3 MM 
Whatman filter paper and autoradiographed (24-72 h).
Deduced nucleotide sequences were analysed using the Genetics 
Computer Group (GCG) sequence analysis soft-ware package. For translation and 
comparison with other iga gene sequences the 'Translate' and 'Pile-up' 
programmes were used. For more general data base search comparisons, the 
'FastA' programme allowed access to the Gen Bank, EMBL and the FIR Nucleic 
data bases.
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4.4 APPENDIX I: GENERAL CLONING TECHNIQUES
4.4.1 Purification of DNA by phenohchloroform extraction
Re-distilled phenol was equilibrated to pH >7.8 with 100 mM Tris-HCl,
pH 8 and stored as aliquots (-20 °C). DNA-containing solutions were mixed in 
10 ml polypropylene tubes with an equal volume of phenol: chloroform:isoamyl 
alcohol (25:24:1, by vol.), and separated by centrifugation (12,000 x g, 5 min,
20 °C). The aqueous phase was removed to a fresh tube, re-extracted with an 
equal volume of chloroform:isoamyl alcohol and centrifuged as before. DNA was 
precipitated from the aqueous phase by the addition of 0.1 x vol. 3 M sodium 
acetate (pH 5.2) followed by 2.5 x vol. ethanol. After 10-30 min (4 °C), the DNA 
was pelleted by centrifugation (12,000 x g, 10 min, 4 °C), washed with 1 ml 70% 
(v/v) ethanol, allowed to air-dry and resuspended in the required volume of H2O 
or TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
4.4.2 Estimating DNA concentration, [DNA]
The optical density (OD) of an appropriate dilution of the DNA 
preparation (generally 1/500 in TE buffer) was measured using the 'scan' 
programme (220 nm - 320 nm) on a Perkin-Elmer, Lambda 5 spectrophotometer. 
An absorbance unit of 1 indicated a concentration of:
50 ftg.ml" 1 for single stranded DNA,
40 pg.ml"1 for double stranded DNA,
20 pg.ml‘1 for oligonucleotides.
For pure preparations of DNA, the absorbance ratio at 260 nm and 280 nm 
(260:280) should be between 1.8-2.0. A lower ratio indicates protein or phenol 
contamination and accurate quantitation by this method is not possible.
In these circumstances, or when the sample contained low levels of DNA 
(<250 ng.m_1), preparations were examined by agarose gel electrophoresis 
followed by ethidium bromide staining and DNA concentration was estimated 
from the intensity of fluorescence emitted (see Section 4.4.5).
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4.4.3 Restriction endonuclease digestion.
The restriction enzymes and their appropriate 10 x buffers were obtained 
from Gibco (BRL). A typical reaction contained 0.1-5 pg DNA, 2 pi 10 x buffer, 1-10 
units of restriction enzyme (<1/10 total volume) and H2O, to give a final volume of 
20 pi. Digestion was for 1 h at 37 °C (unless otherwise stated) and was terminated 
by addition of 0.5 M EDTA (pH 8), to a final concentration of 10 mM. When 
simultaneous digestion with two restriction enzymes was required, the reaction 
was performed in the appropriate KGB buffer (Stock solution 2 x KGB; 200 mM 
potassium glutamate, 50 mM Tris-acetate [pH 7.51, 20 mM magnesium acetate,
100 pg.mk1 bovine serum albumin [BSA], 1 mM p mercaptoethanol), as described 
by Sambrook et al, (1989).
4.4.4 Polymerase chain reaction (PCR)
Taq polymerase and 10 x Taq buffer (0.1 M Tris-HCl, pH 8, 15 mM MgCh, 
0.5% [v/v] Tween 20, 0.5% [v/v] NP40) were obtained from Northumbria 
Biologicals Limited (NBL). Deoxyribonucieotide triphosphates (dNTPs; dATP, 
dTTP, dGTP, dCTP, [100 mM], Pharmacia) were prepared to give a single stock 
solution containing 2 mM of each dNTP. Oligonucleotide primers were kindly 
synthesised by I. Armitt (University of St. Andrews) using an Applied Biosystems 
381A DNA synthesiser.
The primers were reconstituted in a solution containing 200 pi H2O, 20 pi 
3M sodium acetate, 2.2 pi magnesium acetate and precipitated with 600 pi ethanol. 
After centrifugation (12,000 x g, 5 min), they were again reconstituted, precipitated 
and collected by centrifugation (as above). The final pellets were air-dried and 
resuspended in 100 pi H2O. Oligonucieotide concentration was determined 
spectrophotometrically at 260 nm (assuming the mass of one base to be 330 
Daltons) and a stock solution (100 pM) of each primer was prepared. The Taq 
buffer, dNTPs and oligonucleotide primers were all aliquoted and stored (-20 °C) 
separately from sources of template DNA and PCR amplification products. 
Amplification reactions, prepared in a laminar-flow hood using PC^R-<^^^si^^^^t:ed. 
Gilson pipettes contained the following components:
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HzO 26 pi
10 x Taq buffer 4 pi
dNTPs (2 mM each) 5 fil
oligonucleotide primer 1 (lOOpM) 1 pi
oligonucleotide primer 2 (100 pM) 1 pi
DNA template (200 ng) 3 pi
[mineral oil 50 pi]
Heat, 94 °C; 5 min
Taq mix 10 pi
[Total volume 50 pi]
A negative control containing no template DNA and a positive control 
containing homologous DNA template were included where possible. The
reaction mixtures were overlaid with mineral oil, to prevent evaporation and pre­
heated to 94 °C, to ensure complete denaturation of template DNA. Amplification 
was initiated by addition of 10 pi Taq mix (1 pi Taq buffer, 8.5 pi H2O, 0.5 pi 
(2.5 U) Taq enzyme) and controlled by a programmable thermal cycler, set to one 
of the following programmes:
Programme A: Programme B:
Step 1
(denaturation)
94 °C, 1.5 min 94 oc, 1.0 min
Step 2 (annealing) 55 °C, 1.5 min 40 °C, 1.5 min
Step 3 (elongation) 72 oc, 2.0 min - 65 °C, 3.0 min
No. cycles 30 40
Final step 72 °C, 10 min 60 °C, 5 min
After amplification was complete, the reaction products were removed 
from beneath the paraffin layer, extracted with an equal volume of chloroform,
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ethanol-precipitated and resuspended in 20 pi of H2O or TE buffer. PCR products 
were either used as DNA probes in Southern blotting or for cloning purposes.
4.4.5 Agarose gel electrophoresis
Samples were separated by horizontal agarose gel electrophoresis using 
submersible gel tanks (Gibco/BRL) with a capacity for 20 ml agarose. The 
concentration of agarose (Sigma) reconstituted in Tris-borate buffer (TBE, 0.09 M 
Tris-borate, 2 mM EDTA, pH 8) ranged from 0.7-2 % (w/v), depending on the size 
of DNA to be analysed. DNA-containing samples (50-1000 ng) were mixed with 
1:6 (v/v) gel loading buffer (0.25% [w/v] bromophenol blue, 0.25% [w/v] xylene 
cyanol, 30% [v/v] glycerol in H2O) and loaded directly into well slots. The amount 
of DNA applied to each well depended on the number of fragments in the sample 
and their respective sizes. For simple populations of DNA, such as PCR products or 
plasmid preparations, 50-500 ng were loaded into a 0.5 cm well slot. If restriction 
digests of ureaplasma or mycoplasma genomic DNA were being examined, 
loading was increased to 1 pg. Phage X:HmdIII (Boehringer/Mannheim) or 
0X174: Haem (New England Biolabs, NEB) digests were included when 
appropriate as DNA size markers. Samples were electrophoresed in TBE buffer for 
1 h at constant voltage (75-100 V), stained in TBE buffer: 1 pg.ml"l ethidium 
bromide (5 min) and DNA was visualised using a UV transilluminator. For 
quantitative estimations, standard DNA solutions (5-100 ng) containing a single 
species of DNA, approximately the same size as the as the test DNA, were loaded 
and the intensities of fluorescence compared by photography following UV 
irradiation,
4.4.6 Recovery of DNA fragments from agarose gels
DNA fragments (>100 ng) were purified from agarose gels (1.5%) by 
electrocution, using 7 cm x 10 cm flat-bed slab gel rigs. After UV exaimnation for 
the minimum time required, a narrow well was cut immediately in front of the 
DNA band of interest, about 2 mm wider on either side of the band. DNA was 
eluted into the well with short pulses of 100 V and DNA-containing buffer (TBE)
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ywas removed after each pulse. For DNA of approximately 5 kbp, pulses of 
1 x 50 sec, followed by 7 x 30 sec were suitable. For smaller fragments, such as a 
500 bp PCR product, a further 3-9 x 40 sec pulses were required. The progress of 
electroelution was monitored by UV examination. DNA was purified from pooled, 
eluted buffer fractions by extraction with phenol alone, phenohchloroform and by 
ethanol precipitation, as previously described in Section 4.4.1. The final pellet was 
resuspended in 20 pi H2O.
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4.5 APPENDIX 2: BACTERIAL GROWTH MEDIA
a) Luria-Bertani medium (LB)
Bacto-tryptone (Difco) 10 g
Yeast extract 5 g
The components were dissolved in 800 ml 0.17 M NaCl, adjusted to pH 7.0 
with NaOH, made up to 11 and autoclaved.
For LB agar, Bacto-agar (Difco) was added to 1.5%.
b) Antibiotic-containing media
If antibiotic-containing agar plates were required, the agar was 
equilibrated to 50 °C following autoclaving and antibiotic added to the 
recommended concentration (see Table 4.1). The plates could be stored at 
4 °C for up to one week and before use, were dried for 15 min in a UV
cabinet, at 45 °C.
Table 4.1. Preparation of antibiotics
Antibiotic Stock solution Working concentration
Ampicillin (amp) 25 mg.mW in H2O, filter 
sterilised.
50-100 pg.ml-»
Streptomycin (strep) 2.5 mg.ml‘1 in H2O, 
filter sterilised
25-50 pg.mW
Tetracycline (tet) 12.5 mg,mW in 50% 
ethanol, filter sterilised
12.5-15 pg.im-i
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c) M9 minimal medium
5 x M9 salts 200 mJ
1 M MgSO4 2 ml
lMCaCh 0,1ml
20 % glucose 20 ml
The components were dissolved in sterile deionised H2O made up to 11. 
For M9 minimum agar, noble agar was added to 1.5%.
C) NZYDT
NZYDT media contained 21.1 g NZYDT (Gibco) in a total volume of 11. 
For NZYDT agar, Noble agar was added to 2%(base agar) or 0.7% (top
agar).
d) SOB
Bactotryptone 20 g
bacto yeast extract 5 g
NaCl 0.5 g
KC1, 250 mM 10 ml
The components were dissolved in deionised H2O (950 mJ) and adjusted 
to pH 7 with 5 M NaOH. The volume was made up to 1 1 with deionised 
H2O and the solution sterilised by autoclaving. Just before use MgCh 
(2 M) was added to a concentration of 20 mM.
For the preparation of SOC, glucose was added to 20 mM.
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e) FSB
Potassium acetate (1 M stock, pH 7.5) 10 mM
MnCl2.4H2O 45 mM
CaCl2.2H2O 10 mM
KCl 100 mM
Hexamminecobak chloride 3 mM
Glycerol 10%
The components were mixed in 800 ml H2O, the pH adjusted to 6.4 with 
0.1 N HCl and the volume made up to 1 1. After filter sterilisation (0.45 pm
filter), the solution was stored as aliquots (40 ml) in tissue-culture flasks
(4 OC).
f) H-agar
Tryptone (Merck) 10 g
NaCl 5 g
Noble agar (Difco) 10 g
The components were made up to 11 with deionised water and
autoclaved.
For H-Top agar. Noble agar was reduced to 6 g.kh
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SECTION B 
RESULTS
4.5 PREPARATION OF U. UREALYTCUM GENOMIC DNA LIBRARY
In order to identify the iga gene in U. urealyticum, a genomic DNA library 
was constructed in the Lambda-based vector, X ZAP (Short et al, 1988). This was 
selected as a suitable cloning vehicle as it combined a high efficiency of cloning 
with ease of library screening, amplification and storage. Positively-selected DNA 
inserts could be excised with helper phage and recircularised to generate 
subclones in a pBluescript phagemid vector. This had the potential to generate 
single-stranded DNA suitable for sequencing reactions.
4.5.1 Isolation of genomic DNA
Ureaplasma DNA was. extracted from ceil harvests using a method based 
on that described by Razin et al., (1983). In initial extractions, it was found that 
very low yields of genomic DNA (100 pg) were purified from large ureaplasma 
cultures (101) and that the extracted DNA did not remain stable upon storage at 
4 °C. It had been reported for Acholeplasma laidlawiiCA. laidlawi) that DNAase 
enzymes released during the process of DNA extraction substantially degraded 
acholeplasma genomic DNA and that addition of 20 mM EDTA into the cell-lysis 
buffer could alleviate this effect (Razin et al, 1983). Increasing EDTA 
concentration to 20 mM in the TE buffer at all stages of ureaplasma DNA extraction 
appeared to improve yields to a limited extent and substantially reduced the DNA 
degradation observed after prolonged storage. As a precaution, a stock of 
ureaplasma DNA (for use in Southern blotting) was stored at -20 °C. Preparations 
required for the construction of a gene library, however, were stored at 4 °C, to 
avoid the shearing of high molecular DNA upon freeze-thawing. Higher yields of 
DNA were also obtained by using freshly harvested cell pellets rather than frozen 
pellets, although other workers had found frozen preparations to be satisfactory 
(Razin et al, 1983, J. Willoughby, personal communication). A reduction in the
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number of phenohchloroform extractions and collection of ethanol-precipitated
DNA by centrifugation (12,000 x g, 30 min) rather than by 'spooling' also resulted
in improved yields, but generally at the expense of DNA purity, as measured by
the spectrophotometric absorbance at 260 nm and at 280 nm (260:280). By
optimising extraction conditions, the maximum yield of genomic DNA obtained J
from 5 1 of freshly harvested cells was approximately 300 pg, which is comparable
to yields reported by Bak and Black (1968) and by Razin et al., (1983).
4.5.2 Ligation and packaging reactions
For the construction of the genomic li^fc^I^ary, ureaplasma DNA was partially 
digested with EcdRl and fragments within the range 1-10 kbp were ligated to the X 
ZAP vector. This was packaged to produce a stock of X phage containing the 
whole ureaplasma genome. By using the blue-white selection property of X ZAP, it 
was estimated that the number of insert-containing phage (white plaques) was 
approximately 7.5 x 105 pfu.ml’i, which was within the range estimated by the 
manufacturer (6 x 105 -6 x 101 pfu.mb1). The number of wild-type phage (blue 
plaques) was approximately 3 x 104 pfu.ml’i, which at 1/25 the number of 
recombinant phage, was within the background levels predicted by the 
manufacturers (1/10-1/100 the number of white plaques). For long-term storage, 
the library was amplified to give a stock of approximately 5 x 101 pfu.mb l.
Although this was at a slightly lower titr'e than recommended by the manufacturer 
(lOiO-lO1) pfu.mb1), it was nevertheless at an acceptable level. To confirm that the 
library contained inserts of ureaplasma DNA, radiolabelled DNA from this 
organism was used to probe a filter containing phage DNA obtained from a 
'plaque lift'. A large proportion of plaques were detected using this probe whereas 
plaque lifts from a second libr^ary containing control DNA inserts (pRhec^-^E^’coRI) 
gave no strongly hybridising plaques.
4.6 SCREENING THE LIBRARY
To establish whether heterologous DNA probes could be used to identify 
the iga gene within the ureaplasma DNA li^br^ary, preliminary hybridisation studies
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were performed. A suitable range of ureaplasma genomic DNA fragments were 
generated by digestion with frequently cutting restriction enzymes (£coRI, BgM, 
Scat) and transferred to 'Hybond N' filters by Southern blotting. In addition, DNA 
from M. hominis, which does not elaborate an IgAl protease, was included as a
control.
4.6.1 Preparation of probes
Heterologous DNA probes were derived from a plasmid containing the 
neisserial iga gene, pIP503, which had been propagated in E. coli strain HB1O1.
1 mg purified plasmid DNA was obtained from 60 ml bacterial culture by an 
adaptation of the 'alkali lysis' method. To identify regions within the iga gene that 
may have been conserved between bacterial genera, nucleotide sequences from 
N. gonorrhoeae and H. influenzae iga genes were obtained from the GenBank 
data base and compared using the 'GAP' programme within the GCG sequencing 
analysis package. An area of DNA homology was located towards the 5' end of the 
gene, in particular between nucleotide bases 189-225 (Fig. 4.2, page 177). To 
generate a suitable DNA probe, which contained this region but not the adjacent 
leader sequence which might have been present in a number of ureaplasma 
secretory proteins, oligonucleotide primers were synthesised, as described in 
Fig. 4.1 and 4.2 (pages 173, 177). When used in a PCR reaction, containing 1 pg 
pIP503 as template DNA, these generated approximately 5 pg of amplified DNA 
(1.76 kbp). The identity of the PCR product was confirmed by digestion with 
specific restriction enzymes (HaeXW, Hindi], Tfmfl) which gave the predicted 
fragment sizes when analysed by agarose gel electrophoresis. The DNA was 
radiolabelled by 'random priming', using [a^2p] atp, to give a probe of high 
specific activity (2 x 109 cpm.pg-1). This was used to probe Southern blot filters at 
a concentration of 10-20 ng.mri1 in SSC-based hybridisation solutions.
4.6.2 Southern blotting
Fig. 4.3 shows the result of hybridisations and washes (down to 2 x SSC) 
conducted at a range of temperatures (42 °C-57 °C). Under low stringency
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Fig. 4.3 Southern blot hybridisation of genomic DNA from U. urealyticum and 
M. hominis using a PCR probe derived from N. gonorrhoeae iga gene.
Genomic DNA from U. urealyticum serotype 8 (1 pg, lane 1) and M. hominis 
(1 pg, lane 2) was digested with EcoRI. Plasmid DNA from pIP503 (containing the 
iga gene from N. gonorrhoeae) wars digested with HindM. and Bgfll (8 ng, lane 3). 
The digestion products were analysed by 0.7% agarose gel electrophoresis and 
X/HindW markers (125 ng, lane 4) were included for size comparisons. Following 
Southern transfer, filt^er^s were hybridised (16 h) with a PCR-derived probe 
(10 rigan?1), containing a portion of the iga gene from N. gonorrhoeae, as 
described in Section 4.2.6. The fi^t^ei's were washed with 2 x SSC:0.1% SDS and 
autoradiographed (6 h). Hybridisations and washes were conducted at 42 °C (a), 
47 °C (b), 52 °C (c) and 57 °C (d).
DNA size markers are to the right of the figure.
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conditions (42 °C, 47 °C) there was detectable binding of the probe to ureaplasma 
DNA but also substantial levels of binding to control M. hominisYMK and X 
markers. As the stringency was increased (52 °C, 57 °C), there was an equivalent 
reduction in hybridisation to mycoplasma and ureaplasma DNA but, even at 57 °C, 
the probe continued to bind to X DNA. This suggested that there may have been 
some unexpected homology between the PCR probe and X DNA. Comparing the 
sequence of the probe with X DNA using the Staden package, no obvious area of 
homology was revealed. Incorporation of X DNA (50-100 pg) into the 
hybridisation reactions appeared to reduce probe binding to both X DNA and 
M, hominis DNA but not to ureaplasma DNA, suggesting that the hybridisation to 
the ureaplasma DNA was specific and that binding to X DNA and M. horninisDNA 
was non-specific (see Fig. 4.4). This was perhaps a surprising result, since carrier 
DNA (calf-thymus DNA at 100 pg.mH) had been incorporated routinely into the 
hybridisation solutions to reduce non-specific binding, although it is possible that 
additional non-specific carrier DNA was required.
Alternatively, and contrary to the comparative sequence analysis, it is 
possible that there was a degree of specific binding to X DNA. To ensure that this 
was not a feature particular to the PCR probe used, two additional probes (3 kb 
and 1.35 kb) were generated from digestion of pIP503 with H/ndlH and BgLl (see 
Fig. 4.1). The fragments were purified from agarose gel electrophoresis and 
radiolabelled, as described previously. The 1.35 kb probe represented an area of 
the iga gene contained within the PCR fragment, but the 3 kb probe spanned the 
second half of the gene not found within the PCR probe. This region was of 
interest as it contained a nucleotide sequence conserved between the 
H. influenzae and N. gonorrhoeae iga genes (Fig. 4.2). This region had been 
originally proposed as the active site of the enzyme (Pohlner eZ al, 1987), when it 
was thought that all IgAl proteases were metallo-enzymes. Although the enzymes 
from these two genera have subsequently been shown to be serine-type enzymes, 
this sequence may still represent a region of conservation between IgAl proteases.
When probe hybridisation and washes (2 x SSC:0.1% SDS) were 
conducted at 47 °C , both probes bound to X DNA and M. hominisDNK in
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Fig. 4.4 The effect of incorporating X DNA into Southern blot hybridisation of 
genomic DNA from U. urealyticum and M. hominis.
Genomic DNA from U. urealyticum, serotype 8 (1 pg, lane 1), U. urealyticum, 
serotype 1 (1.5 pg, lane 2), and M. hominis, PG50 (1 pg, lane 3) was digested with 
EcoKl. Plasmid DNA from pIP503 (containing the iga gene from N. gonorrhoeae) 
was digested with H'ndlH and BgKl (0.8 ng, lane 4). The digestion products were 
analysed by 0.7% agarose gel electrophoresis and X/Hind III markers (125 ng, lane 
5) were included for size comparisons. Following Southern transfer (Section 4.2.6), 
the filters were hybridised (16 h, 47 °C) with a PCR-derived probe (10 ng.im*1, 
containing a portion of the iga gene from N. gonorrhoeae) in the presence of 50 pg 
X DNA (a), 100 pg X DNA (b) and no X DNA (c). The filters were washed with 2 x 
SSC, 0.1% SDS (47 °C) and subjected to autoradiography (16 h).
DNA size markers are to the right of the figure.
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Fig. 4.5 Southern blot hybridisation of genomic DNA from U. urealyticum and 
M. hominis using two probes derived from restriction digests of plasmid 
plP503.
Genomic DNA from U. urealyticum serotype 8 (1 pg, lane 1) and M. homintiVG50 
(1 pg, lane 2) was digested with £coRl. Plasmid DNA from pIP503 (containing the 
iga gene from N. gonorrhoeae) was digested with HindWl and BgAl (8 ng, lane 3). 
The digestion products were analysed by 0.7% agarose gel electrophoresis and 
X/Hindlll markers (125 ng, lane 4, see right of figure) were included for size 
comparisons. Following Southern transfer, fi^l^e^r^s were hybridised (16 h) with a 
3 kb plasmid-derived probe (6 ng.im-1, panel A), or a 1.35 kb plasmid-derived 
probe (2 ng.rm-1, panel B) (Section 4.2.6). The fiJ^t^er^s were washed with 2 x SSC, 
0.1% SDS and autoradiographed (72 h). Hybridisations and washes were 
conducted at either 52 °C (a) or 47 °C (b), as indicated.
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addition to ureaplasma DNA. At 52 °C, there was minimal binding to
U. urealyticum DNA, but some binding to X DNA markers and M. Hominis DNA 
remained. Under conditions of low stringency (47 °C), the hybridisation pattern 
produced by the 3 kb probe appeared to be different from that seen with the PCR 
probe (Fig 4.3 and Fig. 4.5). This was not consistent with both probes binding to 
the same genomic fragment(s) containing the iga gene and suggested that they 
were hybridising non-specifically to different regions of ureaplasma DNA. It is 
possible that all of these bands represent distinct regions of the iga gene and that 
the two probes were binding to different regions of the gene. It is very unlikely, 
however, that the gene would comprise of so many different regions at such high 
molecular weight.
It was clear, therefore, that the conditions employed for these 
hybridisation studies were not able to detect any homology between the 
ureaplasma iga gene and the neisserial iga gene. The experimental conditions 
were altered by using a different s^oli^^^p^h^nse DNA supports and by hybridising in 
formamide-based solutions rather than salt-based solutions. 'Hybond N' filters 
were replaced by nitrocellulose fi^^ers, as there had been reports that nitrocellulose 
reduced some of the non-specific binding found with 'Hybond N' (D. Kirk, 
personal communication). It was found that nitrocellulose simply reduced the 
overall level of hybridisation and did not appear to encourage specific binding in 
favour of non-specific binding (Fig. 4.6). In this experiment, the concentration of 
markers present on filter B was inadvertently higher than on filter A. This 
highlighted a fundamental problem in hybridisation studies; a small increase in 
filter-bound DNA concentrations can change apparently non-specific binding into 
apparently specific binding. This may have been important when comparing 
hybridisation levels to M. hominisDNK and U. urealyticum DNA, particularly 
since the standardisation of genomic DNA concentrations measured by 
spectrophotometric methods is subject to inaccuracy.
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Fig. 4.6 A comparison of nitroceiiuiose and 'Hybond N' in Southern biot 
hybridisations of genomic DNA from U. urealyticum and M. hominis
Genomic DNA from U. urealyticum, serotype 8 (1 pg, lanes land 3) and
M. homing, PG50 (1 pg, lanes 5 and 6) was digested with AcoRl (lanes 1 and 5) or 
BgAl (lanes 3 and 6). Plasmid DNA from pIP503 (containing the iga gene from
N. gonorrhoeae) was digested with BamHl and £coRl (0.8 ng, lane 7). The 
digestion products were analysed by 0.7% agarose gel electrophoresis and 
X/HindUl markers (lane 8, ~75 ng [a], -175 ng [b]) were included for size 
comparisons. Following Southern transfer to 'Hybond N' (a) or nitrocellulose (b), 
the filters were hybridised (16 h, 47 °C) with a PCR-derived probe (10 ng.im*1), 
containing a portion of the iga gene from N. gonorrhoeae. The filters were washed 
with 2 x SSC, 0.1% SDS (47 °C) and subjected to autoradiography (22 h).
DNA size markers are to the right of the figure.
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4.6.3 Varying hybridisation conditions
The hybridisation conditions using formamide-based solutions were 
exactly as described by Koomey and Falkow (1984), for detecting nucleotide 
sequence homology between the iga genes from N. gonorrhoeae and 
H. influenzae. By this method, no further indication of homology between the 
neisserial and the ureaplasmal iga gene was indicated (data not shown). It was of 
interest that these workers only detected specific homology between the genes of 
H. influenzae and N. gonorrhoeae at conditions of apparentty low stringency (25% 
formamide, 37 °C, washed in 5 x SSC, 0.1% SDS, 37 °C) but, upon sequencing, a 
number of regions sharing a high degree of homology were identified between the 
two genes. This suggested that Southern blotting and hybridisation studies were 
only useful for the identification of heterologous genes showing a high degree of 
conservation at the nucleotide level. Such a finding was also reported by Dybvig 
and Woodard (1992), who by hybridisation studies found no apparent homology 
between the recA genes from B. subtilis and Mi. pulmonti, but later sequence 
analysis revealed a 65% nucleotide homology of between the two genes (Dybvig 
et al., 1992). This homology had not allowed identification of the gene by 
hybridisation, but was sufficient for a portion of the gene to be amplified by PCR 
using degenerate primers, directed towards predicted regions of nucleotide 
conservation.
4.7 PCR-BASED ANALYSIS
As synthetic oligonucleotides directed against the N. gonorrhoeae iga gene 
were already available, these were used as primers in preliminary PCR reactions 
using genomic ureaplasma DNA as the template. The annealing step was 
conducted at low temperatures to allow for mismatches between the primer and 
target sequences. At an annealing temperature of 40 °C and elongation at 60 °C, 
two regions of ureaplasma DNA, approximately 1.2 kbp and 400 bp, were 
amplified at low but detectable levels (Fig. 4.7). The 1.2 kbp fragment may have 
represented the portion of the iga gene corresponding to the 1.7 kbp fragment
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Fig. 4.7 Gel electrophoresis of reamplified DNA produced from PCR of 
U. urealyticum genomic DNA
A) PCR of U. urealyticum genomic DNA using synthetic primers 1 and 2 (as 
described in Section 4.4) gave two amplification products of approximate size 1.2 
kb and 0.4 kbp. These were gel-purified, PCR-reampHfied using the same primers 
and 1/10 of the product was analysed by gei electrophoresis (lanes 1 and 2 
respectively). PCR reactions using no DNA template (lane 5) or DNA from plasmid 
pIP503 (containing the iga gene from N. gonorrhoeae, lane 7) were included as 
negative and positive controls.
B) PCR of U. urealyticum genomic DNA using synthetic primers 3 and 4 (as 
described in Section 4.4) gave two amplification products of approximate size 600 
bp and 200 bp. These were gel-purified, PCR-reampHfied with the same primers 
and 1/10 of the product was analysed by gel electrophoresis (lanes 1 and 2 
respectively).
In each case DNA from 0 XlA:HceAW digest (lane 3) provided size markers, as 
indicated to the right of the figures. The gels were stained with ethidium bromide 
(1 pg.ml'1) and photographed using Polaroid film.
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amplified from N. gonorrhoeae. The two bands were gel-purified and reamplified 
using the same primers and standard PCR conditions (annealing at 55 °C, 
amplification at 72 °C), since the primers should have been homologous with the 
flanking regions of the first PCR products. The quantity of amplified DNA was not 
as high as expected but after a third round of amplification sufficient DNA was 
produced to use in hybridisation and cloning experiments (Fig. 4.7). It was not 
clear why an additional band of 300 bp was produced after reamplification of the
1.2 kbp barnd
A proportion of each fragment, was radiolabelled with [a32P] dCTP and 
used as a probe in Southern blotting (Fig. 4.8). Using hybridisation temperatures of 
55 °C, the specific homology between both of the probes and ureaplasma DNA 
was clear. Under these conditions, there was little or no binding to mycoplasma 
DNA or X marker’s. The 1.2 kbp probe, however, did not hybridise with DNA 
isolated from serotype 1 which had already been demonstrated to express an IgAl 
protease enzyme (Section 2.8.2). It was also clear that the two products (1.2 kbp, 
400 bp) had not been amplified from the same region of DNA, as restriction 
fragments of different sizes were highlighted by the two different probes. This cast 
doubt upon the specificity of the PCR and suggested that the primers may not have 
bound specifically to the ureaplasma iga gene but bound randomly to the 
template DNA. Nevertheless, the 400 bp fragment (which had hybridised with 
ureaplasma serotypes 1 and 8) was blunt-end ligated into the Smal site of Ml 3 and 
transformed into competent preparations of &. coli, strain JM1 01. Recombinant 
phage appeared as colourless plaques on a bacterial lawn containing X-gal and 
IPTG. By virtue of the life cycle of M13, single stranded DNA was purified from 
liquid cultures of JM1O1 transfected with these phage and sequenced using the 
dideoxy chain-termination method. The 1.2 kbp amplification product repeatedly 
degraded during purification and therefore was not cloned into M13 or sequenced.
The sequence obtained from the 400 kbp fragment is presented in Fig. 4.9. 
The A+T content is 30 %, suggesting that it is ureaplasma DNA, in agreement with 
the results obtained from Southern Blotting. Using the 'translate facility' in the GCG 
package, an obvious open reading frame could not be found (Fig. 4.9). This
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Fig. 4.8 Southern blot hybridisation of genomic DNA from U. urealyticum and 
M. hominis using PCR-derived probes amplified from ureaplasma template 
DNA.
Genomic DNA from U. urealyticum serotype 1 (1 pg, lane 1), U. urealyticum 
serotype 8 (1 pg, lanes 2-4) and M. hominis PG50 (1 pg, lane 5) was digested with 
EcoRX (lanes 1, 2, 5), Seal (lane 3) and BgM (lane 4). Plasmid DNA from pIP503 
(containing the iga gene from TV. gonorrhoeae) was digested with BamHl and 
EcoRl (200 ng, lane 8). Lane 6 contained size markers (X///mdIII, 125 ng) as 
indicated on the right of the figure. Following gel electrophoresis (0.7% agarose) 
and Southern blotting, fi^t^er^s were hybridised (16 h, 55 °C) with a 400 bp PCR 
probe (10 ng.im-1, panel a), or a 1.2 kbp PCR probe (10 ng. m4, panel b). The 
filters were washed with 2 x SSC, 0.1% SDS and autoradiographed (1 h).
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Primer 1 5'-GCATTGGTGAGAGACGATGTCG
gcctgcaggtcgactctagaggatccccgcattggtgagagacgatgtcgattatcaata1--------- +--------- +--------- +--------- +--------- +--------- + go
a ACRSTLEDPRIGERRCRLSI -
bPAGRL* -
c LQVDSRGSPHW* MSIINS-
gcatcatataattctttagctaataaaatattagtgaatctaaaatccaatgcatcatca 61 + ,---------- 1---------- .---------- + —------- -. 120
a ASYNSLANKILVNLKSNASS -
b M H H H -
c I I * -
TTTGGTTGATCACTATAAATATCAACATCATATTCACCATAAATCTTCGTTGTATTTGAA 
121 +--  ---- 1---------- (---------- 1---------- 1---------- 1_ 180
a I G * -
b LVDHYKYQHHIHHKSSLYLK-
c -
GCTGGAATTGAAACTTGTTGATCATTTGCATCAACAATAGTAATTGTTCCATCGGTTAAG 
181--------- +--------- 4--------- 4--------- +--------- J--------- + 440
a —
b LELKLVDHLHQQ* -
c -
ACATCAACCTTTTTAATTCCTATTTGTAATTTATACCTCAAATCAATCATTGGTGGTGAC 
241 --------- +--------- +--------- +--------- +--------- +--------- + 340
a -
b -
c -
241 --------- +--------- +--------- +--------- +--------- +--------- + 344
CAAACGTG 341-------- 348
Fig. 4.9 Sequence obtained from U. urealyticum PCR-amplified DNA.
The PCR product amplified from U. urealyticum genomic DNA using primers 1 
and 2 (as described in Section 4.4), was cloned into the filamentous bacteriophage 
phage vector, M13. Single-stranded transcripts were sequenced by the dideoxy 
chain-termination reaction and translated into three reading frames (a, b, c) using 
the 'translate' programme in the GCG sequence analysis package. Since there is no 
apparent open reading frame, it is assumed that the product is a result of non­
specific amplification of ureaplasma DNA.
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suggested that the sequence did not represent a coding region. In the event that 
there had been some mistakes in interpretation of the sequence, so preventing 
identification of an open reading frame in the translational analysis, the sequence 
was compared with the FastA data base within the GCG programme. No clear 
homology between the ureaplasma sequence and any other published sequence 
within this data base was found.
It was unfortunately not possible to obtain more than one transformant 
containing this sequence. This was partly due to the failure to obtain large 
quantities of the DNA necessary for blunt ended ligation. In addition the rates of 
transformation were very low for these constmcts; only five plaques were obtained 
from a ligation reaction containing 10 ng DNA. Using wild-type M13, 
transformation rates of 1 x 10^ pfu.pg'1 DNA were produced which suggested that 
the transformation had been efficient but that the ligation reactions had been very 
inefficient. The primers had not originally been designed either for heterologous 
amplification reactions or for subsequent cloning steps. They had demonstrated, 
however, that a PCR-based method was a feasible approach for the identification 
ureaplasma genes.
It was for this reason that two new PCR primers were synthesised (Fig 
4.2). Primer 3 was similar to primer 1 but contained terminal EcoRI restriction 
enzyme sites, enabling the amplified product to be ligated more efficiently into 
EcoR sites within Ml 3 DNA. Primer 4 also contained an EcoRI site but was based 
on different area of nucleotide homology found between the iga genes of 
H. influenzae and N. gonorrhoeae. It has been recently proposed that this area 
codes for the serine protease active site (Poulsen et al, 1992) and as the 
ureaplasma enzyme also appears to be a serine protease (Section 2.8.1), it is 
possible that this sequence has also been conserved within the ureaplasma gene.
Using the newly designed primers, two amplification products of 600 bp 
and 200 bp were obtained by PCR following the protocol described earlier 
(Fig. 4.7). Despite repeated attempts to clone these products into M13 for 
sequence analysis this proved impossible, possibly because of the small quantities
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of DNA obtained from PCR. Their relationship to the iga gene from £7. urealyticum
is at present unknown.
208
SECTION C 
DISCUSSION
To identify the iga gene within U. urealyticum, only a limited number of 
options were available. As ureaplasmas utilse the translational stop codon UGA to 
code for the amino acid tryptophan, it was very unlikely that an active enzyme 
would be expressed from the X ZAP library. A number of E. coli repressor strains 
have been used to express whole mycoplasma proteins from genes with UGA 
codon usage (Dybvig, 1990), but these are not suitable for expression of a whole 
gene library. In M. pneumoniae, a number of genes encoding the adhesin (Pl) and 
related adhesion proteins (HMW 3 and P 30) have been identified from fusion 
proteins in Xgtll using specific monoclonal antibodies (Dallo et al, 1990,
Inamine et al, 1988, Ogle et al, 1991). Although inserted DNA sequences in X 
ZAP could be expressed as fusion proteins, there was no means of identifying 
portions of the IgAl protease as no specific antiserum to this enzyme was 
available. Furthermore, since the ureaplasma IgAl protease had not been purified, 
synthetic DNA probes based on amino acid sequences could not be designed. 
Willoughby et al, (1991) and Su et al, (1987) have used such an approach to 
identify the urease and Pl gene in U. urealyticum and M. pneumoniae, 
respectively.
It was known, however, that in terms of substrate spe^h:icity and enzyme 
classification the ureaplasma IgAl protease was similar to the type 2 enzymes in 
N. gonorrboeae and H. influenzae. Hybridisation studies by Koomey and Falkow 
(1984), had previously identified a significant degree of nucleotide homology 
between the iga gene from these two species. Similar cross-genera relationships 
have been used to isolate a number of other mycoplasma and ureaplasma genes. 
The ATPase gene in M. bominis PG50, the gyrase gene in M. pneumoniae and the 
urease gene in U. urealyticum we re all identified by hybridisation experiments 
using heterologous DNA probes obtained from the genes within E. coli, B. subtilis 
and ProviOencia stuartii, respectively (Rasmussen and Christiansen, 1987, Colman 
et al, 1990, Blanchard and Barile, 1989).
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Hybridisation of Southern-blotted ureaplasma genomic DNA using probes 
derived from the N. gonorrhoeae type 2 iga gene, however, revealed no obvious 
DNA duplexes. Substantial efforts were made to ensure that this result was not due 
to unsuitable experimental conditions. Thus, three different molecular probes 
spanning the whole gonococcal iga gene were used under a variety of 
hybridisation and washing conditions. It was possible that the weakly-hybridising 
ureaplasma DNA fragments observed under low stringency conditions represented 
the iga gene from this organism but there were equivalent levels of probe- 
hybridisation to control DNA from M. hominis and X DNA markers. It is not clear 
why the gonococcal probes bound to X DNA at hybridisation temperatures as high 
as 55 °C, but the reduction in binding observed in the presence of carrier X DNA 
suggested that there may have been some homology between the two species of 
DNA. Nucleotide sequence comparisons between the gonococcal and X DNA and 
did not support this proposal and it is likely that the observed reaction was simply 
a result of the high concentration of filter -bound X DNA in combination with the 
low stringency hybridisation conditions used.
When comparing nucleotide homology between the iga genes from 
N. gonorrhoeae and H, influenzae, Koomey and Falkow (1984) had also reported 
that gonococcal probes bound non-specifically to Southern blot-transferred DNA 
under conditions of low stringency. In this case, however, the non-specific binding 
was to N. gonorrhoeae DNA itself, and it therefore may have been due to a 
repetitive element in the iga gene probes binding to similar sequences in genomic 
DNA. This effect nevertheless called into question the validity of the DNA 
duplexes observed between the gonococcal probe and H. influenzae genomic 
DNA. It was only because two gonococcal probes derived from different regions 
of the iga gene bound to the same H. influenzae DNA restriction fragments that a 
specific reaction was suspected. This was confirmed by cloning H, influenzae 
DNA fragments of the same size range into a pBR322-based plasmid vector and 
identification of IgAl protease activity in 5% of E. co/z-expressed clones.
In contrast, a number of U. urealyticum g^^c^mjic DNA fragments were 
highlighted by the two different gonococcal probes used in this study. While this
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could have been due to the ureaplasma iga gene containing more than one 
restriction site for the particular enzymes used, the size and number of these 
fragments made this explanation unlikely. It was concluded therefore, that the 
hybridisation observed with ureaplasma DNA was non-specific.
This proposal was indirectly supported by similar hybridisation 
experiments using a DNA probe obtained from the ATPase gene in 
M. gallisepticum (experiments performed by P. McCready, University of St. 
Andrews, UK). The filter-bound DNA and the methods employed were identical to 
those developed for the IgAl protease studies. Under relatively stringent 
conditions (55 °C hybridisation, 40 °C washes in 0.2 x SSC:0,5% SDS), distinct 
hybridisation was observed between the mycoplasma gene probe and the 
ureaplasma DNA. There was only minimal binding to M. hominis and X DNA. The 
same restriction fragment was detected by two probes derived from different 
regions of the ATPase gene. These results confirmed that suitable materials and 
methods had been developed for the IgAl protease study but it was clear that if 
there had been meaningful homology between the iga genes it would not have 
been necessai'y to try such a variety of hybridisation and washing conditions. 
Furthermore, although the homology between the ATPase genes was obvious by 
Southern blotting, the hybridisation of the probe to the ureaplasma X library 
'plaque lifts' was less apparent, and prolonged exposure of autoradiograms was 
required. This emphasised that even if the weakly hybridising bands had 
represented the ureaplasma iga gene, the levels of binding were probably 
insufficient to subsequently identify the gene within the genomic X library. Work 
on the ATPase gene nevertheless confirmed that a functional U. urealyticum 
genomic DNA library had been generated.
Although it was a reasonable assumption that genes encoding an enzyme 
with shared biochemical characteristics would have sufficient sequence homology 
to form filter-bound DNA duplexes, this has not been demonstrated for the 
streptococcal (ga genes. The IgAl proteases from 5. sanguis 2nd S. pneumoniae 
are both metallo enzymes with identical substrate specificity but S. sanguis iga 
gene probes showed no detectable hybridisation with chromosomal DNA from
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5. pneumoniae, even under low stringency conditions (Gilbert et al., 1988). The 
iga gene sequence for 5. pneumoniae is not yet available and it may be the case 
that regions encoding streptococcal IgAl protease functions are conserved 
between the species but that the overall level of nucleotide conservation is not 
sufficient to allow the formation of stable hybrids. The same may be true for the 
ureaplasmal and neisserial (ga genes. In order to investigate this, degenerate 
oligonucleotide primers directed towards potential regions of nucleotide 
conservation between iga genes were used in PCR to amplify a portion of the gene 
from ureaplasma genomic DNA. If this had been successful, the amplified product 
could then have been used as a 100% homologous probe to isolate the whole 
ureaplasma iga gene from the genomic library.
A similar approach had been used by Dybvig et al., (1992) to identity the 
recA gene from M, pulmoms. These workers found no apparent homology 
between the recA genes from B. subtilis and M. pulmorisby hybridisation studies 
but were able to identify the gene within A. laidlawii by such methods (Dybvig 
and Woodard, 1992). A comparison of the nucleotide sequences from E. col,
B. subtilis and A. laidlawii recA genes revealed regions of nucleotide conservation 
which were used to design a number of degenerate synthetic oligonucleotide 
primers. By using various combinations of these primers in PCR, a 323 bp region 
was amplified which, when sequenced, was identified as a portion of the 
M. pulmonis recA gene. Comparative sequence analysis revealed a 65% nucleotide 
identity with the recA genes from B. subtiHs, which had not been detected by 
hybridisation studies.
Using the same PCR-based approach, it was not possible to identify the 
iga gene within U. urealyticum. This could have been due to a number of reasons. 
It was not that the condition of the template DNA was unsuitable for PCR, since a 
portion of this DNA was used to amplify a region of the urease gene using the 
specific oligonucleotide primers described by Willoughby et al., (1991). 
(Experiment performed by I. Leith, University of St. Andrews). In the iga study, the 
synthetic primers chosen for PCR may not have been complementary for any 
regions within the ureaplasma gene. Since the IgAl protease from U. urealyticum
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appeared to have identical substrate specificity and reaction mechanism to the 
type 2 genes from N. gonorrhoeae and H. influenzae, it was predicted that 
nucleotide regions conserved between these genera, particularly in the putative 
active site, may also have been conserved with ureaplasmas. This may not 
necessarily be the case.
Future work should concentrate on designing alternative degenerate 
primers, particularly since Dybvig et al, (1992) used various combinations of five 
degenerate primers to optimise PCR amplification of the recA gene. These could 
be based on the 370 bp cleavage site specificity determinant (CSD) identified 
within the H influenzae type 2 iga gene (Grundy et al, 1990). Although the 
precise nucleotide sequences controlling the cleavage specificity of type 2 IgAl 
proteases have not been clearly defined, it has been shown that this region is more 
strongly conserved between type 2 gonococcal and Haemophilus genes than 
between the type 1 and type 2 Haemophilus genes and therefore may be 
conserved within the ureaplasma gene.
As an adaptation of the PCR-based method, it may also be possible to 
amplify the iga gene from the ureaplasma genomic % library using one primer 
directed towards a known X sequence, such as the multiple cloning site and 
another directed towards a region within the iga gene, such as the putative serine 
protease active site. By this approach, it is only necessary to predict one conserved 
sequence between iga genes.
It ultimately may not be possible to isolate the iga gene from 
£7. urealyticum by the prediction of regions of nucleotide conservation, iga genes 
have already demonstrated considerable divergence within the genus 
Streptococcus and since it has been proposed that ureaplasmas are evolving more 
rapidly than other prokaryotes (Woese, 1987), it is likely that there is yet further 
divergence within the genus Ureaplasma.
To isolate the ureaplasma iga gene, it may therefore be necessary to return 
to protein purification experiments to obtain specific tools for gene identification 
such as a monoclonal antibody or a portion of amino acid sequence.
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Concluding Remarks
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To investigate the IgAl protease from U. urealyticum, a variety of different 
approaches have been employed. Using crude enzyme preparations, it has been 
established that the enzyme cleaves between a Thr-Pro peptide bond within a 
stretch of IgAl heavy chain amino acids that are absent in the hinge-region of 
IgA2. All fourteen serotypes have an apparently identical substrate specificity and 
enzyme activity levels are comparable, if not identical, between each serotype. By 
using a range of class-specific .inhibitors, it has been suggested that the enzyme is a 
serine protease.
In order to confirm and extend these fi^n<iin^g;s, attempts were made to 
purify the enzyme by conventional chromatography. Due to low levels of starting 
material and losses sustained during the separation steps, the attempts proved 
unsuccessful. By examining the localisation of the IgAl protease in
U. urealyticum, however, it was established that a large proportion, if not all of the 
enzyme activity, is cell-associated rather than extracellularly expressed. The failure 
of the enzyme to digest a synthetic peptide, based on the site cleaved by the 
gonococcal IgA protease during its processing and secretion, supported this 
proposal.
Expression of the iga gene in a bacterial host may have served to provide 
large quantities of ureaplasmai IgAl protease for purification purposes. Sequence 
analysis of the iga gene may also have confirmed the proposed reaction 
mechanism and cellular location of the ureaplasmai enzyme. To identify the iga 
gene within a ureaplasma genomic DNA library, heterologous DNA probes 
derived the N. gonorrhoeae iga gene were used in Southern blotting hybridisation 
studies. Although the ureaplasma enzyme shared a substrate specificity and serine 
protease class with the type 2 enzyme from this organism, there was insufficient 
nucleotide homology between the two iga genes to allow stable duplex formation 
and gene identification. In a PCR-based approach, using synthetic primers based 
on predicted conserved regions between iga genes, amplification of specific 
sequences was also not achieved.
The progress achieved in any one of the areas described above has been 
highly dependant upon the degree of success achieved in each of the other areas.
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Thus, in the absence of a purified enzyme or iga gene sequence, biochemical 
characterisation was limited. Likewise, gene isolation has been hampered by the 
lack of specific antibody or protein sequence and protein purification would have 
been greatly facilitated by bacterial gene expression.
To further characterise the enzyme, advancement in one of these areas is 
necessary. It is possible that additional synthetic primers and a variety of PCR 
reaction conditions may allow amplification of specific ureaplasma iga sequences. 
Alternatively, purification of the IgAl protease followed by limited protein 
sequencing may provide more suitable probes for iga gene isolation.
To repeat the purification attempts, a more rapid and quantifiable assay is 
required. The HPLC-based method showed promise as a quantitative assay for 
future use, but the recent cloning and expression of IgA in mammalian tissue 
culture cells may provide a cheaper and more rapid means of identifying IgAl 
protease activity.
As far as IgAl proteases in general are concerned, characterisation of the 
U. urealyticum IgAl protease has confirmed tliat a high level of diversity exists 
between this group of enzymes. Although it was thought that all IgAl proteases 
were extracellularly expressed, this does not appear to be the case for the 
ureaplasmal enzyme. Recent reports have indicated that bacterial IgAl proteases 
also show a degree of cell-association (Pohlner et al. 1991). The distinct nature of 
the ureaplasma enzyme is highlighted by the apparent lack of nucleotide 
conservation between genomic DNA and the gonococcal iga gene. Since the two 
enzymes show similar properties, a significant role for the IgAl protease is 
suggested.
If the small and simple ureaplasma has only retained the essential genetic 
information required for growth and survival, expression of the IgAl protease by 
all fourteen serotypes further attests to its significance. While the function of the 
IgAl protease in U. urealyticum (or any bacteria) is unclear, it seems likely that 
enzyme expression may contribute to the virnlence of this organism. Since a 
species-specific enzyme has been identified in tlne canine ureaplasma, progress in
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elucidating this function by animal-based pathogenicity studies may be possible. 
These preliminary studies serve as a basis for such future work.
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